### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/52, C12P 17/18, 17/10, C12N (11) International Publication Number:

WO 98/07868

9/00, 1/21, 15/70, C12Q 1/68

(43) International Publication Date:

26 February 1998 (26,02.98)

(21) International Application Number:

PCT/EP97/04495

A1

(22) International Filing Date:

18 August 1997 (18.08.97)

(30) Priority Data:

96810551.0 20 August 1996 (20.08.96) EP (34) Countries for which the regional or international application was filed:

DE et al.

(71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): SCHUPP, Thomas [CH/CH]; Fröschmattweg 5, CH-4313 Möhlin (CH). TOUPET, Christiane [FR/FR]; 12/5, rue de l'Ours, F-68200 Mulhouse (FR). ENGEL, Nathalie [FR/FR]; 29, rue de la Doller, F-68260 Kingersheim (FR).
- (74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

#### (54) Title: RIFAMYCIN BIOSYNTHESIS GENE CLUSTER

#### (57) Abstract

The present invention primarily relates to a DNA fragment which is obtainable from the gene cluster responsible for rifamycin biosynthesis within the genome of Amycolatopsis mediterranei, and comprises at least one gene or a part of a gene which codes for a polypeptide which is directly or indirectly involved in the biosynthesis of rifamycin, and to a method for preparing said DNA fragment. The present invention furthermore relates to recombinant DNA molecules which comprise one of the DNA fragments according to the invention, and to the plasmids and vectors derived therefrom. Host organisms transformed with said plasmid or vector DNA are likewise embraced.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВЈ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	İtaly	MX	Mexico	UZ.	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam
CG	Congo	KE	Кепув	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

### Rifamycin biosynthesis gene cluster

Rifamycins form an important group of macrocyclic antibiotics (Wehrli, Topics in Current Chemistry (1971), 72, 21-49). They consist of a naphthoquinone chromophore which is spanned by a long aliphatic bridge. Rifamycins belong to the class of ansamycin antibiotics which are produced by several Gram-positive soil bacteria of the actinomycetes group and a few plants.

Ansamycins are characterized by a flat aromatic nucleus spanned by a long aliphatic bridge joining opposite positions of the nucleus. Two different groups of ansamycins can be distinguished by the structure of the aromatic nucleus. One group has a naphthoquinoid chromophore, with the typical representatives being rifamycin, streptovaricin, tolypomycin and naphthomycin. The second group, which has a benzoquinoid chromophore, is characterized by geldanamycin, maytansines and ansamitocines (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327). In contrast to antibiotics of the macrolide type, the ansamycins contain in the aliphatic ring system not a lactone linkage but an amide linkage which forms the connection to the chromophore.

The discovery of the rifamycins produced by the microorganism *Streptomyces mediterranei* (as the organism was called at that time, see below) was described for the first time in 1959 (Sensi et al., Farmaco Ed. Sci. (1959) 14, 146-147). Extraction with ethyl acetate of the acidified cultures of *Streptomyces mediterranei* resulted in isolation of a mixture of antibiotically active components, the rifamycins A, B, C, D and E. Rifamycin B, the most stable component, was separated from the other components and isolated on the basis of its strongly acidic properties and ease of salt formation.

Rifamycin B has the structure of the formula (1)

PCT/EP97/04495

Rifamycin B is the main component of the fermentation when barbiturate is added to the fermentation medium and/or improved producer mutants of *Streptomyces mediterranei* are used.

The rifamycin producer strain was originally classified as *Streptomyces mediterranei* (Sensi et al., Farmaco Ed. Sci. (1959) 14, 146-147). Analysis of the cell wall of *Streptomyces mediterranei* by Thiemann et al. later revealed that this strain has a cell wall typical of *Nocardia*, and the strain was reclassified as *Nocardia mediterranei* (Thieman et al. Arch. Microbiol. (1969), 67 147-151). *Nocardia mediterranei* has been reclassified again on the basis of more recent accurate morphological and biochemical criteria. Based on the exact composition of the cell wall, the absence of mycolic acid and the insensitivity to *Nocardia* and *Rhodococcus* phages, the strain has been assigned to the new genus *Amycolatopsis* as *Amycolatopsis mediterranei* (Lechevalier et al., Int. J. Syst. Bacteriol. (1986), 36, 29).

Rifamycins have a strong antibiotic activity mainly against Gram-positive bacteria such as mycobacteria, neisserias and staphylococci. The bactericidal effect of rifamycins derives from specific inhibition of the bacterial DNA-dependent RNA polymerase, which interrupts RNA biosynthesis (Wehrli and Staehelin, Bacteriol. Rev. (1971), 35, 290-309). The semisynthetic rifamycin B derivative rifampin (rifampicin) is widely used clinically as antibiotic against the agent causing tuberculosis, *Mycobacterium tuberculosis*.

The naphthoquinoid ansamycins of the streptovaricin and tolypomycin group show, like rifamycin, an antibacterial effect by inhibiting bacterial RNA polymerase. By contrast, naphthomycin has an antibacterial effect without inhibiting bacterial RNA polymerase. The

benzoquinoid ansamycins show no inhibition of bacterial RNA polymerase, and they therefore have only relatively weak antibacterial activity, if any. On the other hand, some representatives of this class of substances have an effect on eukaryotic cells. Thus, antifungal, antiprotozoal and antitumour properties have been described for geldanamycin. On the other hand, antimitotic (antitubilin), antileukaemic and antitumour properties are ascribed to the maytansines. Some rifamycins also show antitumour and antiviral activity, but only at high concentrations. This biological effect thus appears to be nonspecific.

Despite the great structural variety of the ansamycins, their biosynthesis appears to take place by a metabolic pathway which contains many common elements (Ghisalba et al. Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327). The aromatic nucleus for all ansamycins is probably built up starting from 3-amino-5-hydroxybenzoic acid. Starting from this molecule, which is presumably activated as coenzyme A, the entire aliphatic bridge is synthesized by a multifunctional polyketide synthase. The length of the bridge and the processing of the keto groups, which are initially formed by the condensation steps, are controlled by the polyketide synthase. To build up the complete aliphatic bridge for rifamycins, 10 condensation steps, 2 with acetate and 8 with propionate as building blocks, are necessary. The sequence of these individual condensation steps is likewise determined by the polyketide synthase. Structural comparisons and studies with incorporation of radioactive acetate and propionate have shown that the sequence of acetate and propionate incorporation for the various ansamycins takes place in accordance with a scheme which appears to be identical or very similar in the first condensation steps. Thus, from a common synthesis scheme of the ansamycin polyketide synthases (the rifamycin synthesis scheme), the syntheses of the various ansamycins sooner or later branch off, in accordance with their structural difference from the rifamycin structure, into side branches of the synthesis (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327).

Because of the great structural variety of the rifamycins and their specific and interesting biological effect, there is great interest in understanding the genetic basis of their synthesis in order to create the possibility of specifically influencing it. This is particularly desirable because, as explained above, there is much in common between the synthesis of rifamycins and that of other ansamycins. This similarity in the biosynthesis, which probably derives from a common evolutionary origin of this metabolic pathway, naturally has a genetic basis.

- 4 -

The genetic basis of secondary metabolite biosynthesis essentially exists in the genes which code for the individual biosynthetic enzymes, and in the regulatory elements which control the expression of the biosynthesis genes. The secondary metabolite synthesis genes of actinomycetes have hitherto been found as clusters of adjacent genes in all the systems investigated. The size of such antibiotic gene clusters extends from about 10 kilobases (kb) up to more than 100 kb. The clusters often contain specific regulator genes and genes for resistance of the producer organism to its own antibiotic (Chater, Ciba Found. Symp. (1992), 171, 144-162).

The invention described herein has now succeeded, by identifying and cloning genes of rifamycin biosynthesis, in creating the genetic basis for synthesizing by genetic methods rifamycin analogues or novel ansamycins which combine structural elements from rifamycin with other ansamycins. This also creates the basis for preparing novel collections of substances based on the rifamycin biosynthesis gene cluster by combinatorial biosynthesis.

It was possible in a first step to identify and clone a DNA fragment from the genome of *A. mediterranei*, which shows homology with known polyketides synthase genes. After obtaining the sequence information from this DNA fragment which confirmed a typical sequence for polyketide synthases it was possible to screen a cosmid library of *A. mediterranei* with specific DNA probes derived from this fragment in a screening program for further DNA fragments which are involved in the rifamycin gene cluster. As a result, the complete rifamycin polyketide synthase gene cluster was identified and subjected to sequence determination (see SEQ ID NO 3). The gene cluster comprises six open reading frames, which are referred to hereinafter as ORF A, B, C, D, E and F and which code for the proteins and polypeptides depicted in SEQ ID NOS 4 to 9.

The gene cluster isolated and characterized in this way represents the basis, for example, for targeted optimization of the production of rifamycin, ansamycins or analogues thereof. Examples of techniques and possible areas of application available in this connection are as follows:

- Overexpression of individual genes in producer strains with plasmid vectors or by incorporation into the chromosome.
- Study of the expression and transcriptional regulation of the gene cluster during fermentation with various producer strains and optimization thereof through physiological parameters and appropriate fermentation conditions.

- 5 -
- Identification of regulatory genes and of the DNA binding sites of the corresponding regulatory proteins in the gene cluster. Characterization of the effect of these regulatory elements on the production of rifamycins or ansamycins; and influencing them by specific mutation in these genes or the DNA binding sites.
- Duplication of the complete gene cluster or parts thereof in producer strains.

Besides these applications of the gene cluster to improve production by fermentation as described above, it can likewise be employed for the biosynthetic preparation of novel rifamycin analogues or novel ansamycins or ansamycin-like compounds in which the aliphatic bridge is connected at only one end to the aromatic nucleus. The following possibilities come into consideration here, for example:

- Inactivation of individual steps in the biosynthesis, for example by gene disruption.
- Mutation of individual steps in the biosynthesis, for example by gene replacement.
- Use of the cluster or fragments thereof as DNA probe in order to isolate other natural microorganisms which produce metabolites similar to rifamycin or ansamycins.
- · Exchange of individual elements in this gene cluster by those from other gene clusters.
- Use of modified polyketide synthases for setting up libraries of various rifamycin analogues or ansamycins, which are then tested for their activity (Jackie & Khosla, Chemistry & Biology, (1995), 2, 355-362).
- Construction of mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted, and can thus be used for expressing genetically modified gene clusters.
- Exchange of individual elements within the gene cluster.

### Detailed description of the invention

The invention relates to a DNA fragment from the genome of *Amycolatopsis mediterranei*, which comprises a DNA region which is involved directly or indirectly in the gene cluster responsible for rifamycin synthesis; and the adjacent DNA regions; and functional constituents or domains thereof.

The DNA fragments according to the invention may moreover comprise regulatory sequences such as promoters, repressor or activator binding sites, repressor or activator genes, terminators; or structural genes. Likewise part of the invention are any combinations of these DNA fragments with one another or with other DNA fragments, for example combinations of promoters, repressor or activator binding sites and/or repressor or activator genes from an ansamycin gene cluster, in particular from the rifamycin gene cluster, with

foreign structural genes or combinations of structural genes from the ansamycin gene cluster, especially the rifamycin gene cluster, with foreign promoters; and combinations of structural genes with one another or with gene fragments which code for enzymatically active domains and are from various ansamycin biosynthesis systems. Foreign structural genes, and foreign gene fragments coding for enzymatically active domains, code, for example, for proteins involved in the biosynthesis of other ansamycins.

A preferred DNA fragment is one directly or indirectly involved in the gene cluster responsible for rifamycin synthesis.

The gene cluster or DNA region described above contains, for example, the genes which code for the individual enzymes involved in the biosynthesis of ansamycins and, in particular, of rifamycin, and the regulatory elements which control the expression of the biosynthesis genes. The size of such antibiotic gene clusters extends from about 10 kilobases (kb) up to over 100 kb. The gene clusters normally comprise specific regulatory genes and genes for resistance of the producer organism to its own antibiotic. Examples of what is meant by enzymes or enzymatically active domains involved in this biosynthesis are those necessary for synthesizing, starting from 3-amino-5-hydroxybenzoic acid, the ansamycins such as rifamycin, for example polyketide synthases, acyltransferases, dehydratases, ketoreductases, acyl carrier proteins or ketoacyl synthases.

Thus, the complete sequence of the gene cluster shown in SEQ ID NO 3, as well as DNA fragments which comprise sequence portions which code for a polyketide synthase or an enzymatically active domain thereof, are particularly preferred. Examples of such preferred DNA fragments are, for example, those which code for one or more of the proteins and polypeptides depicted in SEQ ID ID NOS 4, 5, 6, 7, 8 and 9, or functional derivatives thereof, also including partial sequences thereof which comprise, for example, 15 or more consecutive nucleotides. Other preferred embodiments relate to DNA regions of the gene cluster according to the invention or fragments thereof, like those present in the deposited clones pNE95, pRi44-2 and pNE112, or derived therefrom. Further preferred DNA fragments are those comprising sequence portions which display homologies with the sequences comprised by the clones pNE95, pRi44-2 and/or pNE112 or with SEQ ID ID NOS 1 and/or 3, and therefore can be used as hybridization probe within a genomic gene bank of an ansamycin-, in particular, rifamycin-producing organism for finding constituents

-7-

of the corresponding gene cluster. The DNA fragment may moreover, for example, comprise exclusively genomic DNA. A particularly preferred DNA fragment is one which comprises the nucleotide sequence depicted in SEQ ID NO 1 or 3, or partial sequences thereof, which, by reason of homologies, can be regarded as structural or functional equivalent to said sequence or partial sequence therefrom, and which therefore are able to hybridize with this sequence.

The DNA fragments according to the invention comprise, for example, sequence portions which comprise homologies with the above-described enzymes, enzyme domains or fragments thereof.

The term homologies and structural and/or functional equivalents refers primarily to DNA and amino acid sequences with few or minimal differences between the relevant sequences. These differences may have very diverse causes. Thus, for example, this may entail mutations or strain-specific differences which occur naturally or are artificially induced. Or the differences observed from the initial sequence are derived from a targeted modification, which can be introduced, for example, during a chemical synthesis.

Functional differences can be regarded as minimal if, for example, the nucleotide sequence coding for a polypeptide, or a protein sequence has essentially the same characteristic properties as the initial sequence, whether in respect of enzymatic activity, immunological reactivity or, in the case of a nucleotide sequence, gene regulation.

Structural differences can be regarded as minimal as long as there is a significant overlap or similarity between the various sequences, or they have at least similar physical properties. The latter include, for example, the electrophoretic mobility, chromatographic similarities, sedimentation coefficients, spectrophotometric properties etc.

In the case of nucleotide sequences, the agreement should be at least 70%, but preferably 80% and very particularly preferably 90% or more. In the case of the amino acid sequence, the corresponding figures are at least 50%, but preferably 60% and particularly preferably 70%. 90% agreement is very particularly preferred.

The invention furthermore relates to a method for identifying, isolating and cloning one of the DNA fragments described above. A preferred method comprises, for example, the following steps:

- a) setting up of a genomic gene bank,
- b) screening of this gene bank with the assistance of the DNA sequences according to the invention, and
- c) isolation of the clones identified as positive.

A general method for identifying DNA fragments involved in the biosynthesis of ansamycins comprises, for example, the following steps

- 1) Cloning of a DNA fragment which shows homology with known polyketide synthase genes.
  - a) The presence of DNA fragments having homology with the polyketide synthase genes according to the invention is detected in the strains of the microorganism to be investigated by a Southern experiment with chromosomal DNA of this strain. The size of such homologous DNA fragments can be determined by digesting the DNA with a suitable restriction enzyme.
  - b) Production of a plasmid gene bank comprising the above digested chromosomal fragments. Normally, individual clones of this gene bank are tested once again for homology with the polyketide synthase genes according to the invention. Clones with recombinant plasmids comprising fragments having homology with the polyketide probe are then normally isolated on the basis of this homology.
- 2) Analysis of the cloned region
  - a) Restriction analysis of the isolated recombinant plasmids and checking of the identity of these cloned fragments with one another.
  - b) By a chromosomal Southern with DNA of the original microorganism and the isolated DNA fragment as probe it can be demonstrated that the cloned fragment is an original chromosomal DNA fragment from the original microorganism.
  - c) It is possible as an option to demonstrate a significant homology of the cloned DNA fragment with chromosomal DNA from other ansamycin producers (streptovaricin, tolypomycin, geldanamycin, ansamitocin). This would confirm that the cloned DNA is typical of gene clusters of ansamycin biosynthesis and thus also of rifamycin biosynthesis.

- d) DNA sequencing of an internal restriction fragment and demonstration by comparative sequence analysis that the cloned region is a typical DNA sequence of polyketide synthases, coding for the biosynthesis of polyketide antibiotics from actinomycetes.
- 3) Isolation and characterization of adjacent DNA regions
  - a) Construction of a cosmid gene bank from the original microorganism and analysis thereof for homology with the isolated fragments. Isolation of cosmids having homology with this fragment.
  - b) Demonstration by restriction analysis that the isolated cosmid clones comprise a DNA region of the original microorganism which overlaps with the original fragment.

As described above, the first step in the isolation of the DNA fragments according to the invention is normally the setting up of genomic gene banks from the organism of interest, which synthesize the required ansamycin, especially rifamycin.

Genomic DNA can be obtained from a host organism in various ways, for example by extraction from the nuclear fraction and purification of the extracted DNA by known methods.

The fragmentation, which is necessary for setting up a representative gene bank, of the genomic DNA to be cloned to a size which is suitable for insertion into a cloning vector can take place either by mechanical shearing or else, preferably, by cutting with suitable restriction enzymes.

Suitable cloning vectors, which are already in routine use for producing genomic gene libraries, comprise, for example, cosmid vectors, plasmid vectors or phage vectors.

It is then possible in a screening program to obtain suitable clones which comprise the required gene(s) or gene fragment(s) from the gene libraries produced in this way.

One possibility for identifying the required DNA region consists in, for example, using the gene bank described above to transform strains which, because of a blocked synthetic pathway, are unable to produce ansamycins, and identifying those clones which are again able after the transformation to produce ansamycin (revertants). The vectors which lead to revertants comprise a DNA fragment which is required in ansamycin synthesis.

- 10 -

Another possibility for identifying the required DNA region is based, for example, on using suitable probe molecules (DNA probe) which are obtained for example as described above. Various standard methods are available for identifying suitable clones, such as differential colony hybridization or plaque hybridization.

It is possible to use as probe molecule a previously isolated DNA fragment from the same or a structurally related gene or gene cluster which, because of the homologies present, is able to hybridize with the corresponding sequence section within the required gene or gene cluster to be identified. Preferably used as probe molecule for the purpose of the present invention is a DNA fragment obtainable from a gene or a DNA sequence involved in the synthesis of polyketides such as ansamycins or soraphens.

If the nucleotide sequence of the gene to be isolated, or at least parts of this sequence, are known, it is possible in an alternative embodiment to use, based on this sequence information, a corresponding synthesized DNA sequence for the hybridizations or PCR amplifications.

In order to facilitate detectability of the required gene or else parts of a required gene, one of the DNA probe molecules described above can be labelled with a suitable, easily detectable group. A detectable group for the purpose of this invention means any material which has a particular, easily identifiable, physical or chemical property.

Particular mention may be made at this point of enzymatically active groups such as enzymes, enzyme substrates, coenzymes and enzyme inhibitors, furthermore fluorescent and luminescent agents, chromophores and radioisotopes such as <sup>3</sup>H, <sup>35</sup>S, <sup>32</sup>P, <sup>125</sup>I and <sup>14</sup>C. Easy detectability of these markers is based, on the one hand, on their intrinsic physical properties (for example fluorescent markers, chromophores, radioisotopes) or, on the other hand, on their reaction and binding properties (for example enzymes, substrates, coenzymes, inhibitors). Materials of these types are already widely used in particular in immunoassays and, in most cases, can also be used in the present application.

General methods relating to DNA hybridization are described, for example, by Maniatis T. et al., Molecular Cloning, Cold Spring Harbor Laboratory Press (1982).

Those clones within the previously described gene libraries which are able to hybridize with a probe molecule and which can be identified by one of the abovementioned detection methods can then be further analysed in order to determine the extent and nature of the coding sequence in detail.

An alternative method for identifying cloned genes is based on constructing a gene library consisting of plasmid or expression vectors. This entails, in analogy to the methods described previously, the genomic DNA comprising the required gene being initially isolated and then cloned into a suitable plasmid or expression vector. The gene libraries produced in this way can then be screened by suitable procedures, for example by use of complementation studies, and those clones which comprise the required gene or else at least a part of this gene as insert can be selected.

It is thus possible with the aid of the methods described above to isolate a gene, several genes or a gene cluster which code for one or more particular gene products.

For further characterization, the DNA sequences purified and isolated in the manner described above are subjected to restriction analysis and sequence analysis.

For sequence analysis, the previously isolated DNA fragments are first fragmented using suitable restriction enzymes, and then cloned into suitable cloning vectors. In order to avoid mistakes in the sequencing, it is advantageous to sequence both DNA strands completely.

Various alternatives are available for analysing the cloned DNA fragment in respect of its function within ansamycin biosynthesis.

Thus, for example, it is possible in complementation experiments with defective mutants not only to establish involvement in principle of a gene or gene fragment in secondary metabolite biosynthesis, but also to verify specifically the synthetic step in which said DNA fragment is involved.

In an alternative type of analysis, evidence is obtained in exactly the opposite way. Transfer of plasmids which comprise DNA sections which have homologies with appropriate sections

- 12 -

on the genome results in integration of said homologous DNA sections via homologous recombination. If, as in the present case, the homologous DNA section is a region within an open reading frame of the gene cluster, plasmid integration results in inactivation of this gene by so-called gene disruption and, consequently, in an interruption in secondary metabolite production. It is assumed according to current knowledge that a homologous region which comprises at least 100 bp, but preferably more than 1000 bp, is sufficient to bring about the required recombination event.

However, a homologous region which extends over a range of from 0.3 to 4 kb, but in particular over a range of from 1 to 3 kb, is preferred.

To prepare suitable plasmids which have sufficient homology for integration via homologous recombination there is preferably provision of a subcloning step in which the previously isolated DNA is digested, and fragments of suitable size are isolated and subsequently cloned into a suitable plasmid. Examples of suitable plasmids are the plasmids generally used for genetic manipulations in streptomycetes or *E. coli*.

It is possible in principle to use for the preparation and multiplication of the previously described constructs all conventional cloning vectors such as plasmid or bacteriophage vectors as long as they have replication and control sequences derived from species compatible with the host cell.

The cloning vector usually has an origin of replication plus specific genes which result in phenotypical selection features in the transformed host cell, in particular resistances to antibiotics. The transformed vectors can be selected on the basis of these phenotypical markers after transformation in a host cell.

Selectable phenotypical markers which can be used for the purpose of this invention comprise, for example, without this representing a limitation of the subject-matter of the invention, resistances to thiostrepton, ampicillin, tetracycline, chloramphenicol, hygromycin, G418, kanamycin, neomycin and bleomycin. Another selectable marker can be, for example, prototrophy for particular amino acids.

Mainly preferred for the purpose of the present invention are streptomycetes and E. coli plasmids, for example the plasmids used for the purpose of the present invention.

Host cells primarily suitable for the previously described cloning for the purpose of this invention are prokaryotes, including bacterial hosts such as streptomycetes, actinomycetes, *E. coli* or pseudomonads.

E. coli hosts are particularly preferred, for example the E. coli strain HB101 or X-1 blue MR\*(Stratagene) or streptomyces such as the plasmid-free strains of Streptomyces lividans TK23 and TK24.

Competent cells of the *E. coli* strain HB101 are produced by the methods normally used for transforming *E. coli*. The transformation method of Hopwood *et al.* (Genetic manipulation of streptomyces a laboratory manual. The John Innes Foundation, Norwich (1985)) is normally used for streptomyces.

After transformation and subsequent incubation on a suitable medium, the resulting colonies are subjected to a differential screening by plating out on selective media. It is then possible to isolate the appropriate plasmid DNA from those colonies which comprise plasmids with DNA fragments cloned in.

The DNA fragment according to the invention, which comprises a DNA region which is involved directly or indirectly in the biosynthesis of ansamycin and can be obtained in the previously described manner from the ansamycin biosynthesis gene cluster, can also be used as starter clone for identifying and isolating other adjacent DNA regions overlapping therewith from said gene cluster.

This can be achieved, for example, by carrying out a so-called chromosome walking within a gene library consisting of DNA fragments with mutually overlapping DNA regions, using the previously isolated DNA fragment or else, in particular, the sequences located at its 5' and 3' margins. The procedures for chromosome walking are known to the person skilled in this art. Details can be found, for example, in the publications by Smith *et al.* (Methods

- 14 -

Enzymol (1987), 151, 461-489) and Wahl et al. (Proc Natl. Acad. Sci, USA (1987), 84, 2160-2164).

The prerequisite for chromosome walking is the presence of clones having coherent DNA fragments which are as long as possible and mutually overlap within a gene library, and a suitable starter clone which comprises a fragment which is located in the vicinity or else, preferably, within the region to be analysed. If the exact location of the starter clone is unknown, the walking is preferably carried out in both directions.

The actual walking step starts by using the identified and isolated starter clone as probe in one of the previously described hybridization reactions in order to detect adjacent clones which have regions overlapping with the starter clone. It is possible by hybridization analysis to establish which fragment projects furthest over the overlapping region. This is then used as starting clone for the 2nd walking step, in which case there is establishment of the fragment which overlaps with said 2nd clone in the same direction. Continuous progression in this manner on the chromosome results in a collection of overlapping DNA clones which cover a large DNA region. These can then, where appropriate after one or more subcloning steps, be ligated together by known methods to give a fragment which comprises parts or else, preferably all of the constituents essential for ansamycin biosynthesis.

The hybridization reaction to establish clones with overlapping marginal regions preferably makes use not of the very large and unwieldy complete fragment but, in its place, a partial fragment from the left or right marginal region, which can be obtained by a subcloning step. Because of the smaller size of said partial fragment, the hybridization reaction results in fewer positive hybridization signals, so that the analytical effort is distinctly less than on use of the complete fragment. It is furthermore advisable to characterize the partial fragment in detail in order to preclude its comprising larger amounts of repetitive sequences, which may be distributed over the entire genome and thus would greatly impede a targeted sequence of walking steps.

Since the gene cluster responsible for ansamycin biosynthesis covers a relatively large region of the genome, it may also be advantageous to carry out a so-called large-step walking or cosmid walking. It is possible in these cases, by using cosmid vectors which

permit the cloning of very large DNA fragments, to cover a very large DNA region, which may comprise up to 42 kb, in a single walking step.

In one possible embodiment of the present invention, for example, to construct a cosmid gene bank from streptomycetes or actinomycetes, complete DNA is isolated with the size of the DNA fragments being of the order of about 100 kb, and is subsequently partially digested with suitable restriction endonucleases.

The digested DNA is then extracted in a conventional way in order to remove endonuclease which is still present, and is precipitated and finally concentrated. The resulting fragment concentrate is then fractionated, for example by density gradient centrifugation, in accordance with the size of the individual fragments. After the fractions obtainable in this way have been dialysed they can be analysed on an agarose gel. The fractions which contain fragments of suitable size are pooled and concentrated for further processing. Fragments to be regarded as particularly suitable for the purpose of this invention have a size of the order of 30 kb to 42 kb, but preferably of 35 kb to 40 kb.

In parallel with the fragmentation described above, or later, for example a suitable cosmid vector pWE15° (Stratagene) is completely digested with a suitable restriction enzyme, for example BamHI, for the subsequent ligase reaction.

Ligation of the cosmid DNA to the streptomyces or actinomycetes fragments which have been fractionated according to their size can be carried out using a T4 DNA ligase. The ligation mixture obtainable in this way is, after a sufficient incubation time, packaged into  $\lambda$  phages by generally known methods.

The resulting phage particles are then used to infect a suitable host strain. A recA<sup>-</sup> E. coli strain is preferred, such as E. coli HB101 or X-1 Blue<sup>o</sup> (Stratagene). Selection of transfected clones and isolation of the plasmid DNA can be carried out by generally known methods.

The screening of the gene bank for DNA fragments which are involved in ansamycin biosynthesis is carried out, for example, using a specific hybridization probe which is assumed (for example on the basis of DNA sequence or DNA homology or

- 16 -

complementation tests or gene disruption or the function thereof in other organisms) to comprise DNA regions from the 'ansamycin gene cluster'.

A plasmid which comprises an additional fragment of the required size or has been identified on the basis of hybridizations can then be isolated from the gel in the previously described manner. The identity of this additional fragment with the required fragment of the previously selected cosmid can then be confirmed by Southern transfer and hybridization.

Function analysis of the DNA fragments isolated in this way can be carried out in a gene disruption experiment as described above.

Another possible use of the DNA fragments according to the invention is to modify or inactivate enzymes or domains involved in ansamycin and, in particular, rifamycin biosynthesis, or to synthesize oligonucleotides which are then in turn used for finding homologous sequences in PCR amplification.

Besides the DNA fragments according to the invention as such, also claimed are their use firstly for producing rifamycin, rifamycin analogues or precursors thereof, and for the biosynthetic production of novel ansamycins or of precursors thereof. Included in this connection are those molecules in which the aliphatic bridge is connected only at one end to the aromatic nucleus.

The DNA fragments according to the invention permit, for example, by combination with DNA fragments from other biosynthetic pathways or by inactivation or modification thereof, the biosynthesis of novel hybrid compounds, in particular of novel ansamycins or rifamycin analogues. The steps necessary for this are generally known and are described, for example, in Hopwood, Current Opinion in Biotechnol. (1993), 4, 531-537.

The invention furthermore relates to the use of the DNA fragments according to the invention for carrying out the novel technology of combinatorial biosynthesis for the biosynthetic production of libraries of polyketide synthases based on the rifamycin and ansamycin biosynthesis genes. If, for example, several sets of modifications are produced, it is possible in this way to produce, by means of biosyntheses, a library of polyketides, for example ansamycins or rifamycin analogues, which then needs to be tested only for the

activity of the compounds produced in this way. The steps necessary for this are generally known and are described, for example, in Tsoi and Khosla, Chemistry & Biology (1995), 2, 355-362 and WO-9508548.

Besides the DNA fragment as such, also claimed is its use for the genetic construction of mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted, and which can thus be used for expressing genetically modified ansamycin or rifamycin biosynthesis gene clusters.

The invention furthermore relates to a hybrid vector which comprises at least one DNA fragment according to the invention, for example a promoter, a repressor or activator binding site, a repressor or activator gene, a structural gene, a terminator or a functional part thereof. The hybrid vector comprises, for example, an expression cassette which comprises a DNA fragment according to the invention which is able to express one or more proteins involved in ansamycin biosynthesis and, in particular in rifamycin biosynthesis, or a functional fragment thereof. The invention likewise relates to a host organism which comprises the hybrid vector described above.

Suitable vectors representing the starting point of the hybrid vectors according to the invention, and suitable host organisms such as bacteria or yeast cells are generally known.

The host organism can be transformed by generally customary methods such as by means of protoplasts, Ca<sup>2+</sup>, Cs<sup>+</sup>, polyethylene giycol, electroporation, viruses, lipid vesicles or a particle gun. The DNA fragments according to the invention may then be present both as extrachromosomal constituents in the host organism and integrated via suitable sequence sections into the chromosome of the host organism.

The invention likewise relates to polyketide synthases which comprise the DNA fragments according to the invention, in particular those from *Amycolatopsis mediterranei* which are involved directly or indirectly in rifamycin synthesis, and functional constituents thereof, for example enzymatically active domains.

The invention furthermore relates to a hybridization probe comprising a DNA fragment according to the invention, and to the use thereof, in particular for identifying DNA fragments involved in the biosynthesis of ansamycins.

In order to obtain unambiguous signals in the hybridization, DNA bound to the filter (for example made of nylon or nitrocellulose) is normally washed at 55-65°C in  $0.2 \times SSC$  (1  $\times SSC = 0.15$  M sodium chloride, 15 mM sodium citrate).

### Examples

#### <u>General</u>

General molecular genetic techniques such as DNA isolation and purification, restriction digestion of DNA, agarose gel electrophoresis of DNA, ligation of restriction fragments, cultivation and transformation of *E. coli*, plasmid isolation from *E. coli*, are carried out as described in Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982).

Culture conditions and molecular genetic techniques with *A. mediterranei* and other actinomycetes are as described by Hopwood et al. (Genetic manipulation of streptomyces a laboratory manual, The John Innes Foundation, Norwich, 1985). All liquid cultures of *A. mediterranei* and other actinomycetes are carried out in Erlenmeyer flasks at 28°C on a shaker at 250 rpm.

### Nutrient media used:

- LB Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982)
- NL148 Schupp + Divers FEMS Microbiology Lett. **36**, 159-162 (1986) (NL148 = NL148G without glycine)
- R2YE Hopwood *et al.* (Genetic manipulation of streptomyces a laboratory manual. The John Innes Foundation, Norwich, 1985)

- 19 -

TB: 12 g/l Bacto tryptone

24 g/l Bacto yeast extract

4 mi/l glycerol

### Example 1: Detection of chromosomal DNA fragments from A. mediterranei having homology with polyketide synthase genes of other bacteria

To obtain genomic DNA from *A. mediterranei*, cells of the strain *A. mediterranei* wt3136 (= LBGA 3136, ETH collection of strains) are cultivated in NL148 medium for 48 hours. 1 ml of this culture is then transferred into 50 ml of NL148 medium (+ 2.5 g/l glycine) in a 200 ml Erlenmeyer flask, and the culture is incubated for 48 h. The cells are removed from the medium by centrifugation at 3000 g for 10 min. and are resuspended in 5 ml of SET (75 mM NaCl, 25 mM EDTA, 20 mM Tris, pH 7.5). High molecular weight DNA is extracted by the method of Pospiech and Neumann (Trends in Genetics (1995), 11, 217-218).

In order to detect, by a Southern blot, individual fragments from the isolated *A. mediterranei* DNA which have homology with polyketide synthase genes, a radioactive DNA probe is prepared from a known polyketide synthase gene cluster. To do this, the Pvul fragment 3.8 kb in size is isolated from the recombinant plasmid p98/1 (Schupp et al. J. of Bacteriol. (1995), 177, 3673-3679), which comprises a DNA region, about 32 kb in size, from the polyketide synthase for the antibiotic soraphen A. About 0.5 µg of the isolated 3.8 kb Pvul DNA fragment is radiolabelled with <sup>32</sup>P-d-CTP by the nick translation system from Gibco/BRL (Basle) in accordance with the manufacturer's instructions.

For the Southern blot, about 2 µg of the genomic DNA isolated above from *A. mediterranei* are completely digested with the restriction enzyme BgIII (Böhringer, Mannheim), and the resulting fragments are fractionated on a 0.8% agarose gel. A Southern blot with this agarose gel and the DNA probe isolated above (3.8 kb Pvul fragment) detects a DNA BgIII-cut fragment which is about 13 kb in size from the genomic DNA of *A. mediterranei*, and which has homology with the DNA probe used. It can be concluded on the basis of this homology that the detected DNA fragment from *A. mediterranei* is a genetic region which codes for a polyketide synthase and thus is involved in the synthesis of a polyketide antibiotic.

### Example 2: Production of a specific recombinant plasmid collection comprising BgIIIdigested chromosomal fragments from A. mediterranei 12-16 kb in size

The *E. coli* positive selection vector plJ4642 (derivative of plJ666, Kieser & Melton, Gene (1988), **65**, 83-91) developed at the John Innes Centre (Norwich, UK) is used to produce the plasmid gene bank. This plasmid is first cut with BamHI, and the two resulting fragments are fractionated on an agarose gel. The smaller of the two fragments is the filler fragment of the vector and the larger is the vector portion which, on self-ligation after deletion of the filler fragment, forms, owing to the flanking fd termination sequences, a perfect palindrome, which means that the plasmid cannot be obtained as such in *E. coli*. This vector portion 3.8 kb in size is isolated from the agarose gel by electroelution as described on page 164-165 of Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982).

To prepare the BgIII-cut DNA fragments from *A. mediterranei*, the high molecular weight genomic DNA prepared in Example 1 is used. About 10 μg of this DNA are completely digested with the restriction enzyme BgIII and subsequently fractionated on a 0.8% agarose gel. DNA fragments with a size of about 12 - 16 kb are cut out of the gel and detached from the gel block by electroelution (see above). About 1 μg of the BgIII fragments isolated in this way is ligated to about 0.1 μg of the BamHI portion, isolated above, of the vector pIJ4642. The ligation mixture obtained in this way is then transformed into the *E. coli* strain HB101 (Stratagene). About 150 transformed colonies are selected from the transformation mixture on LB agar with 30 μg per ml chloramphenicol. These colonies contain recombinant plasmids with BgIII-cut genomic DNA fragments from *A. mediterranei* in the size range 12 - 16 kb.

## Example 3: Cloning and characterization of chromosomal A. mediterranei DNA fragments having homology with bacterial polyketide synthase genes

150 of the plasmid clones prepared in Example 2 are analysed by colony hybridization using a nitrocellulose filter (Schleicher & Schuell) as described on pages 318-319 of Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982). The DNA probe used is the 3.8 kb Pvul fragment, radiolabelled with <sup>32</sup>P-d-CTP and isolated in Example 1, of the plasmid p98/1. The plasmids are isolated from 5 plasmid clones which show a hybridization signal, and are characterized by two restriction digestions with the enzymes HindIII or KpnI. HindIII cuts

twice in the vector portion of the clones, 0.3 kb to the right and left of the BamHI cleavage site into which the *A. mediterranei* DNA has been integrated. KpnI does not cut in the plJ 4642 vector portion. This restriction analysis shows that the investigated clones comprise both identical HindIII fragments of about 14 and 3.1 kb and identical KpnI fragments approximately 11.4 kb and 5.7 kb in size. This shows that these clones comprise the same genomic BglII fragment of *A. mediterranei*, and that the latter has a size of about 13 kb. It can additionally be concluded from this restriction analysis that this cloned BglII fragment has no internal HindIII cleavage site, but has 2 KpnI cleavage sites which afford an internal KpnI fragment 5.7 kb in size.

The plasmid DNA of the above 5 clones with identical restriction fragments is further characterized by a Southern blot. For this purpose, the plasmids are cut with HindIII and KpnI, and the DNA probe used is the <sup>32</sup>P-radiolabelled 3.8 kb PvuI fragment of the plasmid p98/1 used above. This experiment confirms that the 5 plasmids contain identical A. mediterranei DNA fragments and that these have significant homology with the DNA probe which is characteristic of bacterial polyketide synthase genes. In addition, the Southern blot shows that the internal KpnI fragment 5.7 kb in size likewise has significant homology with the DNA probe used. The plasmid called pRi7-3 is selected from the 5 plasmids for further processing.

To demonstrate that the cloned Bglll fragment about 13 kb in size from *A. mediterranei* is an original chromosomal DNA fragment, another Southern blot is carried out. Chromosomal DNA from *A. mediterranei* which has been cut with Bglll, Kpnl or BamHl is employed in this blot. Two BamHl fragments which are about 1.8 and 1.9 kb in size and are present in the 5.7 kb Kpnl fragment of pRi7-3 are used as radiolabelled DNA probe. This experiment confirms that the Bglll DNA fragment about 13 kb in size cloned in the recombinant plasmid pRi7-3 is an authentic genomic DNA fragment from *A. mediterranei*. In addition, this experiment confirms that the cloned fragment comprises an internal Kpnl fragment 5.7 kb in size and two BamHl fragments about 1.8 and 1.9 kb in size, and that these DNA fragments are likewise authentic genomic DNA fragments from *A. mediterranei*.

## Example 4: Demonstration of a significant homology of the cloned genomic 13 kb Bglll fragment from A. mediterranei with chromosomal DNA from other actinomycetes which produce ansamycins

Demonstration of a significant homology between the cloned chromosomal DNA region of A. mediterranei and chromosomal DNA from other ansamycin-producing actinomycetes takes place by a Southern blot experiment. The following ansamycin-producing strains are employed for this purpose (the ansamycins produced by the strains are in parentheses): Streptomyces spectabilis (streptovaricins), Streptomyces tolypophorus (tolypomycins), Streptomyces hygroscopicus (geldanamycins), Nocardia species ATCC31281 (ansamitocins). Genomic DNA from these strains is isolated as described for A. mediterranei in Example 1 and digested with the restriction enzyme KpnI, and the restriction fragments obtained in this way are fractionated on an agarose gel for the Southern blot. Two BamHI fragments about 1.8 and 1.9 kb in size from A. mediterranei, which are used in Example 3 and are isolated from the plasmid pRi7-3, are used as radioactive probe. This experiment shows that these ansamycin-producing strains have a significant DNA homology with the DNA probe used and thus with the cloned chromosomal region of A. mediterranei. It is to be observed in this connection that the homology in the case of producers of ansamycins with a naphthoquinoid ring system (streptovaricin, tolypomycin) is greater than in the case of those with a benzoquinoid ring system (geldanamycin, ansamitocin). This result suggests that the cloned chromosomal DNA region from A. mediterranei is typical of ansamycin biosynthesis gene clusters and, especially, of gene clusters for ansamycins with naphthoquinoid ring systems, corresponding to the ring system in rifamycins.

## Example 5: DNA sequence determination of the Kpnl fragment 5.7 kb in size located within the cloned 13 kb Bglll fragment

For the sequencing, the 5.7 kb KpnI fragment is isolated from the plasmid pRi7-3 (DSM 11114) (Maniatis et. al. 1992) and subcloned into the KpnI cleavage site of the vector pBRKanf4, which is suitable for the DNA sequencing, affording the plasmids pTS004 and pTS005. The vector pBRKanf4 (derived from pBRKanf1; Bhat, Gene (1993) 134, 83-87) is suitable for introducing sequential deletions of Sau3A fragments in the cloned insert fragment, because this vector does not itself have a GATC nucleotide sequence. In addition, the BamHI fragments 1.9 and 1.8 kb in size present in the 5.7 kb KpnI fragment are subcloned into the BamHI cleavage site of pBRKanf4, resulting the plasmids pTS006 and pTS007, and pTS008 and pTS009, respectively.

To prepare subclones sequentially truncated by Sau3A fragments for the DNA sequencing, the plasmids pTS004 to pTS009 are partially digested with Sau3A and completely digested with Xbal or HindIII (a cleavage site in the multiple cloning region of the vector). The DNA obtained in this way (consisting of the linearized vector with inserted DNA fragments truncated by Sau3A fragments) is filled in at the ends using Klenow polymerase (fragment of polymerase I, see Maniatis et al. pages 113-114), self-ligated with T4 DNA ligase and transformed into E. coli DH5a. The plasmid DNA which corresponds to the pTS004 to pTS009 plasmids, but has DNA regions, which are truncated from one side by Sau3A fragments, from the original integrated fragments of A. mediterranei, is isolated from individual transformed clones obtained in this way.

The DNA sequencing is carried out with the plasmids obtained in this way and with pTS004 to pTS009 using the reaction kit from Perkin-Elmer/Applied Biosystems with dye-labelled terminator reagents (Kit N° 402122) and a universal primer or a T7 primer. A standard cycle sequencing protocol with a thermocycler (MJ Research DNA Engine Thermocycler, Model 225) is used, and the sequencing reactions are analysed by the Applied Biosystems automatic DNA sequencer (Modell 373 or 377) in accordance with the manufacturer's instructions. To analyse the results, the following computer programs (software) are employed: Applied Biosystems DNA analysis software, Unix Solaris CDE software, DNA assembly and analysis package GAP licensed from R. Staden (Nucleic Acid Research (1995)23, 1406-1410) and Blast (NCBI).

The methods described above can be used to sequence completely both DNA strands of the 5.7 kb KpnI fragment from *A. mediterranei* strain wt3136. The DNA sequence of the 5.7 kb fragment with a length of 5676 base pairs is depicted in SEQ ID NO 1.

### Example 6: Analysis of the protein-encoding region (genes) on the 5.7 kb Kpnl fragment from A. mediterranei

The nucleotide sequence of the 5.7 kb Kpnl fragment is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that this fragment is over its whole length a protein-encoding region and thus forms part of a larger open reading frame (ORF). The codons used in this ORF are typical of

streptomycetes and actinomycetes genes. The amino acid sequence derived from the DNA sequence from this ORF is depicted in SEQ ID NO 2.

Polyketide synthases for macrolide antibiotics (such as erythromycin, rapamycin) are very large multifunctional proteins which comprise several enzymatically active domains which are now well characterized (Hopwood und Khosla, Ciba Foundation Symposium (1992), 171, 88-112; Donadio and Katz, Gene (1992), 111, 51-60; Schwecke et al., Proc. Natl. Acad. Sci. U.S.A. (1995) 92 (17), 7839-7843). Comparison of the amino acid sequence depicted in SEQ ID NO 2 with that of the very well-characterized erythromycin polyketide synthase, eryA ORF1 (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession NO M63676) gives the following results:

Region from SEQ ID NO 2: amino acids 2 - 325: is 40% identical to the acyltransferase domain of module 2 of the *eryA* locus of *Saccharopolyspora erythraea*.

Region from SEQ ID NO 2: amino acids 325 - 470: is 43% identical to the dehydratase domain of module 4 of the *eryA* locus of *Saccharopolyspora erythraea*.

Region from SEQ ID NO 2: amino acids 762 - 940: is 48% identical to the ketoreductase domain of module 2 of the *eryA* locus of *Saccharopolyspora erythraea*.

Region from SEQ ID NO 2: amino acids 1024- 1109: is 57% identical to the acyl carrier protein domain of module 2 of the *eryA* locus of *Saccharopolyspora erythraea*.

Region from SEQ ID NO 2: amino acids 1126 - 1584: is 59% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

The very large similarities found in the amino acid sequence and in the size and arrangement of the enzymatic domains suggest that the cloned KpnI region 5.7 kb in size from A. mediterranei codes for part of a polyketide synthase which is typical of polyketides of the macrolide type.

### Example 7: Construction of a cosmid gene bank from A. mediterranei

The cosmid vector employed is the plasmid pWE15 which can be purchased (Stratagene, La Jolla, CA, USA). pWE15 is completely cut with the enzyme BamHI (Maniatis *et al.* 1989) and precipitated with ethanol. For ligation to the cosmid DNA, chromosomal DNA from *A. mediterranei* is isolated as described in Example 1 and partially digested with the restriction enzyme Sau3A (Böhringer, Mannheim) to form DNA fragments most of which have a size of 20 - 40 kb. The DNA pretreated in this way is fractionated by fragment size by centrifugation (83,000 g, 20°C) on a 10% to 40% sucrose density gradient for 18 h. The gradient is fractionated in 0.5 ml aliquots and dialysed, and samples of 10 µl are analysed on a 0.3% agarose gel with DNA size standard. Fractions with chromosomal DNA 25 - 40 kb in size are combined, precipitated with ethanol and resuspended in a small volume of water.

Ligation of the cosmid DNA to the *A. mediterranei* Sau3A fragments isolated according to their size (see above) takes place with the aid of a T4-DNA ligase. About 3 μg of each of the two DNA starting materials are employed in a reaction volume of 20 μl, and the ligation is carried out at 12°C for 15 h. 4 ml of this ligation mixture are packaged into lambda phages using the *in vitro* packaging kit which can be purchased from Stratagene (La Jolla, CA, USA) (in accordance with the manufacturer's instructions). The resulting phages are introduced by infection into the *E. coli* strain X-1BlueMR<sup>®</sup> (Stratagene). Titration of the phage material reveals about 20,000 phage particles per ml, analysis of 12 cosmid clones shows that all the clones contain plasmid DNA inserts 25 - 40 kb in size.

# Example 8: Identification, cloning and characterization of the chromosomal A. mediterranei DNA region which is adjacent to the cloned 5.7 kb Kpnl fragment

To identify and clone the chromosomal *A. mediterranei* DNA region which is adjacent to the 5.7 kb Kpnl fragment described above in Examples 3 and 5, firstly a radioactive DNA probe is prepared from this 5.7 kb Kpnl fragment. This is done by radiolabelling approximately 0.5 µg of the isolated DNA fragment with <sup>32</sup>P-d-CTP by the nick translation system of Gibco/BRL (Basle) in accordance with the manufacturer's instructions.

Infection of *E. coli* X-1 Blue MR (Stratagene) with an aliquot of the lambda phages packaged *in vitro* (see Example 7) results in more than 2000 clones on several LB + ampicillin (50 µg/ml) plates. These clones are tested by colony hybridization on nitrocellulose filters (see Example 3 for method). The DNA probe used is the 5.7 kb Kpnl DNA fragment from *A. mediterranei* which is radiolabelled with <sup>32</sup>P-d-CTP and was prepared above.

5 cosmid clones showing a significant signal with the DNA probe are found. The plasmid DNA of these cosmids is isolated (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), digested with KpnI and analysed in an agarose gel. Analysis reveals that all 5 plasmids have integrated chromosomal *A. mediterranei* DNA with a size of the order of about 25-35 kb, and all contain the 5.7 kb KpnI fragment.

To characterize the chromosomal *A. mediterranei* DNA region which is adjacent to the cloned KpnI fragment, the plasmid DNA of one of the 5 cosmid clones is subjected to restriction analysis. The selected plasmid of the cosmid clone has the number pNE112 and likewise comprises the 13 kb BgIII fragment described in Example 3.

Digestion of the plasmid pNE112 with the restriction enzymes BamHI, BgIII, HindIII (singularly and in combination) allows a restriction map of the cloned region of A. mediterranei to be prepared, and this permits this region about 26 kb in size in the chromosome of A. mediterranei to be characterized. This region is characterized by the following restriction cleavage sites with the stated distance in kb from one end: BamHI in position 3.2 kb, HindIII in position 6.6 kb, BgIII in position 11.5 kb, BamHI in position 16.6 kb, BamHI in position 24 kb.

## Example 9: Determination of the sequence of the chromosomal A. mediterranei DNA region present in the plasmid pNE112 and overlapping with the cloned 5.7 kb Kpnl fragment

The plasmid pNE112 DNA is split up into fragments directly using an Aero-Mist nebulizer (CIS-US Inc., Bedford, MA, USA) under a nitrogen pressure of 8-12 pounds per square inch. These random DNA fragments are treated with T4 DNA polymerase, T4 DNA kinase and E. coli DNA polymerase in the presence of the 4 dNTPs in order to generate blunt ends

on the double-stranded DNA fragments (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The fragments are then fractionated in 0.8% low melting agarose (FMC SeaPlaque Agarose, Catalogue N° 50113), and fragments 1.5-2 kb in size are extracted by hot phenol extraction (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The DNA fragments obtained in this way are then ligated with the aid of T4 DNA ligase to the plasmid vector pBRKanf4 (see Example 5) or pBlueScript KS+ (Stratagene, La Jolla, CA, USA), each of which is cut once with square ends by appropriate restriction digestion (Smal for pBRKanf4 and EcoRV for pBlueScript KS+), and is dephosphorylated on the ends by a treatment with alkaline phosphatase (Böhringer, Mannheim). The ligation mixture is then transformed into E. coli DH5α, and the cells are incubated overnight on LB agar with the appropriate antibiotic (kanamycin 40 µg/ml for pBRKanf4, ampicillin 100 µg/ml for pBlueScript KS+). Grown colonies are transferred singly into 1.25 ml of liquid TB medium with antibiotic in 96-well plates with wells of a volume of 2 ml, and incubated at 37°C overnight. Template DNA for the sequencing is prepared directly from these cultures by alkaline lysis (Birnboim, Methods in Enzymology (1983) 100, 243-255). The DNA sequencing takes place using the Perkin Elmer/Appled Biosystems reaction kit with dye-labelled terminator reagents (Kit N° 402122) and universal M13 mp18/19 primers or T3, T7 primers, or with primers prepared by us which bind to internal sequences. A standard cycle sequencing protocol with 20 cycles is used with a thermocycler (MJ Research DNA Engine Thermocycler, Model 225). The sequencing reactions are precipitated with ethanol, resuspended in formamide loading buffer and fractionated and analysed by electrophoresis using the Applied Biosystems automatic DNA sequencer (Model 377) in accordance with the manufacturer's instructions. Sequence files are produced with the aid of the Applied Biosystems DNA Analysis Software computer program and transferred to a SUN UltraSpark computer for further analysis. The following computer programs (software) are employed for analysing the results: DNA assembly and analysis package GAP (Genetics Computer Group, University of Wisconsin, R. Staden, Cambridge University UK) and the four programs: Phred, Cross-match, Phrad and Consed (P. Green, University of Washington, B. Ewing and D. Gordon, Washington University in Saint Louis). After the original sequences have been connected together to give longer coherent sequences (contigs), missing DNA sections are specifically sequenced with the aid of new primers (binding to sequenced sections), or by longer sequencing or sequencing the other strand.

It is possible with the method described above to sequence the entire chromosomal DNA region 26 kb in size from *A. mediterranei* which is cloned in pNE112. The DNA sequence is depicted in SEQ ID NO 3 in the base pair 27801 - 53789 section. The DNA sequence of the 5.7 kb KpnI fragment described in Example 5 is present in pNE112, and is depicted in SEQ ID NO 3 in the base pair 43093 - 48768 region.

# Example 10: Identification and characterization of cosmid clones with chromosomal DNA fragments from A. mediterranei which overlap with one end of the 26 kb A. mediterranei region of pNE112

To identify cosmid clones which comprise chromosomal DNA fragments from *A. mediterranei* located directly in front of the 26 kb region of pNE112, the plasmid pNE112 is cut with the restriction enzyme BamHI, and the resulting BamHI fragment 3.2 kb in size is separated from the other BamHI fragments in an agarose gel and isolated from the gel. This BamHI fragment is located at one end of the incorporated *A. mediterranei* DNA in pNE112 (see Example 8) and can thus be used as DNA probe for finding the required cosmid clones. Approximately 0.5 μg of the isolated 3.2 kb BamHI DNA fragment is radiolabelled with <sup>32</sup>P-dCTP by the nick translation system from Gibco/BRL (Basel) in accordance with the manufacturer's instructions.

The cosmid gene bank from *A. mediterranei* described in Example 7 is then analysed by colony hybridization (Method of Example 3) using this 3.2 kb DNA probe for clones with overlaps. Two cosmid clones with a strong hybridization signal can be identified in this way and are given the numbers pNE95 and pRi44-2. It is possible by restriction analysis and Southern blot to confirm that the plasmids pNE95 and pRi44-2 comprise chromosomal DNA fragments from *A. mediterranei* which overlap with the 3.2 kb BamHI fragment from pNE112 and together cover a 35 kb chromosomal region of *A. mediterranei* which is directly adjacent to the 26 kb *A. mediterranei* fragment of pNE112 cloned in pNE112.

## Example 11: Restriction analysis of the chromosomal A. mediterranei DNA region cloned with the cosmid clones pNE112, pNE95 and pRi44-2

- 29 -

PCT/EP97/04495

The chromosomal *A. mediterranei* DNA region cloned with the cosmid clones pNE112, pNE95 and pRi44-2 is characterized by carrying out a restriction analysis. Digestion of the plasmid DNA of the three cosmids with the restriction enzymes EcoRI, BgIII and HindIII (singly and in combination) produces a rough restriction map of the cloned region of *A. mediterranei*. Overlapping fragments of the three plasmids are in this case established and confirmed by Southern blot. This chromosomal region of *A. mediterranei* has a size of about 61 kb and is characterized by the following restriction cleavage sites with the stated distance in kb from one end: EcoRI in position 7.2 kb, HindIII in position 21 kb, BgIII in position 31 kb, HindIII in position 42 kb, BgIII in position 47 kb and BgIII in position 59 kb. In this region in the *A. mediterranei* chromosome, the plasmid pRi 44-2 covers a region from position 1 to approximately 37 kb, plasmid pNE95 covers a region of approximate position 9 kb - 51 kb and plasmid pNE 112 covers a region of approximate position 35 kb - 61 kb.

## Example 12: Determination of the sequence of the chromosomal A. mediterranei DNA region described in Example 11 from the EcoRI cleavage site in the 7.2 kb position up to the 61 kb end

Determination of the DNA sequence of the chromosomal region described in Example 11 from *A. mediterranei* (EcoRl cleavage site in the 7.2 kb position to 51 kb) is carried out with the plasmids pRi 44-2 and pNE95, using exactly the same method as described in Example 9. Analysis of the DNA sequence obtained in this way confirms the rough restriction map described in Example 11 and the overlaps of the cloned *A. mediterranei* fragments in the plasmids pNE112, pNE95 and pRi44-2.

The DNA sequence of the chromosomal *A. mediterranei* DNA region described in Example 11 from the EcoRI cleavage site in the 7.2 kb position up to the end at 61 kb is depicted in SEQ ID NO 3 (length 53789 base pairs).

## Example 13: Analysis of a first protein-encoding region (ORF A) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence shown in SEQ ID NO 3 is analysed with the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a very large open reading frame (ORF A) which codes for a protein is present in

WO 98/07868

the first third of the sequence (position 1825 - 15543 including stop codon in SEQ ID NO 3). The codons used in ORF A are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF A (SEQ ID NO 4, size 4572 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase of *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

Region from ORF A, SEQ ID NO 4: amino acids 370 - 451: is 50% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 469 - 889: is 65% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 982 - 1292: is 54% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 1324 - 1442: is 42% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 1664 - 1840: is 56% identical to the ketoreductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 1929 - 2000: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 2032 - 2453: is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 2554 - 2865: is 37% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 2918 - 2991: is 54% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 3009 - 3431: is 65% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 3532 - 3847: is 53% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF A, SEQ ID NO 4: amino acids 4142 - 4307: is 43% identical to the ketoreductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF A, SEQ ID NO 4: amino acids 4405 - 4490: is 50% identical to the acyl

carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

In addition to these significant homologies with the eryA polyketide synthase of *S. erythraea*, the region of ORF A, SEQ ID NO 4: amino acids 1 - 356 is 53% identical to the postulated starter unit activation domain of the rapamycin polyketide synthase from *Streptomyces hygroscopicus* (Aparicio et al. GENE (1996) 169, 9-16)

The great similarities found in the amino acid sequence of the enzymatic domains suggest unambiguously that the protein-encoding region (ORF A) of the *A. mediterranai* chromosomal region depicted in SEQ ID NO 3 codes for a typical modular (type 1) polyketide synthase. This very large *A. mediterranei* polyketide synthase encoded by ORF A comprises three complete bioactive modules which are each responsible for condensation of a C2 unit in the macrolide ring of the molecule and correct modification of the initially formed β-keto groups. Because of the homology with activating domains of the rapamycin polyketide synthase, the first module described above very probably comprises an enzymatic domain for activating the aromatic starter unit of rifamycin biosynthesis, 3-amino-5-hydroxybenzoic acid (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327).

## Example 14: Analysis of a second protein encoding region (ORF B) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that another large open reading frame (ORF B) which codes for a protein is present in the middle region of the sequence (position 15550 - 30759 including stop codon in SEQ ID NO 3). The codons used in ORF B are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF B (SEQ ID NO 5, length 5069 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase of *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

Region of ORF B, SEQ ID NO 5: amino acids 44 - 468: is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 571 - 889: is 56% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 921 - 1055: is 47% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B. SEQ ID NO 5; amino acids 1353 - 1525: is 49% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 1621 - 1706: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 1726 - 2148: is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B. SEQ ID NO 5: amino acids 2251 - 2560: is 55% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B. SEQ ID NO 5: amino acids 2961 - 3132: is 49% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 3228 - 3313: is 52% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 3332 - 3755: is 63% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 3857 - 4173: is 52% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 4664 - 4799: is 47% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF B, SEQ ID NO 5: amino acids 4929 - 5014: is 52% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

## Example 15: Analysis of a third protein-encoding region (ORF C) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF C) which codes for a protein is present in the middle region of the sequence (position 30895 - 36060 including stop codon in SEQ ID NO 3). The codons used in ORF C are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF C (SEQ ID NO 6, length 1721 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

Region of ORF C, SEQ ID NO 6: amino acids 1 - 414: is 63% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF C, SEQ ID NO 6: amino acids 514 - 828: is 54% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF C, SEQ ID NO 6: amino acids 1290 - 1399: is 49% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF C, SEQ ID NO 6: amino acids 1563 - 1648: is 55% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

## Example 16: Analysis of a fourth protein-encoding region (ORF D) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF D) which codes for a protein is present in the middle region of the sequence (position 36259 - 41325 including stop codon in SEQ ID NO 3). The codons used in ORF D are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF D (SEQ ID NO 7, length 1688 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence genes/EMBL accession N° M63676) gives the following results:

Region of ORF D, SEQ ID NO 7: amino acids 1 - 418: is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF D, SEQ ID NO 7: amino acids 524 - 841: is 54% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF D, SEQ ID NO 7: amino acids 1260 - 1432: is 51% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF D, SEQ ID NO 7: amino acids 1523 - 1608: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

## Example 17: Analysis of a fifth protein-encoding region (ORF E) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF E) which codes for a protein is present in the rear region of the sequence (position 41373 - 51614 including stop codon in SEQ ID NO 3). The codons used in ORF E are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF E (SEQ ID NO 8, length 3413 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

Region of ORF E, SEQ ID NO 8: amino acids 31 - 451: is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E. SEQ ID NO 8: amino acids 555 - 874: is 37% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 907 - 1036: is 49% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 1336 - 1500: is 52% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 1598 - 1683: is 51% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 1702 - 2124: is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 2229 - 2543: is 53% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

- 35 -

Region of ORF E. SEQ ID NO 8: amino acids 2573 - 2700: is 47% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 3054 - 3227: is 52% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 3324 - 3405: is 51% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

# Example 18: Analysis of a sixth protein-encoding region (ORF F) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that an open reading frame (ORF F) which codes for a protein is present in the rear region of the sequence (position 51713 - 52393 including stop codon in SEQ ID NO 3). The codons used in ORF F are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF F (SEQ ID NO 9, length 226 amino acids) with proteins from the EMBL databank (Heidelberg) shows a great similarity with the N-hydroxyarylamine O-acyltransferase from Salmonella typhimurium (29% identity over a region of 134 amino acids). There is also significant homology with arylamine acyltransferases from other organisms. It can be concluded from these agreements that the ORF F found in A. mediterranei in SEQ ID No 3 codes for an arylamine acyl transferase, and it can be assumed that this enzyme is responsible for the linkage of the long acyl chain produced by the polyketide synthase to the amino group on the starter molecule, 3-amino-5-hydroxybenzoic acid. This reaction would close the rifamycin ring system correctly after completion of the condensation steps by the polyketide synthase.

# Example 19: Summarizing assessment of the function of the proteins encoded by ORF A - F in SEQ ID NO 3, and their role in the biosynthesis of rifamycin

The five protein-encoding regions (ORF A-E), described in Examples 13 - 17, of SEQ ID NO 3 comprise proteins with very great similarity (in the amino acid sequence and the arrangement of the enzymatic domains) to polyketide synthases for polyketides of the macrolide type. Taken together, these five multifunctional enzymes comprise 10 polyketide

synthase modules which are each responsible for a condensation step in the polyketide synthesis. 10 such condensation steps are likewise necessary for rifamycin biosynthesis (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327). The processing of the particular keto groups required by the enzymatic domains within the modules substantially corresponds to the activity required by the rifamycin molecule, if it is assumed that the polyketide synthesis takes place "colinearly" with the arrangement of the modules in the gene cluster of *A. mediterranei* (this is so for other macrolide antibiotics such as erythromycin and rapamycin). It may be added here that it is not certain whether transcription of the five ORFs results in five proteins; in particular, ORF C and ORF D might possibly be translated to a large protein.

An enzymatic domain which is very probably responsible for activating the starter molecule, 3-hydroxy-5-aminobenzoic acid, of rifamycin biosynthesis can be found at the N terminus of ORF A, the start of the polyketide synthase. Directly below the described rifamycin polyketide synthase gene cluster there is a gene (ORF F) which very probably determines a protein which brings about ring closure of the rifamycin molecule after completion of the condensation steps by the polyketide synthase.

It can be concluded on the basis of these findings that the *A. mediterranei* chromosomal region described in SEQ ID NO 3 is responsible for the ten condensation steps required for rifamycin polyketide synthesis, including activation of the starter molecule 3-hydroxy-5-aminobenzoic acid, and the concluding ring closure.

### Deposited microorganisms

The following microorganisms and plasmids have been deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg 1b, D-38124 Braunschweig, in accordance with the requirements of the Budapest Treaty.

Microorganism/Plasmid	Date of deposit	Deposit number
E. coli with plasmid pRi7-3	10.08.96	DSM 11114
E. coli with plasmid pNE112	14.07.97	DSM 11657
E. coli with plasmid pNE95	14.07.97	DSM 11656
E. coli with plasmid pRi44-2	14.07.97	DSM 11655

- 37 -

### SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT:
  - (A) NAME: Novartis AG
  - (B) STREET: Schwarzwaldallee 215
  - (C) CITY: Basel
  - (E) COUNTRY: Switzerland
  - (F) POSTAL CODE (ZIP): 4058
  - (G) TELEPHONE: +41 61 324 1111
  - (H) TELEFAX: + 41 61 322 75 32
- (ii) TITLE OF INVENTION: Rifamycin biosynthesis gene cluster
- (iii) NUMBER OF SEQUENCES: 9
- (iv) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGTACCCGG	GTTCGCGACG	GCGTTCGACG	AGGCTTGCGA	GCAGCTGGAC	GTCTGTCTGG	60
CCGGCCGTGC	C CGGGCACCGC	GTGCGGGACG	TCGTGCTCGG	CGAAGTGCCC	GCCGAAACCG	120
GGCTGCTGAL	A CCAGACGGTC	TTCACCCAAG	CCGGGCTGTT	CGCGGTGGAG	AGCGCGCTGT	180
TCCGGCTCG	CGAATCCTGG	GGTGTCCGGC	CGGACGTGGT	GCTCGGCCAC	TCCATCGGGG	240
AGATCACCGO	CGCGTATGCC	GCGGGCGTCT	TCTCGCTGCC	GGACGCCGCC	CGGATCGTCG	300
ceececec	G CCGGCTGATG	CAGGCGCTGG	cecceecee	GGCGATGGTC	GCCGTCGCCG	360
CCTCCGAAGO	CGAGGTGGCC	GAACTGCTCG	GCGACGCGT	GGAACTCGCC	GCCGTCAACG	420
GCCCTTCGG	GGTAGTCCTT	TCCGGGGACG	CGGACGCGGT	CCTCGCGGCC	GCCGCCCGCA	480
TGCGCGAGC	G CGGGCACAAG	ACCAAGCAGC	TCAAGGTTTC	GCACGCGTTC	CACTCCGCGC	540
GGATGGCGC	CATGCTGGCG	GAGTTCGCCG	CCGAGCTGGC	CGGCGTGACG	TGGCGCGAGC	600
CGGAGATCC	GGTGGTCTCC	AACGTGACCG	CCCGCTTCGC	CGAGCCCGGC	GAACTGACCG	660
AGCCGGGCT	CTGGGCCGAG	CACGTGCGGC	GCCGGTGCG	GTTCGCCGAG	GGCGTCGCGG	720
CCGCGACGG	A GTCCGGCGGC	TCGCTGTTCG	TGGAGCTCGG	ccccccccc	GCGCTGACCG	780
CCCTCGTCG	A GGAGACGCC	GAGGTCACCT	GCGTCGCGGC	CCTGCGGGAC	GACCGCCCGG	840
AGGTCACCGC	C GCTGATCACC	GCGGTCGCCG	AGCTGTTCGT	CCGCGGGGTT	GCGGTCGATT	900
GGCCGGCCC	GCTGCCGCCG	GTCACCGGGT	TCGTCGACCT	GCCGAAGTAC	GCCTTCGACC	960
AGCAGCACTA	TTGGCTGCAG	cccccccc	AGGCCACGGA	CGCGGCCTCG	CTCGGGCAGG	1020

TCGCGGCCGA	CCACCCGCTG	CTGGGCGCGG	TGGTCCGGCT	GCCGCAGTCG	GACGGCCTGG	1080
TCTTCACCTC	GCGGCTGTCA	TTGAAATCGC	ACCCGTGGCT	GGCCGACCAC	GTCATCGGCG	1140
GGGTGGTGCT	CGTCGCGGC	ACCGGGCTCG	TCGAGCTGGC	CGTCCGGGCC	GGGGACGAGG	1200
CCGGCTGCCC	GGTCCTCGAA	GAACTCGTCA	TCGAGGCTCC	GCTGGTCGTC	CCCGACCACG	1260
GCGGGGTCCG	GATCCAGGTC	GTCGTGGGGG	CACCGGGGGA	GACCGGTTCG	CGCGCGGTCG	1320
AGGTGTACTC	CCTGCGCGAG	GACGCCGGTG	CCGAAGTGTG	GGCCCGGCAC	GCCACCGGGT	1380
TCCTGGCTGC	GACGCCGTCG	CAGCACAAGC	CGTTCGACTT	CACCGCCTGG	ccccccccc	1440
GCGTCGAGCG	CGTCGACGTC	GAGGACTTCT	ACGACGCCTT	CGTCGACCGC	GGGTACGCCT	1500
ACGGGCCGTC	GTTCCGGGGC	CTGCGGGCGG	TGTGGCGGCG	CGGCGACGAA	GTGTTCGCCG	1560
AGGTCGCCCT	GGCCGAGGAC	GACCGCGCGG	ACGCGGCCCG	GTTCGGCATC	CACCCCGGCC	1620
TGCTGGACGC	CGCCCTGCAC	GCGGGCATGG	CCGGTGCCAC	CACCACGGAA	GAGCCCGGCC	1680
GCCCGTCCT	GCCGTTCGCC	TGGAACGGCC	TGGTGCTGCA	CGCGGCCGGG	GCGTCCGCGC	1740
TGCGGGTCCG	GCTCGCCCCG	AGCGGTCCGG	ACGCCCTGTC	GGTCGAGGCC	GCGGACGAGG	1800
CCGCCGCTCT	CGTTGTGACG	GCGGACTCGC	TGGTCTCCCG	GCCGGTGTCG	GCCGAACAGC	1860
TGGGCGCGC	GGCGAACCAC	GACGCGTTGT	TCCGCGTGGA	GTGGACCGAG	ATTTCCTCGG	1920
CTGGAGACGT	TCCGGCGGAC	CACGTCGAAG	TGCTCGAAGC	CGTCGGCGAG	GATCCCCTGG	1980
AACTGACCGG	CCGGGTCCTG	GAGGCCGTGC	AGACCTGGCT	CGCCGACGCA	GCCGACGACG	2040
CTCGCCTGGT	CGTGGTGACC	ceceecece	TCCACGAGGT	GACTGACCCG	GCCGGTGCCG	2100
CGGTGTGGGG	CCTGATCCGG	GCCGCGCAGG	CGGAAAACCC	GGACCGGATC	GTGCTGCTGG	2160

ACACCGACGG	TGAAGTGCCG	CTAGGCCGGG	TGCTGGCCAC	CGGCGAGCCC	CAAACAGCCG	2220
TCCGAGGCGC	CACGCTGTTC	GCCCCGCGGC	TGGCCCGCGC	CGAGGCCGCG	GAGGCACCGG	2280
CAGTGACCGG	CGGGACGGTC	CTGATCTCGG	GCGCCGGCTC	GCTGGGCGCG	CTCACCGCCC	2340
GGCACCTGGT	CGCCCGGCAC	GGAGTCCGGC	GGCTGGTGCT	CGTCAGCCGC	CGTGGCCCCG	2400
ACGCCGACGG	CATGGCCGAA	CTGACCGCTG	AACTCATCGC	TCAGGGCGCC	GAGGTCGCCG	2460
TAGTCGCTTG	CGACCTGGCC	GACCGGGACC	AGGTCCGGGT	ACTGCTGGCC	GAGCACCGCC	2520
CGAACGCCGT	CGTGCACACG	GCCGGTGTTC	TCGACGACGG	CGTCTTCGAG	TCGCTGACGC	2580
GGGAGCGGCT	GGCCAAGGTC	TTCGCGCCCA	AAGTTACTGC	TGCCAATCAC	CTCGACGAGC	2640
TGACCCGCGA	ACTGGATCTT	CGCGCGTTCG	TCGTGTTCTC	CTCCGCCTCC	GGGGTCTTCG	2700
GCTCCGCCGG	GCAGGGCAAC	TACGCCGCTG	CCAACGCCTA	CCTGGACGCC	GTGGTCGCCA	2760
ACCGCCGGGC	CGCGGGCCTG	CCCGGCACAT	CGCTGGCCTG	GGGCCTGTGG	GAACAGACCG	2820
ACGGGATGAC	CGCGCACCTC	GCCGACCCCG	ACCAGGCGCG	GGCGAGTCGC	GGCGGGGTCC	2880
TCGCCATCTC	ACCCGCCGAA	GGCATGGAGC	TGTTCGACGC	AGCGCCGGAC	GGGCTCGTCG	2940
TCCCGGTCAA	GCTGGACCTG	CGCAAGACCC	GCGCCGGCGG	GACGGTGCCG	CACCTGCTGC	3000
GCGGCCTGGT	CCGCCCGGGA	CGGCAGCAGG	CCCGTCCGGC	GTCCACTGTG	GACAACGGAC	3060
TGGCCGGGCG	ACTCGCCGGG	CTCGCGCCGG	CGGAGCAGGA	GGCGCTGCTG	CTCGACGTCG	3120
TCCGCACGCA	GGTCGCGCTG	GTGCTCGGGC	ACGCCGGGCC	GGAGGCCGTC	CGCGCGGACA	3180
CGGCGTTCAA	GGACACCGGC	TTCGACTCGC	TGACGTCGGT	GGAACTGCGC	AACCGGCTGC	3240

GCGAGGCGAG CGGCTGAAG CTGCCCGCGA CGCTCGTCTT CGACTACCCG ACGCCGGTCG 3300 CGCTGGCCG CTACCTGCGT GACGAATTCG GCGACACGGT GGCAACAACT CCGGTGGCCA 3360 CCGCGCCCC AGCGGACGCC GGCGAGCCGA TCGCCATCGT CGGCATGGCG TGCCGGCTGC 3420 CGGGCGGGGT CACCGATCCC GAAGGCCTGT GGCGCCTGGT GCGCGACGGC CTCGAAGGGC 3480 TGTCTCCCTT CCCCGAGGAC CGGGGCTGGG ACCTGGAGAA CCTGTTCGAC GACGACCCCG 3540 ACCECTCCGG CACGACGTAC ACCAGCCGGG GCGGGTTCCT CGACGGCGCC GGCCTGTTCG 3600 ACGCGGCTT CTTCGGGATT TCGCCGCGC AGGCGCTGGC CATGGACCCG CAGCAGCGGC 3660 TGCTGCTCGA GGCGGCCTGG GAAGCCCTCG AAGGCACCGG TGTCGACCCG GGCTCGTTGA 3720 AGGGCGCCGA CGTCGGGGTG TTCGCCGGGG TGTCCAACCA GGGCTATGGG ATGGGCGCGG 3780 ATCCGGCCGA ACTGGCGGGG TACGCGAGCA CGGCGGGCGC TTCGAGCGTC GTCTCGGGCC 3840 GAGTCTCGTA CGTCTTCGGG TTCGAAGGAC CGGCGGTCAC GATCGACACG GCTTGCTCGT 3900 CGTCGCTGGT GGCGATGCAC CTGGCCGGGC AGGCGCTGCG GCAGGGCGAG TGCTCGATGG 3960 CCCTGGCCGG TGGCGTCACG GTGATGGGGA CGCCCGGCAC GTTCGTGGAG TTCGCGAAGC 4020 AGCGCGGCCT GGCCGGCGAC GGCCGGTGCA AGGCCTACGC CGAAGGCGCG GACGGCACGG 4080 GCTGGGCCGA GGGCGTCGGG GTCGTCGTGC TGGAGCGGCT GTCGGTGGCG CGCGAGCGCG 4140 GGCACCGGGT GCTGGCCGTG CTGCGCGGCA GCGCGGTCAA CTCCGACGGC GCGTCCAACG 4200 GCCTGACCGC CCCCAACGGG CCGTCGCAGC AACGGGTGAT CCGCCGGGCC CTGGCCGGCG 4260 CCGGCCTCGA ACCGTCCGAT GTGGACATCG TGGAAGGGCA CGGCACCGGG ACGGCGCTGG 4320 GCGACCCGAT CGAGGCGCAG GCCCTGCTGG CCACCTACGG CAAGGACCGC GACCCGGAGA 4380

WO 98/07868

CGCCGTTGTG	CCTCCCCTCC	GTGAAGTCGA	ACTTCGGCCA	CACGCAGTCC	GCGGCCGGCG	- 4440
TGGCCGGGGT	GATCAAGATG	GTGCAGGCGC	TGCGCCACGG	CGTCATGCCG	CCCACCCTGC	4500
ACGTGGACCG	GCCCACCAGC	CAGGTCGACT	GGTCCGCGGG	GGCCGTCGAA	GTGCTGACCG	4560
AGGCACGGGA	GTGGCCGCGG	AACGGCCGTC	CGCGCCGGGC	CGGGGTGTCC	TCGTTCGGGA	4620
TCAGCGGCAC	GAACGCCCAC	CTGATCATCG	AAGAAGCACC	GGCCGAGCCA	CAGCTTGCCG	4680
GACCACCGCC	GGACGGCGGT	GTGGTGCCGC	TGGTCGTCTC	GGCTCGCAGC	CCCGGTGCCC	4740
TGGCCGGTCA	GCCCCTCGC	CTGGCCACGT	TCCTCGGCGA	CGGGCCCCTT	TCCGACGTCG	4800
CCGGTGCGCT	GACGAGCCGC	GCCCTGTTCG	GCGAGCGCGC	GGTCGTCGTG	GCGGATTCGG	4860
CCGAGGAAGC	CCGCGCCGGT	CTGGGCGCAC	TGGCCCGCGG	CGAAGACGCG	CCGGGCCTGG	4920
TCCGCGGCCG	GGTGCCCGCG	TCCGGCCTGC	CGGGCAAGCT	CGTGTGGGTG	TTCCCCGGGC	4980
AGGGGACGCA	GTGGGTGGGC	ATGGGCCGCG	AACTCCTCGA	AGAGTCTCCG	GTGTTCGCCG	5040
AGCGGATCGC	CGAGTGTGCG	GCCGCGCTGG	AGCCGTGGAT	CGGCTGGTCG	CTGTTCGACG	5100
TCCTCCGTGG	CGACGGTGAC	CTCGATCGGG	TCGATGTGCT	GCAGCCCGCG	TGCTTTGCGG	5160
TGATGGTCGG	CTTGGCCGCG	GTGTGGTCCT	CGGCCGGGGT	GGTCCCCGAT	GCGGTGCTCG	5220
GCCACTCCCA	GGGTGAGATC	GCCGCGCGT	GCGTGTCGGG	TGCGTTCTCG	CTGGAGGATG	5280
CGGCGAAGGT	GGTTGCCCTG	CGCAGCCAGG	CCATCGCCGC	GAAGCTCTCC	GCCGCGCGC	5340
GGATGGCTTC	GGTCGCCTTG	GGCGAAGCCG	ATGTGGTGTC	GCGGCTGGCG	GACGGGTCG	5400
AGGTGGCTGC	CGTCAACGGT	CCGGCGTCCG	TGGTGATCGC	GGGGGATGCC	CAGGCCCTCG	5460

- 43 -

ACGAAACGCT	GGAAGCGCTG	TCCGGTGCGG	GAATCCGGGC	TCGGCGGGTG	GCGGTGGACT	5520
ACGCCTCGCA	CACCCGGCAC	GTCGAAGACA	TCGAAGACAC	CCTCGCCGAA	GCGCTGGCCG	5580
GGATCGACGC	CCGGGCGCCG	CTGGTGCCGT	TCCTCTCCAC	CCTCACCGGC	GAGTGGATCC	5640
GGGACGAGGG	CGTCGTGGAC	GGCGGCTACT	GGTACC			5676

- (2) INFORMATION FOR SEQ ID NO: 2:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1891 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Tyr Pro Val Phe Ala Thr Ala Phe Asp Glu Ala Cys Glu Gln Leu Asp 1 5 10 15

Val Cys Leu Ala Gly Arg Ala Gly His Arg Val Arg Asp Val Val Leu 20 25 30

Gly Glu Val Pro Ala Glu Thr Gly Leu Leu Asn Gln Thr Val Phe Thr 35. 40 45

Gln Ala Gly Leu Phe Ala Val Glu Ser Ala Leu Phe Arg Leu Ala Glu 50 55 60

Ser Trp Gly Val Arg Pro Asp Val Val Leu Gly His Ser Ile Gly Glu 65 70 75 80

WO 98/07868

Ile	Thr	Ala	Ala	<b>Tyr</b> 85	Ala	Ala	Gly	Val	Phe 90	Ser	Leu	Pro	Asp	Ala 95	Ala
Arg	Ile	Val	Ala 100	Ala	Arg	Gly	Arg	Leu 105	Met	Gln	Ala	Leu	Ala 110	Pro	Gly
Gly	Ala	Met 115	Val	Ala	Val	Ala	Ala 120	Ser	Glu	Ala	Glu	Val 125	Ala	Glu	Leu
Leu	Gly 130	Asp	Gly	Val	Glu	Leu 135	Ala	Ala	Val	Asn	Gly 140	Pro	Ser	Ala	Val
Val 145	Leu	Ser	Gly	Asp	Ala 150	Ąsp	Ala	Val	Val	Ala 155	Ala	Ala	Ala	Arg	Met 160
Arg	Glu	Arg	Gly	His 165	Lys	Thr	Lys	Gln	Leu 170	Lys	Val	Ser	His	Ala 175	Phe
His	Ser	Ala	Arg 180	Met	Ala	Pro	Met	Leu 185	Ala	Glu	Phe	Ala	Ala 190	Glu	Leu
Ala	Gly	Val 195	Thr	Trp	Arg	Glu	Pro 200	Glu	Ile	Pro	Val	Val 205	Ser	Asn	Val
Thr	Gly 210	Arg	Phe	Ala	Glu	Pro 215	Gly	Glu	Leu	Thr	Glu 220	Pro	Gly	Tyr	Trp
Ala 225	Glu	His	Val	Arg	Arg 230	Pro	Val	Arg	Phe	Ala 235	Glu	Gly	Val	Ala	Ala 240
Ala	Thr	Glu	Ser	Gly 245	Gly	Ser	Leu	Phe	Val 250	Glu	Leu	Gly	Pro	Gly 255	Ala
Ala	Leu	Thr	Ala 260	Leu	Val	Glu	Glu	Thr 265	Ala	Glu	Val	Thr	Cys 270	Val	Ala

Ala Leu Arg Asp Asp Pro Glu Val Thr Ala Leu Ile Thr Ala Val Ala Glu Leu Phe Val Arg Gly Val Ala Val Asp Trp Pro Ala Leu Leu Pro Pro Val Thr Gly Phe Val Asp Leu Pro Lys Tyr Ala Phe Asp Gln Gln His Tyr Trp Leu Gln Pro Ala Ala Gln Ala Thr Asp Ala Ala Ser Leu Gly Gln Val Ala Ala Asp His Pro Leu Leu Gly Ala Val Val Arg Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys Ser His Pro Trp Leu Ala Asp His Val Ile Gly Gly Val Val Leu Val Ala Gly Thr Gly Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys Pro Val Leu Glu Glu Leu Val Ile Glu Ala Pro Leu Val Val Pro Asp His Gly Gly Val Arg Ile Gln Val Val Val Gly Ala Pro Gly Glu Thr Gly Ser Arg Ala Val Glu Val Tyr Ser Leu Arg Glu Asp Ala Gly Ala Glu Val Trp Ala Arg His Ala Thr Gly Phe Leu Ala Ala Thr Pro Ser Gln His Lys Pro Phe Asp Phe Thr Ala Trp Pro Pro Pro Gly

465					470					475					480
Val	Glu	Arg	Val	Asp 485	Val	Glu	Asp	Phe	Tyr 490	Asp	Gly	Phe	Val	Asp 495	Arg
Gly	Tyr	Ala	Туг 500	Gly	Pro	Ser	Phe	<b>Ar</b> g 505	Gly	Leu	Arg	Ala	Val 510	Trp	Arg
Arg	Gly	Asp 515	Glu	Val	Phe	Ala	Glu 520	Val	Ala	Leu	Ala	Glu 525	Asp	Asp	Arg
Ala	<b>Asp</b> 530	Ala	Ala	Arg	Phe	Gly 535	Ile	His	Pro	Gly	Leu 540	Leu	Asp	Ala	Ala
Leu 545	His	Ala	Gly	Met	Ala 550	Gly	Ala	Thr	Thr	Thr 555	Glu	Glu	Pro	Gly	<b>Ar</b> g 560
Pro	Val	Leu	Pro	Phe 565	Ala	Trp	Asn	Gly	Leu 570	Val	Leu	His	Ala	Ala 575	Gly
Ala	Ser	Ala	Leu 580	Arg	Val	Arg	Leu	Ala 585	Pro	Ser	Gly	Pro	Asp 590	Ala	Leu
Ser	Val	Glu 595	Ala	Ala	Asp	Glu	Ala 600	Gly	Gly	Leu	Val	Val 605	Thr	Ala	Asp
Ser	Leu 610	Val	Ser	Arg	Pro	Val 615	Ser	Ala	Glu	Gln	Leu 620	Gly	Ala	Ala	Ala
Asn 625	His	Asp	Ala	Leu	Phe 630	Arg	Val	Glu	Trp	Thr 635	Glu	lle	Ser	Ser	Ala 640
Gly	Asp	Val	Pro	Ala 645	Asp	His	Val	Glu	Val 650	Leu	Glu	Ala	Val	Gly 655	Glu
Asp	Pro	Leu	Glu 660	Leu	Thr	Gly	Arg	Val 6€5	Leu	Glu	Ala	Val	Gln 670	Thr	Trp

WO 98/07868

850

Leu	Ala	<b>A</b> sp 675		Ala	Asp	Asp	Ala 680	Arg	Leu	Val	Val	Val 685		Arg	Gly
Ala	Val 690		Glu	Val	Thr	Asp 695	Pro	Ala	Gly	Ala	Ala 700	Val	Trp	Gly	Leu
Ile 705	Arg	Ala	Ala	Gln	Ala 710	Glu	Asn	Pro	Asp	Arg 715	Ile	Val	Leu	Leu	Asp 720
Thr	Asp	Gly	Glu	<b>Val 72</b> 5	Pro	Leu	Gly	Arg	Val 730	Leu	Ala	Thr	Gly	Glu 735	Pro
Gln	Thr	Ala	Val 740	Arg	Gly	Ala	Thr	Leu 745	Phe	Ala	Pro	Arg	Leu 750	Ala	Arg
Ala	Glu	Ala 755	Ala	Glu	Ala	Pro	Ala 760	Val	Thr	Gly	Gly	Thr 765	Val	Leu	Ile
Ser	Gly 770	Ala	Gly	Ser	Leu	Gly 775	Ala	Leu	Thr	Ala	Arg 780	His	Leu	Val	Ala
Arg 785	His	Gly	Val	Arg	<b>A</b> rg 790	Leu	Val	Leu	Val	Ser 795	Arg	Arg	Gly	Pro	<b>As</b> p 800
Ala	Asp	Gly	Met	Ala 805	Glu	Leu	Thr	Ala	Glu 810	Leu	Ile	Ala	Gln	Gly 815	Ala
Glu	Val	Ala	Val 820	Val	Ala	Cys		Leu 825	Ala	Asp	Arg	qaA	Gln 830	Val	Arg
Val	Leu	Leu 835	Ala	Glu	His	Arg	Pro 840	Asn	Ala	Val		His 845	Thr	Ala	Gly

Val Leu Asp Asp Gly Val Phe Glu Ser Leu Thr Arg Glu Arg Leu Ala

860

855

Lys	Val	Phe	Ala	Pro	Lys	Val	Thr	Ala	Ala	Asn	His	Leu	Asp	Glu	Leu
865					870					875					880
Thr	Arg	Glu	Leu	Asp	Leu	Arg	Ala	Phe	Val	Val	Phe	Ser	Ser	Ala	Ser
				885					890					895	
Glv	Val	Phe	Glv	Ser	Ala	Glv	Gln	Glv	Asn	Tvr	Ala	Ala	Ala	Asn	Ala
- 1			900					905					910		
													210		
Tvr	Leu	Asp	Ala	Val	Val	Ala	Asn	Ara	Arg	Ala	Ala	Glv	Ten.	Pro	ឲាម
-1-		915					920		9			925	200	110	GLY
		710					,_,					,,,			
Thr	Ser	Leu	βla	Trn	Glv	Leu	Ψгъ	Glu	Gln	ጥ h r	Asn	Glv	Met	Thr	Δla
	930				OL1	935			02		940	017			744
	<i></i>					,,,					340				
Hic	Ten	Glu	) Aen	A) a	y e.c.	Gln	212	۸ra	Al a	Sor	Ara	Glar	C111	Val	T 011
945	Leu	GIY	Asp	Ala	950	GIII	ма	мy	Ma	955	Arg	GTĀ	GIY	vai	
343					930					900					960
תות	Tla	Cor	Dwo	<b>71</b> -	~1	~1··	Wat	C1	Tou	Dho	<b>3.0</b> -	<b>7</b> 1-	77.	Pro	N
Ma	116	Ser	PIO	965	GIU	Gry	Mec	GIU	970	FILE	MSD	ATG	міа		weō
				363					970					975	
, (1)	T	**- 7	**- 7	D	*** 1	T	¥	<b>&gt;</b>	T	<b>.</b>	<b>T</b>	mb	•		<b>~1</b>
GIY	Leu	vai		PIO	vaı	гÀг	Leu	_	Leu	Arg	rys	Thr	_	Ala	GIĀ
			980					985					990		
			_	•• •	_	_	_					_		_	
GIÀ	Thr		Pro	HIS	Leu	Leu	_	_	ьeu	Val	Arg		_	Arg	Gin
		995					1000	)				1005	•		
					_										
Gln		_	Pro	Ala	Ser			Asp	Asn	Gly			Gly	Arg	Leu
	1010	)				1015	5				1020	)			
Ala	Gly	Leu	Ala	Pro	Ala	Glu	Gln	Glu	Ala	Leu	Leu	Leu	Asp	Val	Val
1025	5				1030	)				1035	5				1040
Arg	Thr	Gln	Val	Ala	Leu	Val	Leu	Gly	His	Ala	Gly	Pro	Glu	Ala	Val
				1045	;				1050	)				1055	

Arg Ala Asp Thr Ala Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr Ser

- 49 -

			106	0				106	5				107	0	
Val	Glu	Leu 107	_	Asn	Arg	Leu	Arg		Ala	Ser	Gly	Leu 108	_	Leu	Pro
Ala	Thr 109	Leu 0	Val	Phe	Asp	Tyr 109		Thr	Pro	Val	Ala 110		Ala	Arg	Tyr
Leu 110	_	Asp	Glu	Phe	Gly 1110	_	Thr	Val	Ala	Thr 111!		Pro	Val	Ala	Thr 1120
Ala	Ala	Ala	Ala	Asp 1125		Gly	Glu	Pro	Ile 1130		Ile	Val	Gly	Met 1135	
Cys	Arg	Leu	Pro 1140	_	Gly	Val	Thr	Asp 1145		Glu	Gly	Leu	Trp	_	Leu
Val	Arg	Asp 1155	_	Leu	Glu	Gly	Leu 1160		Pro	Phe	Pro	Glu 1169	_	Arg	Gly
Trp	Asp 1170	Leu )	Glu	Asn	Leu	Phe 1175	_	qaA	Asp	Pro	Asp 1180	_	Ser	Gly	Thr
Thr 1185	_	Thr	Ser	Arg	Gly 1190	_	Phe	Leu	Asp	Gly 1195		Gly	Leu	Phe	Asp 1200
Ala	Gly	Phe	Phe	Gly 1205		Ser	Pro	Arg		Ala )			Met	Asp 1215	
Gln	Gln	Arg	Leu 1220		Leu	Glu	Ala	Ala 1225	_	Glu	Ala	Leu	Glu 1230	_	Thr
Gly	Val	Asp 1235		Gly	Ser	Leu	Lys 1240	_	Ala	Asp	Val	Gly 1245		Phe	Ala
_	Val	Ser		Gln	_	_	_	Met	Gly		Asp		Ala	Glu	Leu

Ala 126		Tyr	Ala	Ser	Thr 1270		Gly	Ala	Ser	Ser 127		Val	Ser	Gly	Arg 1280
Val	Ser	Tyr	Val	Phe 1285		Phe	Glu	Gly	Pro 129		Val	Thr	Ile	Asp 129	
Ala	Cys	Ser	Ser 1300		Leu	Val	Ala	Met 130:		Leu	Ala	Gly	Gln 131		Leu
Arg	Gln	Gly 1315		Cys	Ser	Met	Ala 1320		Ala	Gly	Gly	Val 1325		Val	Met
Gly	Thr 1330		Gly	Thr	Phe	Val 1335		Phe	Ala	Lys	Gln 1340	_	Gly	Leu	Ala
Gly 134!		Gly	Arg	Cys	Lys 1350		Tyr	Ala	Glu	Gly 1355		Asp	Gly	Thr	Gly 1360
Trp	Ala	Glu	Gly	Val 1365		Val	Val	Val	Leu 1370		Arg	Leu	Ser	Val 1375	
Arg	Glu	Arg	Gly 1380		Arg	Val	Leu	Ala 1385		Leu	Arg	Gly	Ser 1390		Val
Asn	Ser	Asp 1395	_	Ala	Ser	Asn	Gly 1400		Thr	Ala	Pro	Asn 1405	-	Pro	Ser
Gln	Gln 1410		Val	Ile	Arg	Arg 1415		Leu	Ala	Gly	Ala 1420	_	Leu	Glu	Pro
Ser	Asp	Val	Asp	Ile	Val	Glu	Gly	His	Gly	Thr	Gly	Thr	Ala	Leu	Gly

Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Lys Asp Arg

1450

1455

1445

- 51 -

Asp Pro Glu Thr Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Phe Gly 1460 1465 1470

His Thr Gln Ser Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Gln 1475 1480 1485

Ala Leu Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Arg Pro 1490 1495 1500

Thr Ser Gln Val Asp Trp Ser Ala Gly Ala Val Glu Val Leu Thr Glu 1505 1510 1515 1520

Ala Arg Glu Trp Pro Arg Asn Gly Arg Pro Arg Arg Ala Gly Val Ser 1525 1530 1535

Ser Phe Gly Ile Ser Gly Thr Asn Ala His Leu Ile Ile Glu Glu Ala 1540 1545 1550

Pro Ala Glu Pro Gln Leu Ala Gly Pro Pro Pro Asp Gly Gly Val Val 1555 1560 1565

Pro Leu Val Val Ser Ala Arg Ser Pro Gly Ala Leu Ala Gly Gln Ala 1570 1575 1580

Arg Arg Leu Ala Thr Phe Leu Gly Asp Gly Pro Leu Ser Asp Val Ala 1585 1590 1595 1600

Gly Ala Leu Thr Ser Arg Ala Leu Phe Gly Glu Arg Ala Val Val Val 1605 1610 1615

Ala Asp Ser Ala Glu Glu Ala Arg Ala Gly Leu Gly Ala Leu Ala Arg 1620 1625 1630

7

Gly Glu Asp Ala Pro Gly Leu Val Arg Gly Arg Val Pro Ala Ser Gly 1635 1640 1645

Leu Pro Gly Lys Leu Val Tro Val Phe Pro Gly Gln Gly Thr Gln Tro

WO 98/07868

- 52 -

1650	165	55	1660	
Val Gly Met Gl	y Arg Glu Leu 1670	ı Leu Glu Glu Se	er Pro Val Phe 675	Ala Glu 1680
Arg Ile Ala G	u Cys Ala Ala 1685	Ala Leu Glu Pi 1690	co Trp Ile Gly	Trp Ser
	al Leu Arg Gly 00	Asp Gly Asp Le	eu Asp Arg Val 1710	-
Leu Gln Pro Al	a Cys Phe Ala	Val Met Val G	ly Leu Ala Ala 1725	Val Trp
Ser Ser Ala Gl 1730	y Val Val Pro 173	o Asp Ala Val Le 5	eu Gly His Ser 1740	Gln Gly
Glu Ile Ala Al 1745	a Ala Cys Val 1750	Ser Gly Ala Le	eu Ser Leu Glu 755	Asp Ala 1760
Ala Lys Val Va	l Ala Leu Arg 1765	Ser Gln Ala Il	e Ala Ala Lys.	Leu Ser 1775
	y Met Ala Ser 80	Val Ala Leu Gl 1785	y Glu Ala Asp 1790	
Ser Arg Leu Al 1795	a Asp Gly Val	Glu Val Ala Al 1800	a Val Asn Gly 1805	Pro Ala
Ser Val Val Il 1810	e Ala Gly Asp 181	Ala Gln Ala Le 5	eu Asp Glu Thr 1820	Leu Glu
Ala Leu Ser Gl 1925	y Ala Gly Ile 1830	Arg Ala Arg Ar 18	g Val Ala Val 35	Asp Tyr 1840
Ala Ser His Th	r Arg His Val	Glu Asp Ile Gl	u Asp Thr Leu	Ala Glu

1850

1855

1845

- 53 -

Ala Leu Ala Gly Ile Asp Ala Arg Ala Pro Leu Val Pro Phe Leu Ser 1860 1865 1870

Thr Leu Thr Gly Glu Trp Ile Arg Asp Glu Gly Val Val Asp Gly Gly 1875 1880 1885

Tyr Trp Tyr 1890

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53789 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GAATTCCAGG CCGTCGACGG CTGCGACATC GCGGTCTTCC GGTGGTCGCA CCGCACGAAG 60

ATCGCCGAAT AAGAATTTCC GGATCTCCCA CGGGAAAGGT TTCCATGACC GACGCAATAT 120

CCTTCGAGGT GCCGTGGGAC CGGACCGACA AGTTCGACCC GCCCGCGGTG TTCGACTCTC 180

TGCGCGAAGA ACGTCCGCTC GCGAAGATGG TTTACCCGGA TGGGCACGTC GGCTGGATCG 240

TTTCCAGCTA CGAGCTGGTC CGCGAGGTCC TCAGCGACCT GCGGTTCAGC CACAGCTGCG 300

AAGTCGGCCA CTTCCCGGTG ACCCACCAGG GCCAGGTCAT CCCGACCCAC CCGCTGATCC 360

CCGGCATGTT CATCCACATG GACCCGCCCG AGCACACGCG CTACCGCAAG CTGCTGACCG 420 GCGAGTTCAC CGTCCGCCGC GCCAGCAGGC TGATCCCGCG GGCCGAGGCC GTGGCCGCCG 480 AGCAGATCGA GGTCATGCGG GCCAAGGGCG CCCCGCGGA CGTGGTCATG GACTTCGCCA 540 ACCCCTCGT CCTCCCGATC CTCGCCGACC TCCTCGCCCT CCCCTACGAC GAACCCGACC 600 GGTACGTGCC CGCGGTGACC CTCCTGCACG ACGCCGAAGC GGACCCGGCC GAGGCCGCGG 660 CCGCCTACGA GGTGGCCGGG AAGTTCTTCG ACGAGGTCAT CGAGCGCCGC CGGCAGCGGC 720 CCCAGGACGA CCTCATCAGC TCGCTCGTCA CCGAGGACCT GACCCAGGAG GAGCTGCGCA 780 ACATCGTCAC CCTGCTGCTG TTCGCCGGGT ACGAGACCAC CGAGGGCGCG CTCGCCACCG 840 GCGTCTTCGC GCTGCTGCAC CACACCGATC AGCTGGCGGC ACTGCGCGCG GAGCCGGAAA 900 AGCTCGACGC CGCGATCGAA GAGCTGCTGC GCTACCTGAC CGTCAACCAG TACCACACCT 960 ACCGCACCGC GCTGGAGGAC GTGAAGCTGG AGGGCGAGCT GATCAAGAAG GGCGACACGG 1020 TGACGGTGTC GCTGCCCGCG GCCAACCGCG ACCCGGCCAA GTTCGGCTGT CCCGCGGAGC 1080 TCGACATCGA GCGGGACACC TCCGGCCACG TCGCGTTCGG CTTCGGCATC CACCAGTGCC 1140 TGGGCCAGAA CCTGGCGCGC ATCGAGCTGC GGGCCGGCTT CACGGCGCTC CTGCGGGCGT 1200 TCCCCGAGCT CCGCTGGCC GTCCCGGCCG ACGAGGTTCC GCTGCGGCTG AAGGGTTCCG 1260 TCTTCTCGGT GAAGAAGCTG CCCGTCTCCT GGTGAGCGTT CTTCCCCTCG AACACCCGAA 1320 AGGATCTGCG GCACAGTGCG CACCGATCTC ATCAAGCCAC TTCACGTCGC ACTCCTGGAG 1380 AACGCGACCC GCTTCGCCGG CAAGCCGGCC TTCGCCGACG ACCACCGGAC GGTCACCTAC 1440 GGCGACCTCG AGGCGCGGAC GCGCCGGCTG GCCGGGCACC TGGCCGGCCT CGGTGTCCGG 1500

PCT/EP97/04495

CACGGCGACC GGGTGGCGAT CTGCCTCGGC AACCGGGTGT CCACTGTGGA GAGTTACTTC 1560 GCGATCCTGC GCGCGGGTGC CGTCGGCGTG CCGCTCAACC CCGGTTCGGC GACGGCCGAG 1620 CTCGAGCACC CGCTGACCGA CAGCGGCGCC ACGGTGGTCG TCACCGACGC CGCCCAGGCG 1680 CCCCGCTCC GCCTCGCGC GCACGTCGAG CTGCTGGTGA CCGGCGACGA CGTCCCGGAG 1740 GGCGCCCACT CCTACGACGA ACTCGCCCTC AGCGAACCGG CCGAGCCCGC CGCGGACGAC 1800 CTCGAGCTCG ACGAGCCGGC GTGGATGTTC TACACGTCGG GCACGACCGG GCGGCCCAAG 1860 1920 GGCGTCGTGT CCACGCAGCG CAACTGCCTC TGGTCCGTCG CTTCCTGCTA CGTGCCGTTC CCCGGGTTGT CGGACCAGGA CCGGGTGCTC TGGCCGCTCC CGCTGTTCCA CAGCCTTTCG 1980 CACATCGCCT GCGTCCTGTC CGCCACCGTG GTCGGGGCCA GCGTCCGGAT CGCCGACGGC 2040 2100 AGCTCCGCCG ACGACGTGAT GCGGCTGATC GAGGCGGAGA GCTCGACCTT CCTGGCCGGC GTGCCGACCA CCTACCACCA CCTGGTGCGG GCCGCCCGGC AGCGCGGTTT CTCCGCGCCG 2160 AGCCTGCGGA TCGGCCTGGC CGGGGCGCG GTCCTCGGCG CCGGGCTGCG AAGCGAGTTC 2220 GAAGAGACCT TCGGGGTCCC GCTGATCGAC GCCTACGGCA GCACCGAGAC CTGCGGGGCG 2280 ATCACCATGA ACCCGCCGGA CGGCGCCCGC GTCGAGGGCT CGTGCGGCTT GGCCGTGCCG 2340 GGCGTCGACG TGCGGGTCGT CGACCCCGAC ACCGGGCTCG ACGTCCCCGC CGGCGAGGAG 2400 GGCGAGGTCT GGGTCAGCGG GCCGAACGTC ATGCTCGGCT ACCACAACAG CCCGGAGGCG 2460 ACCGCCGCG CGATGCGGGA CGGCTGGTTC CGGACCGGG ACCTGGCCCG CCGCGACGAC 2520 GCCGGTTACT TCACCATCTG CGGCCGGATC AAGGAACTCA TCATCCGCGG CGGCGCGAAC 2580

ATCCACCCG GCGAGGTCGA GGCGGTCCTG CGCACGGTCG ACGGCGTCGC GGACGCGCG 2640 GTCGGCGTG TGCCGCACGA CACGCTCGGC GAGGTGCCGG TCGCCTACGT CATCCCCGGA 2700 CCGACCGGTT TCGATCCTGC GGCGTTGATC GAGAAGTGCC GCGAACAGCT GTCCGCCTAC 2760 AAGGTGCCGG ACCGGATCCT CGAGGTCGCC CACATTCCCC GGACCGCGTC GGGCAAGATC 2820 CGGCGCGGC TGCTGACCGA CGAGCCCGCG CAGCTGCGGT ACGCCGCGAC CGAACACGAG 2880 GAACAGTCCC GGCACGCCGA CGAGTCCGTC GCGGCGGCGC TGCGCGCGCG ACTGTCCGGT 2940 TTGGACGAAC GCGCCCAGTG CGAGCTCCTG GAAGACCTCG TCCGCACCCA GGCGGCCGAC 3000 GTGCTGGGGC AGCCGGTCCC GGACGGGCGT GCGTTCCGCG ACCTCGGCTT CACGTCGCTG 3060 GCCATCGTGG AGCTGCGCAA CCGGCTGACC GAGCACACCG GGCTCTGGCT GCCCGCCAGC 3120 GCCGTCTTCG ACCACCCAC GCCGGCGCG CTGGCCGCCC GCGTCCGGGC TGAGCTCCTC 3180 GGGATCACGC AGGCCGTCGC GGAGCCGGTC GTCGCGGCCG ACCCGGGCGA GCCGATCGCG 3240 3300 CTGGTGGCCG AGCGCGTCGA CGCCGTTTCG GAGTTCCCCG GCGACCGCGG CTGGGACCTG 3360 GACAGCCTGA TCGACCCGGA CCGGGAGCGC GCCGGGACGT CGTACGTCGG CCAGGGCGGA 3420 TTCCTGCACG ACGCCGCGA GTTCGACGCC GGGTTCTTCG GGATCTCGCC GCGTGAGGCC 3480 CTCGCGATGG ACCCGCAGCA GCGGTTGCTG CTGGAGACGT CGTGGGAGGC CCTCGAAAAC 3540 GCCGGAGTCG ACCCGATCGC GTTGAAGGGC ACCGACACCG GCGTGTTCTC CGGCCTCATG 3600 GGCCAGGGT ACGGTCCGG CGCGGTGGCG CCGGAGCTCG AAGGTTTCGT CACCACCGGG 3660 GTCGCGTCGA GCGTGGCCTC GGGCCGGGTG TCGTACGTGC TGGGACTGGA AGGCCCGGCG 3720

GTCACCGTGG ACACCGCGTG TTCGTCGTCG CTGGTCGCGA TGCACCTGGC CGCGCAGGCC 3780 CTGCGGCAGG GCGAATGCTC GATGGCGCTC GCCGGCGGG TCACGGTGAT GGCCACGCCG 3840 GGCTCGTTCG TCGAGTTCTC CCGCCAGCGG GCCCTGGCGC CCGACGGGCG CTGCAAGGCC 3900 TTCGCGCGG CGCCGACGG GACCGGCTGG TCCGAGGGTG TCGGCGTGGT CGTCCTCGAG 3960 CGGCTGTCCG TGGCGCGCGA GCGGGGCCAC CGGATCCTGG CCGTTTTGCG TGGCAGCGCG 4020 CTCAACCAGG ACGCCCGTC CAACGGCCTC ACCGCCCGA ACGGCCTCTC GCAGCAGCGG 4080 GTCATCCGCC GCGCGCTGGC CGCGCCGGG CTGGCACCGT CCGATGTGGA CGTCGTCGAG 4140 CCGCACGCA CCGCGACCAC GCTGGGTGAC CCGATCGAGG CGCAGGCCCT GCTGGCGACC 4200 TACGGCCAGG AGCGGAAGCA GCCGTTGTGG CTCGGTTCGC TCAAGTCGAA CATCGGCCAC 4260 CCCCAGCCG CCCCGCCCT TCCGGCCTC ATCAAGATGG TCCAGGCGCT GCGCCACGAG 4320 ACCTTGCCGC CGACGCTGCA TGTCGACAAG CCGACTCTTG AGGTGGACTG GTCCGCCGGT 4380 GCCATTGAAC TGCTGACGGA GGCCCGTGCG TGGCCGCGCA ACGGCCGTCC GCGCCGGGCC 4440 GGGGTGTCGT CGTTCGGCGT CAGCGGGACC AACGCGCACC TGATCCTGGA GGAGGCGCCG 4500 GCCGAGGAGC CGGTCGCTGC CCCGGAACTG CCGGTGGTGC CCCTGGTGGT GTCGGCGCGG 4560 AGCACGGAGT CGCTGTCCGG GCAGGCCGAG CGGCTGGCGT CCCTCCTCGA AGGGGACGTC 4620 TCCCTGACCG AGGTGGCCGG GGCGCTGGTG TCCCGCCGGG CGGTGCTGGA CGAGCGGGCC 4680 GTCGTCGTGG CCGGTTCGCG CGAGGAAGCC GTGACCGGGC TGCGGGCGCT GAACACGGCC 4740 4800 GGTTCGGGGA CGCCGGCAA GGTCGTGTGG GTGTTCCCGG GGCAGGGGAC GCAGTGGGCC

GGGATGGGCC	GTGAGCTGCT	GGCCGAGTCC	CCGGTGTTCG	CCGAGCGGAT	CGCCGAGTGC	4860
GCGGCCGCGT	TGGCGCCGTG	GATCGACTGG	TCGCTCGTCG	ACGTCCTGCG	CGGCGAGGGC	4920
GACCTGGGTC	GGGTCGATGT	GCTGCAGCCG	GCCTGTTTCG	CGGTGATGGT	CGGGCTGGCT	4980
GCCGTCTGGG	AGTCCGTGGG	GGTCCGGCCG	GACGCCGTCG	TCGGGCACTC	GCAGGGTGAG	5040
ATCGCGGCTG	CCTGCGTTTC	GGGGGCGTTG	TCCCTCGAGG	ACGCGGCGAA	GGTGGTGGCC	5100
CTGCGCAGCC	AGGCCATCGC	GGCGGAACTG	TCCGGCCGCG	GCGGGATGGC	GTCGGTCGCC	5160
CTGGGCGAGG	ACGACGTCGT	TTCGCGGCTG	GTGGACGGG	TCGAGGTCGC	CGCCGTCAAC	5220
GGCCCGTCGT	CGGTGGTGAT	CGCCGGGGAT	GCCCATGCCC	TCGACGCGAC	CCTGGAAATC	5280
TTGTCCGGGG	AAGGCATCCG	GGTTCGGCGG	GTGGCGGTGG	ACTACGCCTC	GCACACCCGG	5340
CATGTCGAGG	ACATCCGCGA	CACTCTTGCC	GAAACCTTGG	CCGGGATCAG	TGCGCAGGCG	5400
CCGGCTGTGC	CGTTCTACTC	CACCGTCACG	AGCGAGTGGG	TGCGCGACGC	GGGGTGCTG	5460
GACGGCGGCT	ACTGGTACCG	GAACCTGCGC	AACCAGGTCC	GGTTCGGAGC	GCCCCCACG	5520
GCCCTGCTCG	AGCAGGGCCA	CACGGTGTTC	GTCGAGGTCA	GTGCGCACCC	GGTGACGGTC	5580
CAGCCCTTGA	GCGAGCTCAC	CGGGGACGCG	ATCGGGACAT	TGCGGCGTGA	AGACGGTGGC	5640
CTGCGGCGGT	TGCTGGCTTC	GATGGGTGAG	CTGTTCGTCC	GCGGCATCGA	CGTGGACTGG	5700
ACGGCGATGG	TGCCCGCGGC	CGGCTGGGTC	GACTTGCCGA	CCTACGCGTT	CGAACACCGG	5760
CACTACTGGC	TCGAGCCCGC	CGAGCCCGCT	TCGGCCGGAG	ACCCGCTGCT	GGGCACAGTC	5820
GTCAGCACTC	CCGGTTCGGA	CCGACTCACC	GCCGTGGCGC	AGTGGTCGCG	CCGGGCGCAG	5880
CCCTGGGCGG	TGGACGGCCT	GGTGCCGAAC	GCGGCCCTGG	TCGAGGCGGC	CATCCGGCTC	5940

GGCGACCTGG CCGCCACCCC CGTCGTCGGC GAACTGGTCG TCGACGCGCC GGTGGTGCTG 6000 CCGCGCGCG GCAGCCGCGA GGTCCAGCTG ATCGTCGGCG AGCCCGGCGA GCAGCGGCGG 6060 CGTCCGATCG AGGTCTTTTC CCGGGAAGCC GACGAGCCGT GGACGCGGCA CGCGCACGGC 6120 ACACTCGCTC CCGCCGCCGC TGCGGTGCCA GAACCGGCGG CGGCGGGAGA CGCCACCGAC 6180 GTCACCGTGG CCGCCTGCG CGACGCGGAC CGGTACGGGA TCCACCCCGC GCTGCTGGAC 6240 GCCGCCGTCC GCACGGTCGT CGGCGACGAC CTGCTCCCGT CGGTGTGGAC CGGCGTGTCC 6300 CTGCTGGCCT CCGGGGCCAC GGCCGTGACC GTGACGCCGA CGGCGACCGG CCTGCGGCTG 6360 ACCGACCCGG CCGGCCAGCC CGTCCTGACC GTCGAATCCG TCCGCGCAC GCCGTTCGTC 6420 GCCGAGCAGG GGACCACCGA CGCGCTCTTC CGCGTCGACT GGCCGGAAAT CCCGCTGCCC 6480 ACCGCCGAAA CCGCGGACTT CCTGCCGTAC GAAGCCACGT CGGCCGAGGC GACCCTCTCC 6540 GCGCTCCAGG CCTGGCTGGC AGACCCCGCG GAAACCCGGC TGGCCGTGGT CACCGGGGAC 6600 TGCACCGAAC CCGCCCGCC CGCGATCTGG GGCCTGGTGC GCTCGGCGCA GTCCGAACAC 6660 CCCGGCCGGA TCGTGCTGGC CGACCTCGAC GACCCCGCCG TGCTGCCCGC CGTGGTGGCG 6720 AGCGGCGAAC CGCAGGTGCG GGTGCGCAAC GGCGTCGCCT CGGTGCCGCG CTTGACCCGG 6780 GTTACTCCCC GGCAGGACGC GCGCCCGCTC GACCCCGAGG GCACCGTCCT GATCACCGGC 6840 GGCACCGGCA CGCTCGGTGC GCTGACCGCC CGGCACCTCG TCACCGCGCA CGGCGTCCGG 6900 CACCTGGTGC TGGTCAGCCG CCGCGGTGAG GCTCCCGAGC TGCAGGAAGA ACTGACCGCA 6960 CTGGGGGCAT CCGTCGCCAT CGCCGCCTGC GACGTGGCAG ACCGGGCGCA GCTCGAAGCC 7020

GTCTTGCGCG	CGATCCCGGC	CGAGCACCCG	CTCACCGCCG	TGATCCACAC	CCCGGGGGTC	7080
CTCGACGACG	GCGTCGTCAC	CGAGCTGACC	CCGGACCGGC	TCGCCACCGT	GCGGCGGCCG	7140
AAGGTCGACG	CCGCCCGGCT	CCTGGACGAG	CTCACCCGGG	AGGCCGATCT	CGCCGCGTTC	7200
GTGCTGTTCT	CCTCGGCGGC	GGGTGTGCTG	GGCAACCCCG	GCCAGGCCGG	GTACGCCGCC	7260
GCCAACGCCG	AGCTGGATGC	GTTGGCGCGC	CAGCGGAACA	GCCTCGACCT	GCCCGCGGTG	7320
TCCATCGCAT	GGGGCTACTG	GGCGACGGTC	AGCGGGATGA	CCGAGCACCT	GGGCGACGCC	7380
GACCTGCGGC	GCAACCAGCG	GATCGGCATG	TCCGGGCTTC	CCGCCGACGA	GGGCATGGCG	7440
CTGCTGGACG	CCGCCATCGC	CACCGGTGGC	ACGCTGGTCG	CGGCCAAGTT	CGACGTCGCC	7500
GCGCTGCGGG	CGACGCCGAA	GGCCGGCGGC	CCGGTGCCGC	CGCTGCTGCG	TGGCCTGGCC	7560
CCGCTGCCGC	GCCGGGCGGC	GGCCAAGACC	GCGTCGCTGA	CCGAACGCCT	CGCCGGGCTG	7620
GCCGAGACCG	AGCAGGCCGC	GGCCCTGCTC	GACCTGGTCC	GGCGGCACGC	CGCCGAGGTG	7680
CTCGGGCACA	GCGGCGCCGA	ATCCGTCCAT	TCAGGACGGA	CGTTCAAGGA	CGCCGGCTTC	7740
GACTCGCTGA	CCGCGGTGGA	ACTGCGGAAC	CGCCTCGCGG	CCGCGACCGG	GCTCACCCTG	7800
TCCCCGGCGA	TGATCTTCGA	CTACCCGAAG	ccccccccc	TCGCGGACCA	CCTGCGCGCC	7860
AAGCTCTTCG	GATCGGCGGC	GAACCGCCCG	GCCGAGATCG	GCACCGCCGC	GGCCGAGGAG	7920
CCGATCGCGA	TCGTCGCGAT	GGCGTGCCGC	TTCCCCGGTG	GCGTGCACAG	CCCCGAGGAC	7980
CTGTGGCGGC	TGGTCGCCGA	CGGCGCCGAC	GCCGTCACCG	AGTTCCCCGC	CGACCGCGC	6040
TGGGACACCG	ACCGGCTCTA	CCACGAAGAC	CCCGACCACG	AAGGCACGAC	GTACGTCCGG	8100
CACGCGCCCT	TCCTCGACGA	CGCCGCCGGG	TTCGACGCCG	CCTTCTTCGG	CATCTCGCCG	8160

AACGAGGCGC	TCGCCATGGA	CCCGCAGCAG	CGGCTGCTGC	TGGAGACGTC	CTGGGAGCTG	8220
TTCGAGCGGG	CCGCGATCGA	CCCGACCACG	CTGGCCGGCC	AGGACATCGG	CGTCTTCGCC	8280
GGCGTCAACA	GCCACGACTA	CAGCATGCGG	ATGCACCGGG	CCGCCGGTGT	CGAGGGCTTC	8340
CGGCTCACCG	GCGGTTCGGC	CAGCGTGCTC	TCCGGCCGCG	TCGCCTACCA	CTTCGGCGTC	8400
GAAGGCCCGG	CCGTCACGGT	CGACACGGCC	TGCTCGTCTT	CGCTGGTCGC	GCTGCACATG	8460
GCGGTGCAGG	CCCTGCAGCG	CGGCGAGTGC	TCCATGGCGC	TCGCGGGCGG	CGTGATGGTG	8520
ATGGGCACGG	TCGAGACGTT	CGTCGAGTTC	TCGCGGCAGC	GCGGGCTGGC	CCCCGACGGC	8580
CGCTGCAAGG	CGTTCGCCGA	CGGCGCGGAC	GGCACCGGCT	GGTCCGAGGG	CGTCGGGCTG	8640
CTCCTGGTGG	AGCGGCTGTC	CGAGGCTCAG	CGTCGCGGGC	ACCAGGTCCT	CGCCGTGGTC	8700
CGCGGGTCGG	CGGTCAACTC	CGACGCGCG	TCGAACGCCT	TGACGGCCCC	GAACGCCCG	8760
TCCCAGCAGC	GCGTGATCCG	CAAGGCACTG	ecceccecee	GACTGTCCAC	ATCGGACGTC	8820
GACGCGGTGG	AGGCGCACGG	CACCGGGACG	ACCCTGGGCG	ACCCGATCGA	GGCCGAGGCG	8880
CTGCTGGCCA	CCTACGGCCA	GAACCGGGAA	ACGCCGCTGT	CCCTCCCCTC	GGTGAAGTCG	8940
AACCTCGGGC	ACACGCAGGC	GGCTGCGGGT	GTCGCAGGCG	TGATCAAGAT	GGTCATGGCC	9000
ATGCGCCACG	GCGTCCTGCC	CCGGACGCTG	CACGTCGACC	GGCCGTCGTC	CTATGTGGAC	9060
TGGTCGGCCG	GTGCGGTCGA	GCTGCTGACC	GAGGCACGGG	ACTGGGTGAG	CAACGGCCAC	9120
cccccccc	CGGGCGTGTC	GTCGTTCGGC	ATCGGCGGCA	CCAACGCGCA	CGTCGTCCTC	9180
GAAGAGGTTG	CCGCACCGAT	CACCACGCCG	CAGCCTGAGC	CGGCCGAGTT	CCTGGTGCCG	9240

GTGCTCGTCT CCGCGCGGAC GGCGGCGGGT CTGCGCGGGCC AGGCCGGACG GCTCGCCGCG 9300 TTCCTCGGCG ACCGGACCGA CGTCCGCGTC CCCGATGCCG CCTACGCACT GGCCACCACG 9360 CGCGCCCAGC TCGACCACCG GGCCGTCGTC CTGGCCTCCG ACCGGGCACA GCTCTGCGCG 9420 GACCTTGCCG CGTTCGGCTC CGGCGTCGTG ACCGGAACGC CGGTTGACGG CAAGCTGGCC 9480 GTGCTCTTCA CCGGCCAGGG CAGCCAGTGG GCCGGGATGG GCCGTGAACT CGCCGAGACG 9540 TTCCCGGTCT TCCGCGACGC CTTCGAGGCC GCGTGCGAGG CCGTGGACAC GCACCTGCGT 9600 GAGCGTCCGC TGCGCGAGGT CGTGTTCGAC GACAGCGCGC TGCTCGACCA GACGATGTAC 9660 ACCCAGGGCG CCCTGTTCGC CGTGGAGACC GCGTTGTTCC GGCTCTTCGA GTCCTGGGGT 9720 GTGCGGCCGG GTCTCCTCGC CGGTCACTCG ATCGGCGAGC TCGCCGCCGC GCACGTGTCC 9780 GGCGTGCTGG ACCTGGCCGA CGCGGGCGAG CTGGTCGCCG CGCGGGCCG GCTGATGCAG 9840 GCCCTGCCCG CGGGCGCCC GATGGTCGCC GTCCAGGCGA CCGAGGACGA AGTCGCGCCC 9900 CTGCTCGACG GCACGGTCTG CGTCGCCGCG GTCAACGGTC CGGACTCGGT GGTGCTCTCC 9960 GGCACCGAAG CCGCCGTGCT CGCCGTCGCG GATGAACTGG CTGGTCGCGG CCGTAAGACC 10020 CGACGGCTGG CCGTGAGCCA CGCCTTCCAC TCGCCGCTCA TGGAACCGAT GCTCGACGAC 10080 TTCCGCGCGG TCGCCGAACG CCTGACGTAC CGGGCCGGTT CGCTGCCCGT CGTCTCGACG 10140 CTGACCGGGG AACTCGCGGC GCTCGACAGC CCGGACTACT GGGTCGGCCA GGTGCGCAAC 10200 GCCGTGCGGT TCAGCGACGC CGTCACCGCG CTGGGCGCCC AAGGCGCGTC GACGTTCCTC 10260 GAGCTCGGCC CGGGCGGTGC GCTCGCCGCG ATGGCGCTCG GCACGCTCGG CGGACCCGAG 10320 CAGAGCTGCG TCGCGACCCT GCGCAAGAAC GGCGCCGAGG TGCCCGACGT CCTCACCGCG 10380

CTCGCCGAAC TGCACGTCC	G GGGCGTGGGC	GTCGACTGGA	CGACCGTGCT	CGACGAACCG	10440
GCCACGGCGG TCGGGACCG	T CCTGCCCACC	TACGCGTTCC	AGCACCAGCG	CTTCTGGGTC	10500
GACGTCGACG AAACAGCGG	C CGTCAGCGTC	ACCCCCCCCC	CGGCGGAGCC	GATCGTGGAC	10560
CGGCCGGTGC AGGACGTGC	T GGAGCTGGTC	CGGGAGAGCG	CCGCGGTGGT	GCTCGGGCAC	10620
CGGGACGCCG GCAGTTTCG	A CCTCGACCGG	TCCTTCAAGG	ACCACGGCTT	CGACTCGCTC	10680
AGCGCGGTCA AGCTGCGCA	A CCGTCTGCGC	GACTTCACCG	GCGTGGAGCT	GCCCAGCACC	10740
CTGATCTTCG ACTACCCGA	A CCCGGCCGTC	CTCGCGGACC	ACCTGCGGGC	CGAACTGCTC	10800
GGCGAGCGCC CGGCCGCGC	C GGCCCCGGTG	ACGAGGGACG	TCTCCGACGA	GCCGATCGCG	10860
ATCGTCGGCA TGAGCACCC	G GCTGCCGGGT	GGCGCCGACA	GCCCCGAAGA	GCTGTGGAAG	10920
CTCGTCGCGG AGGGACGGG	A CGCCGTGTCC	GCCTTCCCCG	TCGACCGCGG	CTGGGACCTC	10980
GACGGCCTCT ACCACCCGG	A CCCCGCCCAC	GCCGGGACGA	GCTACACGCG	TTCGGGCGGC	11040
TTCCTGCACG ACGCGGCCC	A GTTCGACGCC	GGGCTCTTCG	GGATCTCACC	GCGTGAGGCC	11100
CTGGCCATGG ACCCGCAGC	A GCGGCTGCTG	CTGGAGACGT	CGTGGGAAGC	CTTGGAGCGC	11160
GCGGGGTCG ACCCGCTGT	C CCCCCCCCCCC	AGCGACGTCG	GCGTCTTCAC	CGGGATCGTC	11220
CACCACGACT ACGTGACGC	G GCTGCGCGAA	GTGCCCGAAG	ACGTCCAGGG	CTACACGATG	11280
ACCGGCACGG CTTCGAGCG	r ggcgtcgggc	CGGGTGGCGT	ACGTCTTCGG	CTTCGAGGGC	11340
CCGCCGTCA CCGTGGACA	CCCCTCTTCC	TCGTCGCTGG	TCGCGATGCA	CCTGGCGGCG	11400
CAGGCGCTGC GGCAGGGGG	A GTGCTCGATG	GCCCTGGCCG	GCGCGCGAC	CGTGATGGCC	11460

AGCCCGGACG	CCTTCCTCGA	GTTCTCCCGC	CAGCGCGGCC	TGTCCGCGGA	CGCCGGTGC	11520
AAGGCGTACG	CGGAAGGCGC	GGACGGCACG	GGCTGGGCCG	AGGGCGTCGG	TGTCGTCGTC	11580
CTCGAACGGC	TTTCGGTGGC	ACGCGAACGT	GGCCACCGGG	TGCTGGCGGT	CCTGCGCGGC	11640
AGCGCGGTGA	ACCAGGACGG	TGCTTCCAAC	GGCCTGACCG	CCCCGAACGG	GCCGTCGCAG	11700
CAGCGGGTGA	TCCGCGGCGC	GCTGGCGAGC	GCCGGGCTGG	CACCGTCCGA	TGTGGACGTC	11760
GTGGAGGGCC	ACGGGACCGG	GACCGCGCTG	GGTGACCCGA	TCGAGGTCCA	GGCGCTGCTG	11820
GCCACCTACG	GGCAGGAGCG	GGAACAGCCG	TTGTGGCTCG	GCTCGCTGAA	GTCGAACCTC	11880
GGGCACACGC	AGGCCGCGGC	CGGGGTCGTG	GGCGTGATCA	AGATGATCAT	GGCCATGCGC	11940
CACGGCGTCA	TGCCGGCCAC	GCTGCACGTC	GACGAGCGCA	CGAGCCAGGT	CGACTGGTCG	12000
GCGGGCGCGA	TCGAGGTGTT	GACCGAGGCC	CGGGAGTGGC	CGCGCACCGG	ACGTCCGCGC	12060
ceeecceee	TGTCCTCCTT	CGGCGCCAGC	GGCACCAACG	CGCACCTGAT	CATCGAGGAA	12120
GGTCCCGCCG	AAGAGGCCGT	GGACGAAGAG	GTGGCCTCCG	TGGTGCCGCT	GGTCGTCTCC	12180
GCCCGCAGCG	CCGGTTCGCT	GGCCGGGCAG	GCCGGGCGCC	TGGCCGCGGT	CCTCGAGAAC	12240
GAATCGTTGG	CCGGGGTGGC	CGGTGCCCTG	GTTTCCGGCC	GCGCGACGCT	GAACGAGCGC	12300
GCGGTCGTCA	TCGCGGGCTC	CCGCGACGAG	GCCCAGGACG	GCCTGCAGGC	ACTGGCCCGC	12360
GGCGAGAACG	CGCCCGGCGT	CGTGACCGGG	ACGGCGGGCA	AGCCGGGCAA	GGTCGTCTGG	12420
GTCTTCCCCG	GCCAGGGCTC	GCAGTGGATG	GGCATGGGCC	GGGACCTCCT	GGACTCCTCG	12480
CCGGTGTTCG	CCGCGCGGAT	CAAGGAATGC	GCTGCGGCAC	TGGAACAGTG	GACCGACTGG	12540
TCGCTGCTGG	ACGTGCTGCG	CGGCGACGCC	GACCTGCTGG	ACCGGGTCGA	CGTGGTGCAG	12600

CCGGCCAGCT TCGCGATGAT GGTCGGGCTC GCCGCGGTGT GGACCTCGCT GGGGGTGACC 12660 CCGGATCCGG TGCTCGGCCA CTCCCAGGCC GAGATCGCCG CGGCGTGCGT GTCCGGCGCG 12720 CTGTCGCTGG ACGACGCGGC GAAGGTGGTC GCGTTGCGCA GCCAGGCGAT CGCGGGGGAG 12780 CTGGCGGGCC GCGGCGGGAT GGCGTCGGTC GCACTGAGCG AAGAGGACGC AGTCGCGCGG 12840 CTGACGCCGT GGGCGAACCG GGTCGAGGTG GCCGCGGTCA ACAGCCCGTC CTCGGTCGTC 12900 ATCGCGGAG ACGCGCAGGC CCTCGACGAA GCCCTCGAAG CCCTGGCCGG CGACGGTGTC 12960 CGGGTCCGGC GGGTCGCGGT GGACTACGCC TCCCACACCC GGCACGTCGA GGCGATCGCC 13020 GAAACCCTGG CCAAGACCTT GGCCGGGATC GACGCGCGGG TTCCGGCGAT TCCGTTCTAT 13080 TCCACCGTCC TGGGCACGTG GATCGAGCAG GCCGTCGTCG ACGCGGGCTA CTGGTACCGG 13140 AACCTGCGGC AGCAGGTGCG GTTCGGCCCC TCGGTGGCGG ACCTGGCCGG GCTGGGGCAC 13200 ACCCTGTTCG TGGAGATCAG CGCCCACCCG GTCCTGGTCC AGCCGCTGAG CGAGATCAGC 13260 GACGACGCG TEGTGACCGG GTCGCTGCGG CGGGACGACG GGGGACTGCG GCGCCTGCTG 13320 GCGTCGGCGG CCGAACTGTA CGTCCGGGGC GTGGCCGTGG ACTGGACGGC GGCCGTGCCC 13380 CCGCCCGCT GGGTGGACCT GCCGACGTAC GCCTTCGACC GCCGCCACTT CTGGCTGCAC 13440 GAAGCCGAGA CCGCCGAAGC CGCCGAGGGC ATGGACGGCG AGTTCTGGAC GGCGATCGAA 13500 CASTCCGATE TEGACAGCTT GCCCGAGCTG CTCGAGCTGG TGCCGGAGCA GCGCGGGCG 13560 CTCAGCACCG TCGTGCCCGT GCTGGCGCAG TGGCGGGACC GGCGCCGCGA GCGCTCGACC 13620 GCGGAGAAGC TGCGCTACCA GGTCACCTGG CAGCCCCTGG AGCGCGAAGC CGCCGGCGTG 13680

cceeccecc	GCTGGCTGGC	CGTCGTCCCG	GCCGGCACCA	CCGACGCGCT	CCTGAAGGAG	13740
CTGACCGGCC	AGGGACTCGA	CATCGTCCGG	CTGGAGATCG	AGGAAGCTTC	GCGGGCACAG	13800
CTCGCCGAGC	AGCTGCGGAA	CGTCCTGGCG	GAGCACGACC	TCACCGGCGT	GCTGTCGCTG	13860
CTCGCTCTCG	ACGGCGGCCC	CGCGGACGCG	GCCGAGATCA	CCGCGTCGAC	GCTCGCGCTG	13920
GTCCAGGCCC	TGGGCGACAC	CACCACGTCC	GCGCCGCTGT	GGTGCCTCAC	TTCCGGCGCG	13980
GTGAACATCG	GCATCCAGGA	CGCCGTGACC	GCACCGGCCC	AGGCGGCCGT	GTGGGGGCTC	14040
GGCCGGGCCG	TCGCGCTGGA	GCGCCTCGAC	CGGTGGGCCG	GCCTGGTCGA	CTTGCCCGCC	14100
GCGATCGACG	CCCGCACGGC	TCAGGCCCTG	CTCGGCGTCC	TGAACGGCGC	CGCCGGGGAA	14160
GACCAGCTCG	CGGTCCGGCG	CTCGGGCGTC	TACCGCAGGC	GGCTGGTCCG	CAAGCCCGTG	14220
CCGGAGTCCG	CGACGAGCCG	GTGGGAACCC	CGCGGCACGG	TCCTGGTGAC	CGGTGGGGCC	14280
GAAGGACTCG	GCCGGCACGC	CTCGGTCTGG	CTCGCGCAGT	CCGGCGCCGA	ACGGCTCATC	14340
GTCACCGGCA	CCGACGCGT	CGACGAACTG	ACGGCCGAGC	TGGCCGAGTT	CGGCACCACG	14400
GTCGAGTTCT	GCGCCGACAC	CGACCGGGAC	GCGATCGCGC	AGCTGGTGGC	GGACTCGGAG	14460
GTCACCGCCG	TGGTGCACGC	CGCGGACATC	GCGCAGACCA	GCTCCGTCGA	CGACACCGGC	14520
GTGGCCGACC	TCGACGAGGT	GTTCGCCGCG	AAGGTGACCA	CCGCGGTGTG	GCTGGACCAG	14580
CTGTTCGAGG	ACACCCCGCT	CGACGCGTTC	GTCGTGTTCT	CCTCGATCGC	CGGCATCTGG	14640
GGCGGTGGCG	GGCAGGGCCC	GGCGGGTGCG	GCGAACGCCG	TCCTCGACGC	CCTGGTCGAA	14700
TGGCGCCGGG	CCCGCGGCCT	CAAGGCGACG	TCGATCGCCT	GGGGCGCGCT	CGACCAGATC	14760
GGCATCGGCA	TGGACGAGGC	CGCCCTCGCC	CAGCTGCGCC	GCCGCGGTGT	CATCCCGATG	14820

GCGCCGCCGC TGGCGGTCAC CGCGATGGTG CAGGCGGTCG CCGCCAACGA GAAGGCCGTG 14880 GCGGTGCCG ACATGGACTG GGCCGCCTTC ATCCCGGCGT TCACCTCGGT CCGGCCCAGC 14940 CCGCTGTTCG CCGATCTGCC CGAGGCGAAG GCCATCCTCC GGGCGCGCA GGACGACGGC 15000 GAAGACGCC ACACCCCTC GTCGCTCGCG GACTCCCTGC GCGCGGTCCC CGACGCCGAG 15060 CAGAACCGCA TCCTGCTGAA GCTGGTCCGC GGCCACGCTT CGACGGTGCT CGGCCACAGC 15120 GGCGCCGAAG GCATCGGCCC GCGCCAGGCG TTCCAGGAGG TCGGCTTCGA CTCGCTGGCC 15180 GCGGTCAACC TCCGCAACAG CCTGCACGCG GCCACCGGGC TGCGGCTGCC CGCGACGCTG 15240 ATCTTCGACT ACCCCACCC GGAGGCGCTG GTCGGCTACC TGCGCGTCGA ACTCCTGCGG 15300 GAGGCCGACG ACGGCCTGGA CGGGCGGGAA GACGACCTCC GGCGAGTCCT CGCGGCCGTG 15360 CCGTTCGCCC GGTTCAAGGA GGCGGGCGTG CTGGACACGC TGCTCGGCCT CGCCGACACC 15420 GGCACCGAAC CGGGCACGGA CGCCGAGACC ACCGAAGCGG CCCCGGCCGC CGACGACGCA 15480 GAACTGATCG ACGCACTGGA CATCTCCGGT CTCGTGCAAC GAGCCCTCGG GCAGACGAGC 15540 TGACCGCCGA TGGCGAACCA ATCGTGGAGG AAGAACATGT CCGCGCCGAA CGAGCAGATC 15600 GTTGACGCAC TGCGCGCGTC GCTGAAGGAG AACGTCCGGC TTCAGCAGGA GAACAGCGCG 15660 CTCGCCGCGG CCGCCGCGA GCCCGTCGCG ATCGTCTCCA TGGCCTGCCG CTACGCGGGC 15720 GGGATCCGCG GCCCGGAGGA CTTCTGGCGG GTGGTGTCGG AAGGCGCCGA CGTCTACACC 15780 GGCTTCCCCG AGGACCGCGG CTGGGACGTC GAAGGCCTCT ACCACCCGGA CCCCGACAAC 15840 CCCGGCACGA CGTACGTGCG GGAGGGCGCC TTCCTGCAGG ACGCGGCCCA GTTCGACGCC 15900

GGGTTCTTCG GCATCTCGCC GCGCGAGGCG CTGGCCATGG ACCCCCAGCA GCGGCAGCTC 15960 CTGGAGGTGT CCTGGGAGAC CTTGGAACGG GCCGCATCG ACCCGCATTC GGTGCGGGGC 16020 AGCGACATCG GCGTCTACGC CGGGGTCGTG CACCAGGACT ACGCCCCCGA CCTCAGCGGG 16080 TTCGAAGGCT TCATGAGCCT GGAGCGCGCC CTGGGCACCG CGGGCGGTGT CGCCTCCGGC 16140 CGGGTCGCCT ACACGCTCGG GCTCGAAGGC CCCGCCGTCA CCGTCGACAC GATGTGCTCG 16200 TCGTCGCTGG TGGCGATTCA CCTTGCCGCG CAAGCTCTTC GCCGTGGTGA GTGCTCGATG 16260 GCCCTCGCGG GCGGCTCGAC CGTGATGGCG ACCCCGGGCG GGTTCGTCGG CTTCGCGCGT 16320 CAGCGGCGT TGGCCTTCGA CGGGCGCTGC AAGTCCTACG CCGCGGCCGC CGACGGTTCC 16380 GSCTGGCCG AGGCGTCGG CGTGCTGCTG CTGGAGCGC TGTCGGTGGC GCGCGAGCGC 16440 GGGCACCAGG TGCTGGCCGT CATCCGCGGC AGCGCGGTCA ACCAGGACGG CGCTTCCAAC 16500 GGCCTGACCG CGCCCAACGG CCCGCGCGCAG CAGCGGGTCA TCCGCAAGGC ACTGGCGAGC 16560 GCCGGCTGA CACCGTCCGA TGTGGACACC GTGGAGGCCC ACGGCACCGG CACCGTCCTC 16620 GCCGACCCGA TCGAGGTCCA GCCGCTGCTG GCCACCTACG GCCAGGGCCG CGACCCGCAG 16680 CAACCGCTGT GGCTGGGCTC GGTCAAGTCC GTCGTCGGGC ACACGCAGGC GGCATCCGGT 16740 GTGGCCGGCG TGATCAAGAT GGTCCAGTCG CTGCGGCACG GGCAGCTCCC GGCGACCCAG 16800 CACGTCGACG CGCCCACGCC GCAAGTGGAC TGGTCGGCCG GAGCGATCGA GCTGCTGGCC 16860 GAGGGCCGGG AGTGGCCGCG CAACGGCCAC CCGCGCCGGG GCGGCATCTC GTCGTTCGGG 16920 CCCAGCGCA CGAACGCGCA CATGATCCTC GAAGAAGCGC CCGAGGACGA GCCGGTGACC 16980 GAAGCGCCGG CGCCCACGGG TGTCGTACCG CTGGTGGTGT CGGCGGCGAC CGCTGCTTCC 17040

- 69 -

CTGGCCGCCC AGGCCGGTCG GCTGGCGGAG GTCGGCGACG TCTCCCTGGC GGATGTCGCC 17100 GGGACGCTGG TGTCCGGCCG CGCGATGCTC AGCGAGCGCG CGGTCGTCGT GGCCGGCTCC 17160 CACGAGAGA CCGTGACCGG GCTGCGGGCG CTGGCCCGCG GCGAGAGCGC GCCCGGCCTG 17220 CTTTCCGGCC GCGCCTCGGG GGTCCCGGGC AAGGTCGTCT GGGTGTTCCC CGGCCAGGGC 17280 ACGCAGTGGG CCGCCATGGG CCGCGAGCTG CTGGACTCCT CGGAGGTGTT CGCCGCGCGG 17340 ATCGCCGAGT GCGAGACCGC GCTCGGGCGG TGGGTCGACT GGTCGCTGAC CGACGTGCTG 17400 CGCGGCGAGG CCGACCTGCT GGACCGGGTC GACGTGGTGC AACCGGCGAG CTTCGCCGTG 17460 ATGGTCGGCC TTGCCGCCGT CTGGGCCTCC CTCGGCGTCG AGCCCGAGGC CGTGGTGGGC 17520 CACTCGCAGG GCGAGATCGC GGCCGCATGC GTGTCCGGGG CACTGTCCCT GGAGGACGCG 17580 CCGAAGGTCG TGCCGTTGCG CAGCCAGCCG ATCGCCGCCT CGCTGGCCGG CCGGGGCGGC 17640 ATGCCGTCGG TCGCGTTGAG CGAAGAAGAC GCGACCGCGC GGCTCGAGCC GTGGGCGGGC 17700 CGCGTGGAGG TCGCCGCCGT CAACGGGCCG ACGTCCGTGG TGATCGCCGG GGACGCCGAG 17760 GCGCTGGACG AAGCCCTCGA CGCGCTCGAC GACCAAGGCG TCCGGATCCG GCGGGTGGCG 17820 GTGGACTACG CCTCCCACAC CCGGCACGTC GAAGCCGCGC GCGACGCACT GGCCGAGATG 17880 CTGGGCGGGA TCCGCGCGCA GGCGCCGGAA GTGCCGTTCT ACTCGACCGT GACCGGCGGC 17940 TEGGTCGAAG ACGCCGCGT GCTCGACGC GGCTACTGGT ACCGGAACCT CCGCCGTCAG 18000 GTGCGGTTCG GCCCGCCGT GGCCGAGCTG ATCGAGCAGG GCCACCGGGT GTTCGTCGAG 18060 GTCAGCGCG ATCCCGTGCT GGTTCAGCCG ATCAACGAAC TCGTCGACGA CACCGAAGCC 18120

## WO 98/07868 PCT/EP97/04495 - 70 -

GTGGTCACCG	GGACGCTGCG	GCGCGAGGAC	GCCGCCTCC	GGCGCCTGCT	GGCCTCGGCG	18180
GCCGAGCTCT	TCGTCCGCGG	CGTGACCGTG	GACTGGTCCG	GTGTGCTGCC	ACCGTCCCGC	18240
CGGGTCGAGC	TGCCGACGTA	CGCCTTCGAC	CACCAGCACT	ACTGGCTGCA	GATGGGCGGG	18300
TCGGCCACCG	ACGCCGTGTC	GCTGGGCCTG	GCCGGCGCCG	ACCACCCGCT	GCTGGGCGCG	18360
GTCGTCCCGC	TGCCGCAGTC	CGACGGGCTC	GTCTTCACCT	CGCGGCTGTC	GCTGAAGTCG	1.8420
CACCCGTGGC	TGGCCGGGCA	CGCGATCGGC	GGGGTCGTGC	TCATTCCGGG	CACGGTGTAC	18480
GTCGACCTCG	CCCTCCCCCC	CGGCGACGAG	CTCGGCTTCG	GCGTCCTGGA	AGAGCTCGTG	18540
ATCGAGGCAC	CGCTGGTGCT	GGGCGAGCGC	GCCGCCTTC	GCGTGCAGGT	CGCCGTGAGC	18600
GGGCCGAACG	AGACCGGCTC	GCGTGCGGTG	GACGTCTTCT	CCATGCGGGA	AGACGGCGAC	18660
GAATGGACCC	GGCACGCGAC	CGGTCTCCTC	GGGGCGTCGA	CGTCCCGGGA	ACCGAGCCGC	18720
TTCGACTTCG	CCGCCTGGCC	ecceccece	GCGGAGCCGA	TCGACGTCGA	AAACTTCTAC	18780
ACCGACCTCA	CCGAGCGCGG	GTACGCCTAC	AGCGGCGCCT	TCCAGGGCAT	GCGGGCGGTC	18840
TGGCGGCGCG	GTGACGAGGT	CTTCGCCGAG	GTCGCGCTGC	CTGACGACCA	CCGCGAGGAC	18900
GCCGGCAAGT	TCGGCCTCCA	CCCCCCCTC	CTCGACGCCG	CTCTGCACAC	GAACGCCTTC	18960
GCGAACCCGG	ACGACGACCG	CAGTGTGCTG	CCGTTCGCGT	GGAACGGCCT	GGTCCTGCAC	19020
CCCTGGGCG	CGTCGGCGCT	GCGGGTGCGG	GTGGCGCCGG	GCGGTCCGGA	CGCGCTGACG	19080
TTCCAGGCCG	CCGACGAGAC	CGGTGGCCTG	GTCGTCACCA	TGGATTCGCT	GGTGTCCCGC	19140
GAGGTGTCGG	CCGCGCAGCT	GGAGACGGCG	GCGGGCGAAG	AGCGCGACTC	GCTGTTCCAG	19200
GTGGACTGGA	TCGAGGTCCC	CGCGACCGAG	ACCGCGGCCA	CCGAGCACGC	CGAGGTGCTC	19260

### WO 98/07868 PCT/EP97/04495 - 71 -

GAAGCCTTCG GCGAGGCAGC GCCCCTCGAG CTGACCAGCC GGGTGCTGGA GGCCGTGCAG 19320 TCCTGGCTCG CCGACGCGGC CGACGAAGCA CGGTTGGTCG TGGTGACCCG TGGCGCCGTG 19380 CGCGAGGTGA CGGACCCGGC CGGTGCCGCC GTGTGGGGTT TGGTGCGAGC CGCCCAGGCG 19440 GAGAACCCGG GCCGGATCAT CCTCGTCGAC ACCGACGGCG ACGTCCCGCT GGGTGCGGTG 19500 CTGGCCAGTG GTGAGCCGCA GCTCGCCGTG CGCGCCAACG CTTTCTCCGT CCCGCGCCTC 19560 GCCCGGGCCA CCGCGAGGT GCCGGAGGCC CCCGCGGTGT TCAGTCCGGA AGGGACGGTC 19620 CTGCTCACCG GCGCCACCGG CTCGCTGGGC GGTCTGGTGG CCAAGCACCT GGTTGCCCGG 19680 CACGGCGTCC GGCGGCTGGT GCTCGCCAGC CGCCGAGGCG TGGCCGCGGA AGACCTCGTC 19740 ACCGAGCTGA CCGAGCAGGG CGCGACGGTG TCCGTGGTGG CTTGCGACGT CTCCGACCGC 19800 GACCAGGTGG CCGCGTTGCT GGCCGAACAC CGCCCGACCG GCATCGTGCA CCTGGCCGGC 19860 CTGCTGGACG ACGCGTCAT CGGAGCCCTG AACCGGGAGC GGCTGGCCGG GGTGTTCGCG 19920 CCCAAGGTCG ATGCCGTCCA GCACCTCGAC GAACTGACCC GCGACCTCGG CCTCGACGCG 19980 TTCGTCGTGT TCTCGTCCGC AGCCGCGCTC ATGGGCTCCG CCGGCCAGGG CAACTACGCG 20040 GCCGCCAACG CCTTCCTCGA CGGCTTGATG GCCGGGCGCC GCGCGGCGGG CCTGCCAGGC 20100 GTGTCCCTGG CGTGGGGCCT GTGGGAGCAG GCGGACGGCC TGACCGCGAA CCTCAGCGCC 20160 ACCGACCAGG CCCGGATGAG CCGCGGCGGC GTGCTGCCGA TGACACCGGC CGAGGCCCTG 20220 GACATCTTCG ACATCGGCCT GGCCGCCGAG CAGGCCCTGC TGGTCCCGAT CAAGCTCGAC 20280 CTGCGGACGC TGCGCGGCCA GGCCACCGCC GGCGGCGAGG TGCCGCACCT GCTGCGCGGC 20340

- 72 -

CTGGTCCGCG CGAGCCGCCG CGTGACCCGC ACGCCTGCCG CGAGTGGCGG CGGTGGCCTG 20400 GTCCACAGC TCGCCGGCG GCCAGCCGAA GAGCAGGAAG CCGTGCTGCT GGGCATCGTC 20460 CAGGCGGAGG CGGCCGCGT GCTCGGCTTC AACGCCCCCG AGCTGGCCCA GGGCACCCGC 20520 GGGTTCAGCG ACCTCGGCTT CGACTCGCTG ACCGCGGTCG AGCTGCGGAA CCGGCTGAGC 20580 GCGCCGACCG GCGTCAAATT GCCCGCCACG CTCGTCTTCG ACTACCCGAC GCCGGTCGCG 20640 CTCGCCCGCC ACCTGCGCGA AGAGCTGGGC GAGACGTTGG CGGGTGCGCC GGCCACGCCG 20700 GTGACGACCG TCGCCGACGC GGGCGAGCCG ATCGCCATCG TCGGCATGGC GTGCCGCCTG 20760 CCGGGCGCG TGATGAGCCC CGACGACCTC TGGCGGATGG TCGCCGAGGG CCGCGATGGG 20820 ATGTCGCCGT TCCCCGGAGA CCGCGGCTGG GACCTGGACG GCCTGTTCGA CTCGGACCCC 20880 GAGCGCCGG GCACCGCCTA CATCCGCCAA GGCGGCTTCC TGCACGAGGC CGCGCTGTTC 20940 GACCCGGCT TCTTCGGGAT CTCGCCGCGC GAAGCCCTGG CCATGGACCC GCAGCAGCGG CTGCTGCTCG AAGCCTCCTG GGAAGCCCTG GACGCGCGG GCATCGACCC GACCAAGGCC 21060 CGCGGTGACG CCGTCGGCGT CTTCTCCGGC GTCTCCATCC ACGACTACCT CGAGTCCCTG 21120 AGCAACATGC CCGCCGAGCT CGAAGGCTTC GTCACCACGG CCACGGCGGG CAGCGTCGCC 21180 TCGGGCCGGG TGTCCTACAC CTTCGGGTTC GAGGGCCCGG CGGTCACGGT GGACACGGCG 21240 TGCTCGTCGT CGCTGGTCGC GATCCACCTG GCCGCACAGG CACTGCGGCA GGGCGAGTGC 21300 ACGATGSCCC TGGCCGGCGG TGTCGCCGTG ATGGGCTCGC CGATCGGTGT CATCGGCATG 21360 TCGCGGCAGC GCGCCATGGC CGAGGACGGC CGGGTCAAGG CGTTCGCCGA CGGCGCGGAC 21420 GGCACCGTCC TGTCCGAAGG CGTCGGCATC GTCGTCCTCG AACGGCTTTC GGTGGCCCGC 21480

GAACGCGGC ACCGGGTGCT CGCCGTGCTC CGCGGCAGCG CGGTCAACCA GGACGCGCT 21540 TCGAACGCC TGACCGCGCC CAACGGCCCG TCGCAGCAGC GGGTGATCCG CAGCGCGCTG 21600 GCCGGGGCCG GACTGCAACC GTCCGAAGTG GACGTCGTCG AAGCGCACGG CACCGGGACC 21660 GCGCTGGCCG AACCGATCGA AGCCCAGGCC CTGCTGGCCA CCTACGGCAA GAGCCGCGAG 21720 ACCCCTTGT GCCTCGGGTC GCTGAAGTCG AACATCGGCC ACACCCAGGC GGCCGGGGC 21780 GTGGCGCCG TGATCAAGAT GGTCCAGGCG CTGCGGCAGG ACACCCTGCC GCCGACCCTC 21840 CACGTGCAGG AACCCACCAA GCAGGTGGAC TGGTCCGCGG GTGCGGTCGA GCTGCTGACC 21900 GAAGGCCGG AGTGGCCCG CAACGGCCAC CCGCGCCGGG CCGGTGTCTC GTCGTTCGGC 21960 ATCAGCGGCA CCAACGCGCA CCTCATCCTG GAAGAGGCGC CCGCCGACGA CACCGCCGAG 22020 GCGGACGTGC CCGACGCCGT GGTGCCCGTG GTGATCTCCG CGCGCAGCAC CGGATCCCTG 22080 GCGGGCCAGG CCGGACGCCT GGCGGCGTTC CTCGACGGAG ACGTCCCGCT GACCCGCGTG 22140 GCGGGTGCCC TGCTGTCGAC CCGGGCGACG CTGACCGACC GGGCCGTCGT CGTGGCGGGC 22200 TCGCCGAGG AGGCCGGGC GGGGCTGACC GCGCTGGCCC GCGGCGAGAG CGCGAGCGGG 22260 CTTGTGACCG GTACCGCAGG GATGCCGGGC AAGACGGTCT GGGTGTTCCC CGGCCAGGGG 22320 ACGCAGTGGG CGGCATGGG CCGGGAGCTC CTCGAAGCGT CCCCGGTGTT CGCCGAGCGC 22380 ATTGAGGAAT GCGCGGCCGC GCTGCAGCCG TGGATCGACT GGTCGCTGCT GGACGTCCTC 22440 CGTGGCGAAG GTGAGCTGGA TCGGGTCGAC GTGCTGCAGC CGGCGTGTTT CGCGGTGATG 22500 GTGGGGCTGG CCGCCGTCTG GGCCTCGGTC GGCGTCGTGC CGGACGCGGT CCTGGGCCAC 22560

TCCCAGGGCG AGATTGCCGC CGCCTGCGTG TCGGGTGCAC TGTCCCTCGA GGACGCAGCC 22620 AAGGTCGTCG CGCTGCGCAG CCAGGCGATC GCGGCGGAGC TGTCGGGCCG CGGGGGCATG 22680 GCGTCGATCC AGCTGAGCCA CGACGAGGTG GCTGCCCGGC TCGCGCCGTG GGCGGGCCGC 22740 GTCGAGATCG CCGCCGTCAA CGGTCCGGCC TCGGTCGTGA TCGCCGGTGA CGCCGAAGCG 22800 CTCACCGAGG CCGTCGAAGT CCTCGGCGGT CGGCGGTGG CGGTGGACTA CGCGTCCCAC 22860 ACGCGCACG TCGAGGACAT CCAGGACACC CTCGCCGAGA CTCTGGCCGG GATCGACGCG 22920 CAGGCCCCG TGGTGCCCTT CTACTCCACG GTCGCCGGCG AGTGGATCAC CGATGCCGGG 22980 23040 GTGGCCGAGC TGATCGAGCA GGGGCACGGG GTGTTCGTCG AGGTCAGTGC GCATCCGGTG 23100 CTGGTGCAGC CGATCAGCGA GCTCACCGAT GCGGTCGTCA CCGGGACGTT GCGGCGCGAC 23160 GACGGTGGGG TGCGGCGGCT GCTGACCTCG ATGGCCGAAC TGTTCGTCCG CGGTGTCCCG 23220 GTCGACTGGG CCACGATGGC GCCGCCCGCG CGCGTCGAGC TGCCGACCTA CGCCTTCGAC 23280 CACCAGCACT TCTGGCTCAG CCCGCCCGCC GTGGCGGACG CGCCCGCGCT CGGCCTGGCC 23340 GGCGCCGACC ACCCGCTGCT GGGGGCGGTT CTCCCGCTGC CGCAGTCCGA CGGCCTGGTG 23400 TTCACCTCGC GCCTGTCGGT GCGGACGCAT CCGTGGCTGG CCGACGGCGT CCCCGCCGCC 23460 GCCTTGGTGG AGCTGGCCGT GCGGGCCGGT GACGAAGCCG GTTGCCCGGT CCTCGCCGAC 23520 CTGACCGTCG AAAAGCTGCT GGTGCTGCCG GAGAGCGGTG GCCTGCGCGT CCAGGTGATC 23580 GTGAGCGCG AGCGCACGGT CGAGGTGTAT TCGCAGCTCG AAGGCGCCGA AGACTGGATC 23640 CGGAACGCCA CCGGGCACCT GTCCGCCACG GCTCCGGCGC ACGAGGCCTT CGACTTCACC 23700

GCCTGGCCGC CCGCCGGAGC CCAGCAGGTC GACGGCCTCT GGCGGCGCGG CGACGAGATC 23760 TTCGCCGAGG TCGCCCTGCC GGAGGAGCTG GACGCCGCG CGTTCGGCAT CCACCCCTTC 23820 CTGCTGGACG CGGCCGTGCA GCCGGTCCTC GCGGACGACG AGCAGCCGGC GGAGTGGCGC 23880 AGCCTGGTCC TGCACGCCGC GGGTGCCTCG GCGCTGCGG TGCGGCTGGT GCCCGGCGGT 23940 GCCCTCCAAG CGCCGCACGA AACCGGCGGG CTGGTCCTCA CGGCGGATTC GGTGGCAGGC 24000 CGGGAACTCT CGGCCGGGAA GACCCGCGCC GGATCGCTGT ACCGGGTCGA CTGGACCGAA 24060 GTGTCCATTG CAGACAGTGC GGTGCCGGCC AACATCGAGG TCGTCGAAGC CTTCGGTGAA 24120 GAGCCCCTGG AACTGACCGG CCGGGTCCTG GAGGCTGTGC AGACCTGGCT CGTCACCGCG 24180 GCCGACGATG CGCGGCTGGT CGTGGTGACC CGCGGCGCCG TGCGCGAGGT GACCGACCCC 24240 GCCGGTGCGG CCGTGTGGGG CCTGGTCCGA GCCGCGCAGG CGGAGAACCC CGGTCGCATC 24300 TTCCTGATCG ACACCGACGG CGAGATCCCG GCCCTGACCG GTGACGAGCC CGAGATCGCG 24360 GTGCGCGCG GGAAGTTCTT CGTGCCCCGC ATCACTCGCG CGGAGCCGAG CGGGCCGCC 24420 GTGTTCCGCC CGGACGGGAC AGTGCTGATC TCGGGCGCGG GTGCGCTCGG TGGCCTGGTG 24480 GCCCGGCGTC TCGTCGAACG CCACGGCGTG CGGAAGCTCG TGCTGGCGTC CCGGCGCGGC 24540 CGAGACCCC ACGCCTCGC CGACCTCGTC CCCGACCTCG CCCCGACCT GTCCGTCGTC 24600 GCTTGCGACG TCTCCGATCG CGCCCAGGTG GCGCCCTGC TCGACGAGCA CCGGCCGACC 24660 GCCGTCGTGC ACACCGCCGG CGTCATCGAC GCGGGCGTGA TCGAGACGCT GGACCGGGAC 24720 CGGCTGGCCA CGGTGTTCGC GCCGAAGGTC GACGCCGTGC GGCACCTCGA CGAGCTGACC 24780

CGCGACCGCG	ACCTCGACGC	CTTCGTCGTC	TACTCCTCGG	TCTCGGCCGT	GTTCATGGGC	24840
GCGGGCAGCG	GCAGTTACGC	CGCGGCGAAC	GCCTTCCTGG	ACGGCCTGAT	GGCGAACCGC	24900
CGGGCGGCGG	GCCTGCCGGG	CCTGTCGCTG	GCGTGGGGCC	TGTGGGACCA	GAGCACCGGT	24960
ATGGCCGCCG	GCACCGACGA	GGCCACCCGG	GCGCGGATGA	GCCGCCGCGG	TGGCCTGCAG	25020
ATCATGACGC	AGGCCGAGGG	CATGGACCTG	TTCGACGCCG	CGCTGTCGTC	GGCCGAGTCG	25080
CTGCTGGTGC	CCGCCAAGCT	CGACCTGCGT	GGGGTGCGCG	CCGACGCCGC	CCCCCCCCC	25140
GTCGTGCCGC	ACATGCTGCG	TGGCCTGGTC	CGCGCGGGCC	GGGCGCAGGC	CCGCGCGGCG	25200
TCCACTGTGG	ACAACGGGCT	GGCCGGACGG	CTGGCCGGGC	TCGCCCCGGC	GGACCAGCTC	25260
ACGCTGCTCC	TGGACCTGGT	CCGGGCGCAG	GTCGCGGCCG	TGCTCGGGCA	CGCCGACGCG	25320
AGCGCCGTCC	GCGTCGACAC	GGCCTTCAAG	GACGCCGGCT	TCGACTCGCT	GACCGCGGTC	25380
GAGCTGCGCA	ACCGCATGCG	GACCGCCACC	GGCCTGAAGC	TGCCCGCGAC	GCTCGTCTTC	25440
GACTACCCGA	ACCCCCAGGC	GCTCGCCCGG	CACCTGCGCG	ACGAACTCGG	TGGTGCGGCC	25500
CAGACGCCGG	TGACCACAGC	GGCCGCGAAG	GCCGACCTCG	ACGAGCCGAT	CGCCATCGTC	25560
GGGATGGCGT	GCCGCTTGCC	GGGCGGGGTC	eccegeccce	AGGACCTCTG	GCGCCTGGTC	25620
GCCGAGGGCC	GGGACGCGGT	GTCGAGCTTC	CCGACCGACC	GCGGCTGGGA	CACCGACAGC	25680
CTGTACGACC	CCGATCCGGC	ccccccccc	AAGACCTACA	CCCGGCACGG	CGGCTTCCTG	25740
CACGAAGCCG	GGCTCTTCGA	CGCGGGCTTC	TTCGGGATCT	CGCCACGCGA	GGCCGTCGCC	25800
ATGGACCCGC	AGCAGCGGCT	GCTGCTGGAG	GCCTCCTGGG	AGGCCATGGA	AGACGCCGGG	25860
GTCGACCCAC	TTTCGCTGAA	GGGCAACGAC	GTCGGCGTGT	TCACCGGCAT	GTTCGGCCAG	25920

GGTTACGTCG	CTCCCGGGGA	CAGCGTCGTC	ACGCCGGAGC	TGGAGGGTTT	CGCGGGCACG	25980
GGCGGGTCGT	CGAGTGTCGC	GTCCGGCCGC	GTGTCGTACG	TGTTCGGGTT	CGAAGGCCCG	26040
GCCGTGACGA	TCGACTCGGC	GTGCTCGTCC	TCGCTGGTCG	CGATGCACCT	CGCCGCGCAG	26100
TCGCTGCGGC	AGGGCGAGTG	CTCGATGGCC	TTGGCCGGCG	GCGCGACGGT	GATGGCGAAC	26160
CCCGGCGCAT	TCGTGGAGTT	CTCGCGGCAG	CGGGGCCTCG	CCGTCGACGG	TCGCTGCAAG	26220
GCGTTCGCCG	CCGCGGCCGA	CGGCACCGGC	TGGGCCGAGG	GCGTCGGTGT	GGTCATCCTC	26280
GAGCGGCTGT	CGCTGGCGCG	GGAACGCGGC	CACCGGATCC	TGGCCGTGCT	GCGCGGCAGC	26340
GCGGTCAACC	AGGACGCCC	CTCGAACGGC	CTGACCGCGC	CGAACGGCC	GTCGCAGCAG	26400
CGGGTGATCC	GCCGGGCGCT	GGTGAGCGCC	CGGCTGGCAC	CGTCCGATGT	GGACGTCGTC	26460
GAGGCGCACG	GCACCGGGAC	CACGCTGGGT	GACCCGATCG	AGGCGCAAGC	TCTGCTGGCT	26520
ACCTACGGCA	AGGACCGCGA	GTCGCCGCTG	TGGCTCGGCT	CGCTGAAGTC	GAACATCGGC	26580
CACGCGCAGG	ccccccccc	GGTCGCCGGC	GTCATCAAGA	TGGTCCAGGC	GCTCCGGCAC	26640
GAAGTCCTGC	CGCCGACGCT	GCACGTCGAC	CGGCCTACCC	CCGAGGTCGA	CTGGTCGGCC	26700
GGTGCCGTCG	AACTGCTGAC	GGAAGCCCGC	GAGTGGCCGC	GCAACGGGCG	ccccccccc	26760
GCCGGGGTCT	CCGCGTTCGG	CGTCAGCGGC	ACGAACGCGC	ACCTGATCCT	GGAGGAGGCG	26820
CCCGCCGAAG	AGCCGGTGCC	CACACCCGAG	GTTCCCCTGG	TGCCGGTCGT	GGTCTCCGCG	26880
CGGAGCAGGG	CGTCCCTGGC	CGGTCAGGCC	GGTCGCCTCG	CCGGATTCGT	GGCGGGTGAC	26940
GCGTCCTTGG	CCGGTGTGGC	CCGGCCGCTG	GTGACGAACC	GGGCCGCGCT	GACCGAGCGC	27000

#### WO 98/07868 PCT/EP97/04495 - 78 -

GCGGTCATGG	TCGTGGGCTC	TCGCGAAGAA	GCCGTGACGA	ACCTGGAAGC	GCTGGCCCGC	27060
GGCGAAGACC	CGGCCGCGGT	GGTCACCGGC	CGGGCGGGTT	CGCCGGGCAA	GCTCGTCTGG	27120
GTCTTCCCCG	GCCAGGGCTC	GCAGTGGATC	GGGATGGGCC	GGGAACTCCT	GGACTCTTCG	27180
CCGGTCTTCG	CCGAGCGGGT	CGCCGAATGC	cccccccc	TGGAACCGTG	GATCGATTGG	27240
TCACTGCTCG	ACGTGCTGCG	CGGGGAGTCC	GACCTGCTGG	ACCGGGTCGA	CGTCGTGCAG	27300
CCCGCCAGCT	TCGCGATGAT	GGTCGGCCTG	GCCGCGCTGT	GCCAGTCGGT	GGGTGTCCGC	27360
CCGGATGCCG	TCGTCGGCCA	CTCGCAGGGC	GAGATCGCCG	CCGCCTGCGT	CTCGGGCGCG	27420
CTGTCGCTGC	AGGACGCCGC	GAAGGTGGTT	GCCTTGCGCA	GCCAGGCGAT	CGCCACCCGG	27480
CTGGCCGGGC	GCGGCGCAT	GGCTTCCGTG	GCGTTGAGCG	AAGAAGACGC	GACCGCGTGG	27540
CTGGCGCCGT	GGGCCGACCG	GGTCCAGGTG	GCCGCGGTCA	ACAGCCCTGC	CTCCGTGGTG	27600
ATCGCCGGGG	AAGCCCAGGC	CCTCGACGAG	GTCGTCGACG	CGTTGTCCGG	TCAGGAAGTC	27660
CGCGTCCGGC	GGGTGGCCGT	GGACTACGGG	TCCCACACCA	ACCAGGTCGA	AGCCATCGAG	27720
GATCTGCTGG	CCGAGACCTT	GGCCGGCATC	GAGGCGCAGG	CCCCGAAGGT	GCCCTTCTAC	27780
TCGACCCTGA	TCGGTGACTG	GATCCGTGAC	GCCGGGATCG	TCGACGGCGG	CTACTGGTAC	27840
CGGAACCTGC	GCAACCAGGT	CGGGTTCGGT	CCGGCCGTCG	CGGAGCTCGT	TCGCCAGGCC	27900
CACGGGGTGT	TCGTCGAGGT	CAGCGCGCAC	CCGGTGCTGG	TCCAGCCGCT	CAGTGAACTC	27960
AGCGACGACG	CGGTGGTGAC	CGGGTCGCTG	CGGCGCGAAG	ACGGTGGCCT	GCGCCGCCTG	28020
CTGACGTCGA	TGGCCGAGCT	GTACGTGCAG	GGTGTCCCGC	TCGACTGGAC	CGCGGTCCTG	28080
CCGCGGACCG	GCCGGGTCGA	CCTGCCGAAG	TACGCCTTCG	ACCACCGGCA	CTACTGGCTG	28140

CGGCCGCCG AGTCCGCGAC CGACGCGGCT TCGCTGGGCC AGGCGGCGGC CGACCACCCG 28200 CTGCTGGGCG CGGTCGTCGA GCTGCCGCAG TCCGACGGCC TGGTGTTCAC CTCGCGGCTG 28260 TCCGTCCGA CGCACCCGTG GCTGCCCGAC CACGCGGTCG GTGGCGTGGT CATCCTCCCC 28320 GGCTCCGGGC TGGCCGAACT GGCCGTCCGG GCCGGCGACG AAGCCGGGTG CACCGCCCTC 28380 GACGAGCTGA TCATCGAAGC TCCGCTGGTC GTGCCCGCCC AAGGCGCGGT CCGCGTCCAG 28440 GTCGCGTTGA CCGCCCGGA CGAGACCGGC TCGCGCACGG TGGACCTCTA CTCCCAGCGC 28500 GACGGGGG CGGGACGTG GACGCGGCAC GCCACCGGCG TGCTGTCGAC GGCCCCGCT 28560 CAGGAACCC AGTTCGACTT CCACGCCTGG CCGCCCGGG ATGCCGAGCG GATCGACGTC 28620 GAGACCTTCT ACACCGACCT GGCCGAGCGT GGTTACGGCT ACGGGCCGGC GTTCCAGGGG 28680 CTGCAAGCGG TGTGGCGGCG TGACGGCGAC GTCTTCGCCG AGGTCGCCCT GCCCGAGGAC 28740 CTGCGCAAGG ACGCGGCCG GTTCGGCGTC CACCCGGCGC TGCTCGACGC GGCGCTGCAG 28800 GCCGCCACGG CCGTGGGCGG CGACGAGCCC GGTCAGCCGG TGCTGGCGTT CGCGTGGAAC 28860 GGCTGGTCC TGCACGCCGC GGGCGCGTCG GCCCTGCGGG TCCGGCTCGC GCCGAGCGGC 28920 CCGGACACGC TGTCCGTGGC AGCCGCCGAC GAAACCGGCG GCTTGGTCCT GACCATGGAA 28980 TCGCTGTCT CCCGCCGGT TTCGGCCGAG CAGCTCGGCG CCGCGGCCGA CGCGGCCAC 29040 GACGCGATGT TCCGCGTCGA CTGGACCGAG CTGCCTGCCG TGCCCCGCGC GGAACTGCCG 29100 CCGTGGGTGC GGATCGACAC CGCCGACGAC GTCGCGGCCT TGGCGGAGAA GGCGGACGCA 29160 CCACCGGTGG TGGTCTGGGA AGCCGCCGGG GGAGACCCGG CCCTGGCCGT GAGTTCCCGG 29220

GTGCTCGAGA	TCATGCAGGC	CTGGCTGGCC	GCGCCCGCGT	TCGAGGAGGC	CCGGCTGGTC	29280
GTGACGACCC	GCGGCGCGGT	ACCCGCCGGC	GGTGACCACA	CACTGACCGA	CCCGGCCGCG	29340
GCCGCGGTGT	GGGGCCTGGT	CCGGTCCGCG	CAGGCGGAAC	ACCCGGACCG	GGTCGTCCTG	29400
CTGGACACCG	ACGGCGAAGT	TCCGCTGGGC	GCGGTGCTGG	CCTCCGGTGA	GCCGCAGCTC	29460
GCGGTGCGCG	GAACGACGTT	CTTCGTGCCC	CGGCTGGCCC	GCGCCACCCG	GCTCTCGGAC	29520
GCGCCTCCTG	CGTTCGACCC	GGACGGGACC	GTGCTGGTCT	ceeececee	ATCGCTGGGC	29580
ACCTTGGTGG	CCCGGCACCT	GGTCACCCGG	CACGGCGTGC	CCCCCTCCT	GCTGGCCAGC	29640
CGGCAGGGCC	GGGACGCCGA	GGGCGCCCAG	GACCTGATCA	CCGAGCTCAC	CGGCGAAGGC	29700
CCGGACGTGT	CCTTCGTGGC	CTGTGACGTC	TCCGATCGCG	ACCAGGTGGC	CGCGCTGCTC	29760
GCGGGCCTCC	CGGACCTGAC	CGGGGTGGTG	CACACCGCCG	GCGTCTTCGA	GGACGCCGTG	29820
ATCGAGGCGC	TGACGCCCGA	CCAGCTCGCG	AACGTGTACG	CGGCCAAGGT	CACGGCCGCG	29880
ATGCACCTCG	ACGAGCTCAC	CCGCGACCGG	GATCTCGGCG	CGTTCGTCGT	GTTCTCCTCC	29940
GTCGCGGGG	TGATGGGTGG	TGGCGGTCAA	GGCCCGTACG	CGGCGGCGAA	CGCCTTCCTG	30000
GACGCGGCGA	TGGCGAGTCG	TCAGGCCGCG	GGCCTGCCGG	GCCTGTCCCT	GGCGTGGGGC	30060
CTCTGGGAAC	GCAGCAGCGG	CATGGCCGCC	CACCTCAGCG	AGGTCGACCA	CGCGCGGGCG	30120
AGCCGCAACG	GTGTCCTGGA	ACTGACCCGG	GCCGAGGGCC	TGGCGCTGTT	CGACCTCGGG	30180
CTGCGGATGG	CCGAGTCGCT	GCTCGTGCCG	ATCAAGCTCG	ACCTCGCCGC	GATGCGGGCG	30240
AGCACGGTCC	CGGTCCTGTT	CCGCGGCCTG	GTCCGGCCGA	GCCGGACCCA	GGCGCGCACG	30300
GCGTCCACTG	TGGACCGGGG	GCTGGCCGGG	CGGCTCGCCG	GGCTGCCGGT	GCCGAGCGG	30360

CCGCCGTGC TGGTCGACCT CGTGCGCGGG CAGGTCGCGG TCGTGCTCGG CTACGACGGG 30420 CCGGAGGCCG TCCGCCCGGA CACGGCGTTC AAGGACACCG GGTTCGACTC GCTGACGTCG 30480 GTGGAACTGC GCAACCGGCT GCGCGAGGCG ACCGGGCTCA AGCTCCCCGC CACGCTCGTC 30540 TTCGACTACC CGAACCCCTT GGCGGTGGCG CGCTACCTGG GCGCGCGGCT GGTCCCGGAC 30600 GGGACCGCGA ACGCCAACGG GAACGGGAAT GGGCACAGCG AAGACGACCG GCTGCGGCAC 30660 GCGCTGGCGG CCATCGCGGC CGAGGACGCG GGCGAGGAGC GGTCGATCGC CGACCTGGGC 30720 GTCGACGACC TCGTGCAACT GGCTTTCGGC GACGAGTGAT TGGGGCAAGT GGTGAGTGCG 30780 TCGTATGAAA AGGTCGTCGA GGCGCTGCGG AAGTCGCTCG AAGAGGTCGG CACGCTGAAG 30840 AAGCGGAACC GGCAGCTCGC CGACGCGGCC GGCGAGCCGA TCGCCATCGT CGCCATGGCC 30900 TGCCGGCTGC CCGGTGGCGT CACCGGGCCC GGTGACCTCT GGCGGCTGGT GGCCGAGGGC 30960 GGCGACGCCG TCTCGGGGTT CCCCACCGAC CGCTGCTGGG ACCTGGACAC CCTGTTCGAC 31020 CCGGATCCCG ACCACGCGG GACGTCGTAC ACCGACCAGG GCGGCTTCCT CCACGACGCG 31080 GCCCTGTTCG ACCCGGGCTT CTTCGGGATT TCGCCGCGCG AGGCGCTGGC CATGGACCCG 31140 CAGCAGCGT TGCTGCTGGA GGCGTCCTGG GAGGCGCTGG AAGGTGTCGG CCTCGACCCG 31200 GCTTCGTTGC AGGGCACCGA CGTCGGCGTG TTCACCGGCG CGGGCGGGTC GGGCTACGGC 31260 GGCGGCCTCA CCGGGCCGGA GATGCAGAGT TTCGCGGGCA CCGGGCTGGC CTCGAGCGTG 31320 GCTTCGGGCC GGGTGTCCTA CGTCTTCGGG TTCGAGGGAC CGGCGGTCAC GATCGACACG 31380 GCGTGCTCGT CGTCGCTGGT GGCGATGCAC CTCGCCGCGC AGGCCCTGCG CCAAGGCGAC 31440

TGCTCGATGG	CACTGGCCGG	CGGCGCGATG	GTGATGTCGG	GCCCGACTC	CTTCGTCGTC	31500
TTCTCCCGGC	AGCGGGGGCT	GGCCACCGAC	GGGCGGTGCA	AGGCGTTCGC	GTCGGGCGCC	31560
GACGGCATGG	TGCTCGCCGA	GGGCATCAGC	GTGGTCGTGC	TGGAGCGGCT	TTCGGTCGCG	31620
CGGGAACGCG	GGCACCGGGT	GCTGGCCGTG	CTGCGCGGCA	GCGCGGTGAA	CCAGGATGGC	31680
GCGTCGAACG	GCCTGACCGC	CCCGAACGGC	CCTTCCCAGC	AGCGCGTGAT	CCGCGCGCG	31740
CTGGCCAACG	CCGGAATCGG	ACCGTCCGAT	GTGGACCTCG	TCGAGGCGCA	CGGGACCGGG	31800
ACGAGCCTGG	GTGATCCCAT	CGAGGCGCAG	GCCTTGCTGG	CGACCTACGG	CCAGGACCGG	31860
GAGACGCCGT	TGTGGCTCGG	CTCGCTGAAG	TCGAACATCG	GGCACACGCA	GCCGCCCCC	31920
GGCGTGGCGA	GCGTGATCAA	GGTCGTGCAG	GCGCTGCGGC	ACGGCGTCAT	GCCGCCGACC	31980
CTGCACGTCG	ACGAGCCCAG	CTCGCAGGTC	GACTGGTCCG	AAGGCGCGGT	GGAACTGCTG	32040
ACCGGGAGCC	GGGACTGGCC	GCGCGGGGAC	CGGCCGCGCC	GGGCCGGGGT	GTCGTCGTTC	32100
GGCGTCAGCG	GGACGAACGT	GCACCTGATC	ATCGAGGAAG	CCCCCGAGGA	GCCCGCTGCG	32160
GCCGTGCCGA	CGTCCGCGGA	CGTCGTGCCG	CTGGTGGTTT	CCGCACGCAG	CACGGGTTCC	32220
CTGGCCGGTC	AGGCCGACCG	GCTGACCGAG	GTGGACGTCC	CCCTCGGACA	CCTCGCCGGG	32280
GCGCTGGTGG	ccegececec	GGTGCTCGAG	GAACGCGCGG	TCGTGGTCGC	CGGTTCGGCC	32340
GAAGAAGCCC	GCGCGGGGCT	GGGTGCGCTG	GCTCGCGGTG	AAGCCGCGCC	CGGCGTCGTG	32400
ACCGGGACCG	CGGGCAAGCC	GGGCAAGGTC	GTCTGGGTGT	TCCCGGGACA	GGGGACGCAG	32460
TGGGTGGGCA	TGGGCCGGGA	GCTCCTCGAC	GCGTCCCCGG	TGTTCGCCGA	GCGGATCAAG	32520
GAGTGCGCGG	CGGCACTGGA	CCAGTGGACC	GACTGGTCGC	TGCTGGACGT	CCTGCGTGGT	32580

GACGGTGACC TGGATTCTGT CGAGGTGCTG CAGCCCGCGT GCTTCGCGGT GATGGTGGGG 32640 CTGGCCGCGG TCTGGGAGTC GGCGGGGGTC CGGCCGGACG CCGTCGTCGG CCACTCGCAG 32700 GGCGAGATCG CCGCGCCTG CGTGTCCGGC GCGCTCACCC TCGACGACGC CGCGAAGGTG 32760 GTGGCCCTGC GCAGCCAGGC GATCGCGGCG CGGCTGTCCG GCCGCGGCGG GATGGCGTCG 32820 GTCGCGTTGA GCGAGGACGA GGCGAACGCA CGGCTGGGTT TGTGGGACGG CCGGATCGAG 32880 GTGGCCGCGG TCAACGGCCC CGCCTCCGTG GTGATCGCGG GGGACGCCCA AGCCCTCGAC 32940 GAGGCTTTGG AGGTGCTGGC CGGGGACGGC GTCCGCGTCC GGCAGGTCGC GGTCGACTAC 33000 GCCTCCCACA CCCGGCACGT CGAGGACATC CGCGACACCC TCGCCGAGAC GCTGGCCGGG 33060 ATCACCGCGC AGGCCCCGGA CGTGCCGTTC CGCTCCACCG TCACCGGCGG CTGGGTGCGG 33120 GACGCCGACG TCCTGGACGG CGGGTACTGG TACCGCAACC TGCGCAACCA GGTCCGGTTC 33180 GCCCGGCCG TGGCCGAGCT GCTCGAGCAG GGCCACGGGG TGTTCGTCGA GGTCAGCGCC 33240 CACCCCGTGC TGGTGCAGCC GATCAGCGAG CTCACCGACG CGGTCGTCAC CGGGACGCTG 33300 CGGCGCGACG ACGCCGCCT GCGCCGCCTG CTGACGTCGA TGGCCGAGCT GTTCGTCCGC 33360 GETGTTCGCG TCGACTGGGC CACGCTGGTG CCGCCCGCGC GCGTGGACCT CCCGACGTAC 33420 GCCTTCGACC ACCAGCACTT CTGGCTCCGG CCGGCCGCGC AGGCGGACGC CGTCTCGCTC 33480 GGCCAGGCCG CGGCGGAGCA CCCGCTGCTC GGCGCGGTCG TCCGGCTGCC GCAGTCGGAC 33540 GGCCTGGTCT TCACCTCGCG GCTGTCGCTG CGGACGCACC CGTGGCTGGC CGACCACACC 33600 ATCGGCGGCG TGGTGCTGTT CCCCGGCACC GGGCTGGTCG AACTGGCCGT GCGGGCCGGC 33660

GACGAGGCCG	GGTGCCCGGT	CCTGGACGAA	CTCGTGACCG	AGGCGCCGCT	GGTCGTGCCC	33720
GGGCAGGGCG	GAGTGAACGT	CCAGGTCACG	GTGAGCGGCC	CGGACCAGAA	CGGCTTGCGC	33780
ACGGTGGACA	TCCACTCCCA	GCGCGACGAC	GTGTGGACCC	GGCACGCGAC	CGGAACGGTC	33840
TCGGCGACCC	CGGCGAGCAG	CCCCGGCTTC	GACTTCACCG	CGTGGCCGCC	GCCGGACGGG	33900
CAGCGCGTCG	AGATCGGCGA	CTTCTACGCC	GACCTCGCCG	AGCGCGGGTA	CGCGTACGGG	33960
CCCTTGTTCC	AGGGCGTGCG	GGCGGTGTGG	CAGCGCGGCG	AAGACGTGTT	CGCCGAGGTC	34020
GCGCTGCCCG	AAGACCGGCG	GGAGGACGCC	GCCCGGTTCG	GCCTGCACCC	GGCGTTGCTG	34080
GACGCGGCCC	TGCAGACCGG	GACGATCGCC	GCGGCCGCGT	CCGGTCAGCC	GGGCAAGTCC	34140
GTGATGCCGT	TCTCGTGGAA	CCGCCTGGCG	CTGCACGCCG	TCGGGGCCGC	GGGCCTCCGG	34200
GTCCGCGTGG	ccccccccc	ACCGGACGCG	CTGACCGTCG	AGGCCGCCGA	CGAGACCGGC	34260
CCCCCCTCC	TCACCATGGA	CTCGCTGATC	CTCCGTGAAG	TCGCCCTCGA	CCAGCTGGAC	34320
ACTGCGCGCG	CCGGCTCGCT	CTACCGGGTG	GACTGGACCC	CACTGCCCAC	TGTGGACAGT	34380
GCGGTGCCCG	CTGGTCGGGC	CGAGGTGCTG	GAAGCTTTCG	GCGAGGAGCC	CCTGGACCTG	34440
ACCGGCCGGG	TGCTGGCCGC	CCTGCAGGCG	TGGCTTTCCG	ACGCGGCGGA	GGAAGCCCGC	34500
CTGGTCGTGG	TGACCCGGGG	TGCGGTGCCC	GCCGGAGACG	GTGTGGTGAG	CGATCCGGCG	34560
GGTGCCGCGG	TGTGGGGCCT	GCTCCGGGCC	GCGCAGGCGG	AGAACCCGGA	CCGGTTCGTC	34620
CTGCTCGACA	CCGACGCGA	GGTGCCGCTG	GAAGCGGTGC	TGGCGACCGG	TGAGCCGCAG	34680
CTCGCGCTGC	GCGGCACGAC	GTTCTCGGTG	CCCCGGCTCG	CCCGCGTCAC	CGAACCGGCG	34740
GAAGCCCCGC	TGACGTTCCG	TCCGGACGGG	ACGGTCCTGG	TCTCCGGCGC	CGGGACGCTG	34800

GGTGCGCTGG CCGCCGCGA CCTCGTCACC CGGCACGCG TCCGGCGGCT CGTGCTGGCC AGCCGGCGCG GCCGGCCGC CGAGGGCATC GACGACCTCG TCGCCGAGCT GACCGGCCAC 34920 GCCCCGAAG TGACGGTCGC CGCCTGCGAC GTCTCCGACC GCGACCAGGT GGCGGCGCTG 34980 CTCAAGGAAC ACGCGCTGAC CGCGGTGGTG CACACGGCGG GCGTGTTCGA CGCCGGTGTC 35040 ACCGCCCC TGACCCGGA GCGCTGGCC AAGGTGTTCG CGCCCAAGGT CGACGCGGCC 35100 AACCACCTCG ACGAGCTGAC CCGCGACCTG GACCTCGACG CGTTCATCGT CTACTCGTCC 35160 GCCTCCTCGA TCTTCATGGG CGCGGCAGC GGCGGGTACG CGCCGGCGAA CGCCTACCTC 35220 GACGCCTGA TGGCCGCCG GCGCGCGCG GGCCTGCCGG GGCTGTCGCT GGCCTGGGGC 35280 CCGTGGGAGC AGCTCACCGG CATGGCCGAC ACCATCGACG ACCTCACCCT GGCCCGGATG 35340 AGCCGCCGG AAGGCCGCGG CGGCGTCCGC GCGCTCGGCT CCGCCGACGG CATGGAGCTG 35400 TTCGACGCCG CGCTCGCGGC CGGCAGGCG CTGCTGGTGC CGATCGAGCT CGACCTGCGC 35460 GAGGTGCGG CCGACGCGGC CGGCGGCGC ACGGTGCCGC ACCTGCTGCG CGGGCTGGTC 35520 CGCGCGGCC GGCAGGCGGC GCGACGGG GCCACCGAGG ACGCGCCT GGAACGCCGG 35580 CTGGCCGGC TCACCGTGGC CGAACAGGAA GCGCTGCTGC TCGACCTCGT CCGCGGTCAG 35640 GTCGCCGTCG TGCTCGGGCA CGCCGACAGC TCCGGCGTCC GCGCCGACGC GGCGTTCAAG 35700 GACGCCGGET TCGACTCGCT GACGTCGGTG GAGCTGCGCA ACCGGCTGCG CGAGACGACC 35760 GGCCTGAAAC TGCCCGCGAC GCTGGTCTTC GACCATCCGA ACCCGCTGGC ACTGGCCCGG 35820 CACCTGCGG CGGAACTCGC CGTCGACGAG GCATCCCCGG CCGATGCGGT GCTGGCCGGG 35880

CTCGCCGGGC	TGGAGGCGGC	CATCGCGGCC	: GCCGGCGCCC	CGGACGCGA	CCGGATCACC	35940
GCGCGGCTGC	GGGAACTGCT	CAAGGCCGCC	GAGGCGGCCG	AGGCCCGGCC	GGGCACCTCC	36000
GGCGATCTCG	ACACGGCCAG	CGACGAGGAA	CTGTTCGCCC	TCGTCGACGG	GCTCGACTGA	36060
AACCGCTGTG	ACATCCGGGG	CTTCGCCACC	CGGGCCCCGA	AAAGCAAGCA	CACGTGAGAG	36120
TTCTGGGACT	TGAGTTCAGT	GGCTGACGAG	GGACAACTCC	GCGACTACCT	CAAGCGGGCC	36180
ATCGCCGACG	CCCGCGACGC	CCGCACGCGG	CTGCGCGAGG	TCGAGGAGCA	GGCGCGGGAG	36240
CCGATCGCCA	TCGTCGCCAT	GCCTGCCGG	TACCCGGGCG	GGGTGTCCTC	GCCCGAGGAC	36300
CTGTGGCGGC	TGGTGGCCGA	GGGGACCGAC	GCCGTCTCCG	CGTTCCCCGG	CGACCGCGGC	36360
TGGGACGTCG	ACGGGCTCGT	CGACCCGGAC	CCCGACCGCC	CGGGCACGAC	GTACACGGAC	36420
CAGGGTGGCT	TCCTCCACGA	GGCCGGCCTC	TTCGACGCGG	GGTTCTTCGG	GATCTCGCCG	36480
CGGGAGGCCG	TCGCGATGGA	CCCGCAGCAG	CGGCTGCTGC	TGGAGACGTC	CTGGGAGGCC	36540
ATCGAACGCA	CCGGCACCGA	CCCGCTTTCG	CTGAAGGGCA	GCGACATCGG	CGTCTTCACC	36600
GGCGTCGCGA	GCATGGGTTA	CGGCGCCGGT	GGCGGCGTGG	TCGCGCCGGA	GCTGGAGGGT	36660
TTCGTCGGCA	CCGGTGCGGC	GCCGTGCATC	GCGTCCGGCC	GGGTGTCGTA	CGTCCTCGGC	36720
TTCGAAGGCC	CGGCGGTCAC	CGTCGACACC	GGGTGTTCGT	CGTCGCTGGT	GGCGATGCAC	36780
CTCGCCGCGC	AGGCGCTGCG	GCGGGGTGAG	TGCTCGATGG	CTCTGGCCGG	CGGCGCGATG	36840
GTGATGGCCC	AGCCGGGTTC	GTTCGTGTCC	TTCTCGCGGC	AACGCGGGCT	CGCCCTGGAC	36900
GGGCGCTGCA	AGGCGTTTTC	GGACAGCGCC	GACGGGATGG	GACTGGCCGA	GGGCGTCGGC	36960
GTCATCGCGC	TGGAACGGCT	GTCGGTCGCC	CGTGAGCGTG	GGCACCGGGT	GCTGGCCGTG	37020

CTGCGCGGTA TCGCGGTGAA CCAGGATGGC GCGTCGAACG GCTTGACCGC CCCGAACGGC 37080 CCGTCCCAGC AGCGGGTGAT CCGCGCCGCG CTGGCCGAAG CCGGGCTGTC GCCGTCCGAT 37140 GTGGACGCCG TCGAAGGCA CGGGACGGC ACGACGCTGG GCGATCCGAT CGAAGCGCAG 37200 GCGTTGCTGG CCACCTACGG CAAGGGCCGG GACCCGGAGA AGCCGCTCTG GCTGGGCTCG 37260 GTGAAGTCGA ACCTCGGGCA CACGCAAGCG GCCGCGGGCG TGGCCAGCGT GATCAAGATG 37320 GTGCAGGCGC TGCGCCACGG CGTGCTGCCC CCGACGCTGC ACGTCGACCG GCCGTCCACC 37380 GAAGTCGACT GGTCGGCCGG TGCGGTCTCG CTGTTGACGG AGGCTCGGGA GTGGCCGCGC 37440 GAAGGCGC CGCCCGGC CGGGTGTCC TCGTTCGGGA TCAGCGGGAC CAACGCGCAC 37500 CTCATCCTGG AGGAAGCGCC CGAGGAGGAG CCGCCCGTCG CCGAAGCGCC TTCCGCCGGA 37560 GTGGTGCCCG TGGTGGTGTC GGCTCGTGGG GCCCTGGCGG GTCAGGCCGG CCGGCTGGCC 37620 GCGTTCCTCG AGGCGTCCGA CGAGCCGTTG GTGACCGTCG CCGGGGCGCT GATCTGCGGC 37680 CGGTCCCGGT TCGGCGACCG GGCCGTCGTG GTGGCGGGCA CGCGCGCAGA GGCGACGGCC 37740 GGGCTGGCCG CGCTGGCCCG CGCGAAAGC GCCGCCGACG TCGTGACCGG CACGGTCGCG 37800 GCCTCGGGCG TGCCGGCAA GCTCGTGTGG GTGTTCCCGG GCCAGGGTTC GCAGTGGGTG 37860 GGCATGGGCC GGGAGCTCCT CGAAGCCTCG CCGGTGTTCG CCGCGCGGAT CGCGGAGTGC 37920 GCGGCTGCCC TCGAACCGTG GATCGACTGG TCGCTGCTGG ACGTCCTCCG TGGCGAGGGC 37980 GACCTCGACC GCGTCGACGT GGTGCAGCCC GCGAGTTTCG CGGTGATGGT CGGCCTGGCC 38040 GCGGTGTGT CGTCCGTCGG GGTGGTGCCC GACGCGGTGC TCGGGCACTC GCAGGGGGAG 38100

ATCGCGGCGG	CGTGCGTGTC	GGGGGCGTTG	TCGCTGCAGG	ACGCGGCGAA	GGTGGTCGCG	38160
TTGCGCAGCC	AGGCGATCGC	GGCGAAGCTG	GCCGGCCGCG	GCGGCATGGC	CTCGGTCGCG	38220
CTGAGCGAGG	AAGACGCGGT	CGCGCGGTTG	CGGCACTGGG	CGGACCGGGT	CGAGGTGGCC	38280
GCGGTCAACA	GCCCGTCGTC	GGTGGTGATC	GCCGGCGACG	CCGAAGCCCT	CGACCAGGCC	38340
CTCGAAGCAC	TGACCGGCCA	GGACATCCGG	GTCCGGCGG	TGGCGGTGGA	CTACGCCTCG	38400
CACACCCGGC	ACGTCGAAGA	CATCCAGGAG	CCCCTCGCCG	AGGCACTGGC	CGGGATCGAG	38460
GCGCACGCGC	CGACCCTGCC	GTTCTTCTCG	ACCCTCACCG	GTGACTGGAT	TCGCGAAGCG	38520
GGCGTCGTGG	ACGGCGGCTA	CTGGTACCGG	AACCTGCGCA	ACCAGGTCGG	TTTCGGCCCG	38580
GCGGTGGCCG	AGCTGCTCGG	CCTCGGCCAC	CGGGTGTTCG	TCGAGGTCAG	CGCGCACCCC	38640
GTGCTCGTCC	AGGCGATCAG	CGCGATTGCC	GACGACACCG	ACGCGGTCGT	CACCGGCTCG	38700
CTGCGGCGCG	AGGAGGGCGG	CCTGCGGCGG	CTGCTGACGT	CGATGGCCGA	GCTGTTCGTC	38760
CGCGGAGTCG	ACGTGGACTG	GGCCACGATG	GTGCCGCCAG	CGCGGGTCGA	TTTGCCGACC	38820
TACGCCTTCG	ACCACCAGCA	CTACTGGCTG	CGGTACGTCG	AGACCGCGAC	CGACGCGGCC	38880
GGTCCGGTGG	TCCGGCTGCC	GCAGACGGGC	GGCCTGGTCT	TCACCACCGA	GTGGTCGCTG	38940
AAGTCACAGC	CGTGGCTGGC	CGAGCACACC	CTGGAAGACC	TGGTCGTCGT	cccceccc	39000
GCACTGGTCG	AGCTGGCCGT	CCGGGCCGGT	GACGAGGCCG	GGACCCCGGT	GCTGGACGAA	39060
CTCGTCATCG	AGACGCCCCT	GGTCGTGCCG	GAACGCGGCG	CGATCCGGGT	GCAGGTCACG	39120
GTGAGCGGAC	CGGACGACGG	CACACGGACC	CTGGAAGTGC	ATTCCCAGCC	CGAAGACGCC	39180
ACCGACGAAT	GGACCCGGCA	CGCCACCGGC	ACGCTGTCGG	CGACCCCGGA	CGAAAGCAGC	39240

GGGTTCGACT TCACGGCCTG GCCGCCCCG GGCGCCCGGC AGCTCGACGG CGTTCCGGCG ATCTGGCGGG CCGCCGACGA GATCTTCGCC GAAGTCTCCC TGCCCGACGA TGCGGACGCC 39360 GAGGCATTCG GCATCCACCC CGCGCTCCTG GACGCGGCCC TGCACCCCGC CCTGCCCGGC 39420 GATGACGGTC TGACGCAGCC CATGGAATGG CGTGGCCTGA CGCTGCACGC CGCGGGGGCG 39480 TCGACGCTGC GGGTCCGGTT GGTGCCCGGC GGGTTCCTGG AAGCGGCCGA CGGCGCCGGC 39540 AGCCTGGTCG TCACGGCGAA GGAGGTTGCC CTCCGCCCGG TGACGATCGC GCGGTCGCGC 39600 ACCACCACC GAGACTCGCT GTTCCAGCTG AACTGGATCG AGCTGCCCGA GAGTGGCGTG 39660 GTGGCCGCGG CAGACGACAC CGAGGTGCTG GAGGTGCCCG CGGCGATTC CCCGCTGGCG 39720 GCGACCTCCC GAGTCTTGGA GCGGCTCCAG ACCTGGCTGA CCGAGCCCGA GGCGGAACAG 39780 CTGGTCGTCG TGACGCGCGG CGCGGTGCCC GCCGGGGACA CCCCGGTGAC CGACCCGGCC 39840 GCGGCGGCGG TCTGGGGCCT GGTCCGGTCC GCGCAGGCGG AGAACCCGGA CCGGATCGTC 39900 39960 GTCGCGGTGC GCGCCACGC GCTGTACGTC CCGCGCCTGG CCCGCGCCCGA CGCGGCCCCG 40020 GTATCCGGTC TACATGGGAC GGTCCTCGTC TCCGGTGCCG GTGTGCTCGG CGAGATCGTG 40080 GCGCGCACC TGGTCACCCG CCACGGCGTG CGCAAGCTGG TGCTCGCCAG CCGCCGCGC 40140 CTGGACGCG ACGCCGCGAA GGACCTCGTC ACCGACCTCA CCGGCGAGGG CGCGGACGTG 40200 TCCGTCGTCG CCTGCGACCT GGCCGATCGG AACCAGGTGG CCGCGCTGCT GGCCGACCAC 40260 CGCCCGGCGA GCGTCATCCA CACGGCGGGC GTCCTCGACG ACGGCGTCAT CGGGACGCTG 40320

- 90 -

ACCCCGGAGC GGCTGGCCAA GGTGTTCGCG CCCAAGGTCG ACGCGGTCCG CCATCTCGAC 40380 GAGCTGACTC GCGACCTCGA CCTCGACGCG TTCGTCGTGT TCTCCTCCGG CTCCGGCGTG 40440 TTCGGTTCGC CGGGCAGGG CAACTACGCG GCGGCGAACG CGTTCCTGGA CGCGGCGATG 40500 GCGAGCCGCC GCGCGGGGG TCTTCCTGGT CTCTCGCTGG CGTGGGGCCT GTGGGAACAG 40560 GCCACCGGCA TGACCGCGCA CCTCGGCGGC ACCGACCAGG CCCGGATGAG CCGGGGCGGG 40620 GTGCGGCCGA TCACGCCCGA GGAAGGCATG GCCCTGTTCG ACACGCCACT GGGTGCGCAG 40680 CCCGCGCTGC TCGTGCCGGT CAAGCTCGAC CTGCGGGGGGGG TGCGGGCCGG CGGGGCCGTG 40740 CCGCACCTGC TGCGCGGCT GGTCCGGGCC GGGCGGCGGC AGGCCCAAGC CGCGTCCACA 40800 GTGGACAACC AGCTGCTGGG CCGGCTGGCC GGGCTGGGG CGCCCGAGCA GGAGGCGCTG 40860 CTCGTCGACC TCGTGCGCGG CCAGGTCGCG GCGGTGCTCG GCCACGCCGG GCCGGACGCG 40920 GTCCGCGCG ACACGGCGTT CAAGGACGCC GGGTTCGACT CGCTCACCTC GGTCGACCTG 40980 CGCAACCGGC TGCGGGAGAG CACCGGGCTG AAGCTGCCCG CCACGCTCGC CTTCGACTAC 41040 CCGACCCCGC TGGTCCTCGC CCGGCACCTG CGTGACGAGC TCGGGGCCGG CGACGACGCG 41100 CTTTCGGTGG TGCACGCGC GCTCGAAGAC GTCGAGGCGC TGCTCGGCGG GCTGCGCCTC 41160 GACGAATCCA CGAAGACCGG TCTCACCCTC CGGCTGCAGG GCCTGGTCGC CCGGTGCAAC 41220 GCCGTGAACG ACCAGACCGG CGGCGAAACG CTGGCGGACC GGCTCGAGGC CGCGTCCGCC 41280 GACGAAGTCC TCGACTTCAT CGACGAGGAG CTGGGTCTCA CCTGACCCCG GTTCGAGACC 41340 GACGTTCCAG CAACCCTTGT GAGGACCCGA GAATGGCCCAC GGACGAGAAA CTCCTCAAAT 41400 ACCTCAAGCG CGTCACGGCG GAGCTGCACA GCCTGCGCAA GCAGGGTGCC CGGCACGCCG 41460

41520 AAGACCTGTG GCAGCTCGTG GCCGGCGGGG TCGACGCCCT TTCGGACTTC CCCGACGACC 41580 GGGGCTGGGA GCTGGACGGC CTGTTCGACC CGGACCCCGA CCACCCCGGG ACGTCGTACA 41640 CCAGCCAGGG CGGCTTCCTG CGTGGCGCCG GGCTGTTCGA CGCGGGCCTG TTCGGCATCT 41700 CGCCGCGCGA GGCCCTCGTC ATGGACCCGC AGCAGCGGGT GCTGCTGGAG ACGTCGTGGG 41760 AGGCCCTCGA AGACGCCGGG GTCGACCCGC TTTCGCTGAA GGGCAGCGAC GTCGGCGTGT 41820 TCTCCGGCGT CTTCACCCAG GGCTACGGCG CCGGGGCGAT CACGCCGGAC CTCGAGGCGT 41880 TCGCGGCAT CGGGGCGCG TCGAGCGTGG CGTCGGGCCG GGTGTCCTAC GTCTTCGGGC 41940 TCGAAGGACC GGCGGTCACC ATCGACACCG CGTGTTCGTC GTCGCTGGTG GCCATCCACC 42000 TCGCCGCGCA GGCCCTGCGC GCGGGCGAGT GCTCGATGGC GCTCGCCGGC GGGGCGACGG 42060 TGATGCCGAC GCCCGCACC TTCGTCGCGT TCTCGCGGCA GCGGGTGCTG GCTGCCGACG 42120 GCCGGTCCAA GGCCTTCTCC TCGACCGCG ACGCCACCGG CTGGGCCGAG GGCGCCGGGG 42180 TGCTCGTCCT CGAACGCTT TCGGTCGCC AGGAGCGCGG CCACCGGATT CTCGCCGTGC 42240 TGCGCGGCAG CGCGGTCAAC CAGGATGGCG CCTCCAACGG CCTGACCGCG CCGAACGGCC 42300 CTTCGCAGCA GCGGGTGATC CGCAAGGCGC TCGCGGGCGC CGGGCTGGTC GCGTCCGATG 42360 TGGACGTCGT GGAGGCGCAC GGCACGGGCA CCGCGCTGGG CGACCCGATC GAAGCGCAGG 42420 CGCTGCTGGC GACCTACGGC CAGGGCCGTG AGCGGCCGCT GTGGCTGGGG TCGGTCAAGT 42480 CGAACTTCGG GCACACGCAG GCGCCGCCG GGGTCGCGGG CGTGATCAAG ATGGTCCAGG 42540

CCCTGCGGCA	CGGCGCCATG	CCGCCGACCC	TGCACGTGGC	CGAGCCGACG	CCGGAGGTCG	42600
ACTGGTCGGC	CGGTGCGGTG	GAACTGCTGA	CCGAGCCGCG	CGAGTGGCCC	GCCGGTGATC	42660
GCCGCGCCG	GCCCGGGTG	TCCGCGTTCG	GGATCAGCGG	GACGAACGCC	CACCTGATCC	42720
TGGAGGAGGC	ecccceecc	GACGCGGTCG	CGGAAGAACC	GGAGTTCAAG	GGGCCGGTGC	42780
CGCTGGTCGT	CTCGGCGGGC	AGCCCCACAT	CTTTGGCGGC	TCAGGCCGGC	CGGCTCGCGG	42840
AGGTCCTGGC	GTCCGGTGGT	GTGTCCCGGG	CCCGGCTGGC	GAGCGGGCTG	CTGTCGGGCC	42900
GGCGCTGCT	CGGTGACCGC	CCCCTCCTCC	TCGCGGGAAC	GGACGAGGAC	GCGGTGGCCG	42960
GGTTGCGTGC	GCTGGCCCGC	GGGGACCGCG	CGCCCGGCGT	GCTGACCGGT	TCGGCCAAGC	43020
ACGGCAAGGT	CGTCTACGTC	TTCCCCGGCC	AGGGTTCGCA	GCGGCTCGGG	ATGGGCCGCG	43080
AGCTCTACGA	CCGGTACCCG	GTGTTCGCGA	CGGCGTTCGA	CGAGGCTTGC	GAGCAGCTGG	43140
ACGTCTGTCT	GGCCGGCCGT	GCCGGGCACC	GCGTGCGGGA	CGTCGTGCTC	GGCGAAGTGC	43200
CCGCCGAAAC	CGGGCTGCTG	AACCAGACGG	TCTTCACCCA	AGCCGGGCTG	TTCGCGGTGG	43260
AGAGCGCGCT	GTTCCGGCTC	GCCGAATCCT	GGGTGTCCG	GCCGGACGTG	GTGCTCGGCC	43320
ACTCCATCGG	GGAGATCACC	GCCGCGTATG	CCGCGGGCGT	CTTCTCGCTG	CCGGACGCCG	43380
CCCGGATCGT	cecececec	GGCCGGCTGA	TGCAGGCGCT	GCCCCCCCC	GGGCGATGG	43440
TCGCCGTCGC	CGCCTCCGAA	GCCGAGGTGG	CCGAACTGCT	CGCCGACGCC	GTGGAACTCG	43500
CCGCCGTCAA	CGGCCCTTCG	GCGGTAGTCC	TTTCCGGGGA	CGCGGACGCG	GTCGTCGCGG	43560
cceccecce	CATGCGCGAG	CGCGGGCACA	AGACCAAGCA	GCTCAAGGTT	TCGCACGCGT	43620
TCCACTCCGC	GCGGATGGCG	CCGATGCTGG	CGGAGTTCGC	CGCCGAGCTG	GCCGGCGTGA	43680

CGTGGCGCGA GCCGGAGATC CCGGTGGTCT CCAACGTGAC CGGCCGGTTC GCCGAGCCCG 43740 GCGAACTGAC CGAGCCGGGC TACTGGGCCG AGCACGTGCG GCGGCCGGTG CGGTTCGCCG 43800 AGGGCGTCGC GGCCGCGACG GAGTCCGGCG GCTCGCTGTT CGTGGAGCTC GGGCCGGGGG 43860 CGGCGCTGAC CGCCCTCGTC GAGGAGACGG CCGAGGTCAC CTGCGTCGCG GCCCTGCGGG 43920 ACGACCGCCC GGAGGTCACC GCGCTGATCA CCGCGGTCGC CGAGCTGTTC GTCCGCGGGG 43980 TTGCGGTCGA TTGGCCGGCC CTGCTGCCGC CGGTCACCGG GTTCGTCGAC CTGCCGAAGT 44040 ACGCCTTCGA CCAGCAGCAC TATTGGCTGC AGCCCGCCGC GCAGGCCACG GACGCGGCCT 44100 CGCTCGGGCA GGTCGCGGCC GACCACCCGC TGCTGGGCGC GGTGGTCCGG CTGCCGCAGT 44160 CGGACGCCT GGTCTTCACC TCGCGGCTGT CATTGAAATC GCACCCGTGG CTGGCCGACC 44220 ACGTCATCGG CGCGGTCGTG CTCGTCGCGG CCACCGGGCT CGTCGAGCTG GCCGTCCGGG 44280 CCGGGGACGA GGCCGCTGC CCGGTCCTCG AAGAACTCGT CATCGAGGCT CCGCTGGTCG 44340 TCCCCGACCA CGGCGGGTC CGGATCCAGG TCGTCGTGGG GGCACCGGGG GAGACCGGTT 44400 CGCGCGCGT CGAGGTGTAC TCCCTGCGCG AGGACGCCGG TGCCGAAGTG TGGGCCCGGC 44460 ACGCCACCGG GTTCCTGGCT GCGACGCCGT CGCAGCACAA GCCGTTCGAC TTCACCGCCT 44520 GGCCGCCGCC CGGCGTCGAC CGCGTCGACG TCGAGGACTT CTACGACGGC CTCGTCGACC 44580 GCGGGTACGC CTACGGGCCG TCGTTCCGGG GCCTGCGGGC GGTGTGGCGG CGCGGCGACG 44640 AAGTGTTCGC CGAGGTCGCC CTGGCCGAGG ACGACCGCGC GGACGCGGCC CGGTTCGGCA 44700 TCCACCCGG CCTGCTGGAC GCCGCCCTGC ACGCGGGCAT GGCCGGTGCC ACCACCACGG 44760

- 94 -

AAGAGCCCGG CCGGCCGGTG CTGCCGTTCG CCTGGAACGG CCTGGTGCTG CACGCGGCCG 44820 GGGCGTCCGC GCTGCGGGTC CGGCTCGCCC CGAGCGGTCC GGACGCCCTG TCGGTCGAGG 44880 CCGCGGACGA GGCCGGCGGT CTCGTTGTGA CGGCGGACTC GCTGGTCTCC CGGCCGGTGT 44940 CGGCCGAACA GCTGGGCGCG GCGGCGAACC ACGACGCGTT GTTCCGCGTG GAGTGGACCG 45000 AGATTTCCTC GGCTGGAGAC GTTCCGGCGG ACCACGTCGA AGTGCTCGAA GCCGTCGGCG 45060 AGGATCCCCT GGAACTGACC GGCCGGGTCC TGGAGGCCGT GCAGACCTGG CTCGCCGACG 45120 CAGCCGACGA CGCTCGCCTG GTCGTGGTGA CCCGCGCGCCC CGTCCACGAG GTGACTGACC 45180 45240 TCGTGCTGCT GGACACCGAC GGTGAAGTGC CGCTAGGCCG GGTGCTGGCC ACCGGCGAGC 45300 CCCAAACAGC CGTCCGAGGC GCCACGCTGT TCGCCCCGCG GCTGGCCCGC GCCGAGGCCG 45360 CGGAGGCACC GGCAGTGACC GGCGGGACGG TCCTGATCTC GGGCGCCGGC TCGCTGGGCG 45420 CGCTCACCGC CCGGCACCTG GTCGCCCGGC ACGGAGTCCG GCGGCTGGTG CTCGTCAGCC 45480 GCCGTGGCCC CGACGCCGAC GGCATGGCCG AACTGACCGC TGAACTCATC GCTCAGGGCG 45540 CCGAGGTCGC CGTAGTCGCT TCCGACCTGG CCGACCGGGA CCAGGTCCGG GTACTGCTGG 45600 CCGAGCACCG CCCGAACGCC GTCGTGCACA CGGCCGGTGT TCTCGACGAC GGCGTCTTCG 45660 AGTCGCTGAC GCGGGAGCGG CTGGCCAAGG TCTTCGCGCC CAAAGTTACT GCTGCCAATC 45720 ACCTCGACGA GCTGACCCGC GAACTGGATC TTCGCGCGTT CGTCGTGTTC TCCTCCGCCT 45780 CCGGGGTCTT CGGCTCCGCC GGGCAGGGCA ACTACGCCGC TGCCAACGCC TACCTGGACG 45840 CCGTGGTCGC CAACCGCCGG GCCGCGGGCC TGCCCGGCAC ATCGCTGGCC TGGGGCCTGT 45900

GGGAACAGAC CGACGGGATG ACCGCGCACC TCGGCGACGC CGACCAGGCG CGGGCGAGTC 45960 GCGCGGGGT CCTCGCCATC TCACCCGCCG AAGGCATGGA GCTGTTCGAC GCAGCGCCGG 46020 ACGGGCTCGT CGTCCCGGTC AAGCTGGACC TGCGCAAGAC CCGCGCCGGC GGGACGGTGC 46080 CCCACCTCCT CCCCCCCCC GTCCCCCCG GACGCAGCA GCCCCGTCCG GCGTCCACTG 46140 TGGACAACGG ACTGGCCGGG CGACTCGCCG GGCTCGCGCC GGCGGAGCAG GAGGCGCTGC 46200 TECTCGACGT CGTCCGCACG CAGGTCGCGC TGGTGCTCGG GCACGCCGGG CCGGAGGCCG 46260 TCCGCGCGGA CACGGCGTTC AAGGACACCG GCTTCGACTC GCTGACGTCG GTGGAACTGC 46320 GCAACCGGCT GCGCGAGGCG AGCGGGCTGA AGCTGCCCGC GACGCTCGTC TTCGACTACC 46380 CGACGCCGGT CGCGCTGGCC CGCTACCTGC GTGACGAACT CGGCGACACG GTGGCAACAA 46440 CTCCGGTGGC CACCGCGGCC GCAGCGGACG CCGGCGAGCC GATCGCCATC GTCGGCATGG 46500 CGTGCCGGCT GCCGGCGGG GTCACCGATC CCGAAGGCCT GTGGCGCCTG GTGCGCGACG 46560 GCCTCGAAGG GCTGTCTCCC TTCCCCGAGG ACCGGGGCTG GGACCTGGAG AACCTGTTCG 46620 ACGACGACCC CGACCGCTCC GGCACGACGT ACACCAGCCG GGGCGGGTTC CTCGACGGCG 46680 CCGCCTGTT CGACGCGGC TTCTTCGGGA TTTCGCCGCG CGAGGCGCTG GCCATGGACC 46740 CGCAGCAGCG GCTGCTGCTC GAGGCGGCCT GGGAAGCCCT CGAAGGCACC GGTGTCGACC 46800 CGGGCTCGTT GAAGGCCGCC GACGTCGGGG TGTTCGCCGG GGTGTCCAAC CAGGGCTATG 46860 GGATGGGCG GGATCCGGCC GAACTGGCGG GGTACGCGAG CACGGCGGGC GCTTCGAGCG 46920 TCGTCTCGGG CCGAGTCTCG TACGTCTTCG GGTTCGAAGG ACCGGCGGTC ACGATCGACA 46980

## WO 98/07868 PCT/EP97/04495 - 96 -

CGGCTTGCTC GTCGTCGCTG GTGGCGATGC ACCTGGCCGG GCAGGCGCTG CGGCAGGGCG 47040 AGTGCTCGAT GGCCCTGGCC GGTGGCGTCA CGGTGATGGG GACGCCCGGC ACGTTCGTGG 47100 AGTTCGCGAA GCAGCGCGGC CTGGCCGGCG ACGGCCGGTG CAAGGCCTAC GCCGAAGGCG 47160 CGGACGCAC GGGCTGGCC GAGGGCGTCG GGGTCGTCGT GCTGGAGCGG CTGTCGGTGG 47220 CGCGCGAGCG CGGCCACCG GTGCTGGCCG TGCTGCGCGG CAGCGCGGTC AACTCCGACG 47280 GCGCGTCCAA CGGCCTGACC GCCCCCAACG GGCCGTCGCA GCAACGGGTG ATCCGCCGGG 47340 CCCTGGCCGG CGCCGGCCTC GAACCGTCCG ATGTGGACAT CGTGGAAGGG CACGGCACCG 47400 GGACGCGCT GGCCGACCCG ATCGAGGCGC AGGCCCTGCT GGCCACCTAC GGCAAGGACC 47460 GCGACCCGGA GACGCCGTTG TGGCTGGGGT CGGTGAAGTC GAACTTCGGC CACACGCAGT 47520 CCGCGGCCGG CGTGGCCGGG GTGATCAAGA TGGTGCAGGC GCTGCGCCAC GGCGTCATGC 47580 CGCCCACCT GCACGTGGAC CGGCCCACCA GCCAGGTCGA CTGGTCCGCG GGGGCCGTCG 47640 AAGTGCTGAC CGAGGCACGG GAGTGGCCGC GGAACGGCCG TCCGCGCCGG GCCGGGTGT 47700 CCTCGTTCGG GATCAGCGGC ACGAACGCCC ACCTGATCAT CGAAGAAGCA CCGGCCGAGC 47760 CACAGCTTGC CGGACCACCG CCGGACGGCG GTGTGGTGCC GCTGGTCGTC TCGGCTCGCA 47820 GCCCCGGTGC CCTGGCCGGT CAGGCGCGTC GGCTGGCCAC GTTCCTCGGC GACGGGCCCC 47880 TTTCCGACGT CGCCGGTGCG CTGACGAGCC GCGCCCTGTT CGGCGAGCGC GCGGTCGTCG 47940 TGGCGGATTC GGCCGAGGAA GCCCGCGCG GTCTGGGCGC ACTGGCCCGC GGCGAAGACG 48000 CGCCGGGCCT GGTCCGCGGC CGGGTGCCCG CGTCCGGCCT GCCGGGCAAG CTCGTGTGGG 48060 TGTTCCCCGG GCAGGGGACG CAGTGGGTCG GCATGGGCCG CGAACTCCTC GAAGAGTCTC 48120

CGGTGTTCGC CGAGCGGATC GCCGAGTGTG CGGCCGCGCT GGAGCCGTGG ATCGGCTGGT 48180 CGCTGTTCGA CGTCCTCCGT GGCGACGGTG ACCTCGATCG GGTCGATGTG CTGCAGCCCG 48240 CGTGCTTTGC GGTCATCGTC GGCTTGGCCG CGGTGTGGTC CTCGGCCGGG GTGGTCCCCG 48300 ATGCGGTGCT CGGCCACTCC CAGGGTGAGA TCGCCGCGC GTGCGTGTCG GGTGCGTTGT 48360 CGCTGGAGGA TGCGGCGAAG GTGGTTGCCC TGCGCAGCCA GGCCATCGCC GCGAAGCTCT 48420 CCGGCCGCG CGGGATGCT TCGGTCGCCT TGGGCGAAGC CGATGTGGTG TCGCGGCTGG 48480 CGGACGGGT CGAGGTGGCT GCCGTCAACG GTCCGGCGTC CGTGGTGATC GCGGGGGATG 48540 CCCAGGCCCT CGACGAAACG CTGGAAGCGC TGTCCGGTGC GGGAATCCGG GCTCGGCGGG 48600 TGGCGGTGGA CTACGCCTCG CACACCCGGC ACGTCGAAGA CATCGAAGAC ACCCTCGCCG 48660 AAGCGCTGGC CGGGATCGAC GCCCGGGCGC CGCTGGTGCC GTTCCTCTCC ACCCTCACCG 48720 GCGAGTGGAT CCGGGACGAG GGCGTCGTGG ACGGCGGCTA CTGGTACCGG AACCTGCGCG 48780 GCCGGGTGCG GTTCGGCCCG GCCGTCGAGG CGCTGCTGGC CCAGGGGCAC GGTGTGTTCG 48840 TCGAGCTCAG CGCCCACCOG GTGCTGGTCC AGCCGATCAC CGAGCTCACC GACGAAACCG 48900 CCGCCGTCGT CACCGGTTCG CTGCGCCGGG ACGACGGTGG CCTGCGCCGG CTGCTGACCT 48960 CGATGGCCGA GCTCTTCGTC CGTGGGGTCG AAGTGGACTG GACGTCGCTG GTGCCGCCGG 49020 CCCGGCCGA CCTCCCGACG TACGCCTTCG ACCACGAGCA CTACTGGCTC CGCGCCGCGG 49080 ACACCECTTC CGACGCCGTC TCGCTGGGGC TGGCCGGGGC GGACCACCCG CTGCTCGGCG 49140 CGGTCGTGCA GCTTCCGCAG TCCGACGGCC TGGTCTTCAC TTCCCGGCTC TCCCTGCGCT 49200

# WO 98/07868 PCT/EP97/04495 - 98 -

CGCACCCTG GCTGGCCGAC CACGCGGTCC GGGACGTCGT GATCGTCCCC GGCACCGGGC 49260 TGGTCGAGCT GGCCGTGCGG GCCGGTGACG AAGCCGGCTG CCCGGTGCTC GACGAGCTGG 49320 TGATCGAGGC GCCGCTCGTG GTGCCCCGCC GCGGCGGGT CCGCGTGCAG GTCGCCCTCG 49380 GCGCCCCGC CGACGACGT TCGCGCACGG TGGACGTCTT CTCCCTGCGC GAAGACGCGG 49440 ACAGCTGGCT CCGGCACGCC ACGGGCGTGC TGGTCCCGGA GAACCGGCCG CGGGGGACCG 49500 CCGCGTTCGA CTTCGCCGCC TGGCCGCCAC CGGAGGCGAA GCCCGTGGAC CTCACCGGTG 49560 CCTACGACGT GCTCGCGGAC GTCGGGTACG GCTACGGGCC CACGTTCCGG GCCGTGCGGG 49620 CCGTGTGCG GCGCGCAGC GGGAACACCA CCGAGACCTT CGCCGAGATC GCCCTGCCCG 49680 AAGACGCCCG CGCGGAAGCC GGCCGGTTCG GCATCCACCC CGCGCTGCTG GACGCGGCCC 49740 TGCACTCGAC GATGGTCAGC GCCGCGGCGG ACACCGAGTC CTACGGCGAC GAAGTGCGGC 49800 TGCCGTTCGC GTGGAACGGG CTGCGGCTGC ACGCGGCCGG CGCCTCGGTG CTGCGGGTGC 49860 GCGTCGCCAA GCCCGAGCGG GACAGTCTGT CGCTGGAGGC CGTCGACGAG TCCGGCGGCC 49920 TGGTCGTGAC GCTGGATTCC CTGGTCGGC GCCCGGTGTC GAACGACCAG CTGACGACGG 49980 CGGCGGGCC GGCGCGCCC GGCTCGCTGT ACCGCGTGGA CTGGACGCCA TTGTCCTCAG 50040 TGGACACTTC GGGACGGGTG CCGTCCTGGC TTCCGGTCGC CACCGCGGAA GAGGTGGCGA 50100 CGCTGGCCGA CGACGTCCTG ACCGGCGCGA CCGAGGCGCC GGCGGTGGCC GTCATGGAGG 50160 CCGTCGCCGA CGAGGGTTCC GTGCTGGCGC TCACCGTCCG GGTGCTGGAC GTGGTCCAGT 50220 GCTGGCTGGC CGGCGGCGGG CTGGAGGGGA CGAAGCTCGC GATCGTGACC CGCGCGCGG 50280 TGCCCGCCGG CGACGGCGTG GTGCACGACC CGGCCGCGGC CGCGGTGTGG GGGCTGGTCC 50340

GGGCCGCGCA GGCGGAGAAC	CCGGACCGGA	TCGTCCTCCT	CGACGTCGAG	CCGGAAGCCG	50400
ACGTACCGCC GCTGCTGGGT	TCGGTGCTCG	CCGACGGCGA	GCCGCAGGTC	GCGGTGCGCG	50460
GAACCACGCT GTCCATCCCC	CGCCTCGCCC	GCGCCGCCCG	GCCCGACCCG	GCCGCCGGGT	50520
TCAAGACCCG GGGACCGGTG	CTGGTCACCG	GCGGGACCGG	GTCGCTCGGC	GGCCTGGTCG	50580
CCCGCCACCT GGTCGAGCGG	CACGGCGTCC	GGCAGCTGGT	GCTGGCGAGT	CCCCGGGGCC	50640
TGGACGCCGA AGGCGCGAAG	GACCTGGTCA	CCGACCTCAC	CGCACTGGGG	GCCGACGTCG	50700
CGGTCGCCGC TTGCGACGTC	GCCGACCGGG	ACCAGGTGGC	GGCCCTGCTG	ACCGAGCACC	50760
GGCCGTCCGC CGTGGTGCAC	ACGGCCGGCG	TCCCGGACGC	CGGGGTGATC	GGGACGGTGA	50820
CCCCGGACCG GCTGGCCGAG	GTGTTCGCGC	CCAAGGTCAC	CGCGGCCCGG	CACCTCGACG	50880
AGCTGACCCG CGACCTGGAC	CTCGACAGTT	TCGTCGTCTA	CTCCTCGGTT	TCCGCGGTGT	50940
TCATGGGCGC CGGCAGCGGC	AGCTACGCCG	CGGCGAACGC	GTACCTGGAC	GGGCTGATGG	51000
CCCACCGGCG CGCGGCCGGC	CTGCCGGGCC	AGTCGCTGGC	GTGGGGGCTG	TGGGACCAGA	51 <b>06</b> 0
CCACCGGCGG CATGGCGGCC	GGGACCGACG	AGGCCGGCCG	GGCCCGGATG	ACCCGGCGCG	51120
GCGGCCTGGT CGCGATGAAA	cccccccc	GACTGGACCT	CTTCGACGCT	GCCATCGGGT	51180
CCGCCGAGCC GCTGCTGGTG	CCCGCCCAGC	TCGACCTGCG	GGGCCTGCGC	GCCGAAGCGG	51240
CGGCGGCAC CGAAGTGCCG	CACCTGCTGC	GCGGCCTGGT	CCGCGCCGGA	CGCCAGCAGG	51300
CCCGTGCGGC GTCCACTGTG	GAGGAGAACT	GGGCCGGCCG	CCTCCCCCGG	CTCGAGCCGG	51360
CCGAGCGGGG CCAGGTCCTC	CTGGAACTGG	TGCGCGCCCA	GGTGGCAGGG	GTCCTGGGCT	51420

ACCGCGCCGC	CCACCAGGTC	GACCCGGACC	AGGGCCTGTT	CGAGATCGGG	TTCGACTCGC	51480
TCACCGCGAT	CGAACTCCGC	AACCGGCTGC	GCGCCAGGAC	CGAACGGAAG	ATCTCGCCCG	51540
GTGTCGTCTT	CGACCATCCC	ACGCCGGCCC	TGCTCGCCGC	GCACTTGAAC	GAGCTGCTCC	51600
GAAAGAAGGT	GTGAACGTGT	TCGACGTGGA	GACCTACCTC	CAGCGGATCG	CCTCCGCCGG	51660
GGAAACCGGC	GTGGACCTCG	AAACGCTGGC	GAAGCTGCAG	AAGAGCCACC	TGATGGCGAT	51720
CCCGTACAGC	AGCCTCGCCT	ACGAACTCCG	GGACGCGGTG	AACGTCCTCG	ACCTCGACGA	51780
GGACGACGTC	TTCGTCACCA	GCATCGCCGA	AGGGCAGGGC	GCCCCTCCT	ACCACCTGAA	51840
CCGGCTGTTC	CACCGGCTCC	TGACCGAACT	CGGCTACGAC	GTCACGCCGC	TGGCCGGCAG	51900
CACCGCCGAA	GGCCGGGAGA	CCTTCGGCAC	CGACGTCGAG	CACATGTTCA	ACCTGGTCAC	51960
CCTGGACGGC	GCCGACTGGC	TCGTGGACGT	CGGCTACCCC	GGCCCCACCT	ACGTCGAGCC	52020
ACTGGCGGTC	TCGCCCGCGG	TGCAGACCCA	GTACGGGAGC	CAGTTCCGGT	TGGTGGAACA	52080
GGAAACCGGT	TATGCGCTGC	AACGCCGGGG	TGCGGTCACC	CGCTGGAGCG	TCGTCTACAC	52140
GTTCACGACG	CAACCGCGTC	AGTGGAGTGA	CTGGAAGGAA	CTGGAGGACA	ACTTCCGGGC	52200
CCTCGTGGGG	GACACCACCC	GCACCGACAC	GCAGGAAACC	CTGTGCGGCC	GCGCGTTCGC	52260
GAACGGCCAG	GTCTTCCTGC	GGCAGCGCCG	CTACCTGACG	GTCGAGAACG	GCCGCGAGCA	52320
GGTGCGCACG	ATCACCGACG	ACGACGAGTT	CCGGGCGCTG	GTGTCCCGCG	TGCTGTCCGG	52380
CGACCACGGC	TGAACTGGCG	AAAGGCACGA	CGATGACGGA	AAAAGCGGGC	CTGCTGGCGA	52440
AGTTCGCCGG	CCTCTGCAAA	ACCGCCTACG	AGCACCACTA	CATCCCGTAC	CTGCACTTCT	52500
TCTACGGCGG	CGAGTACCTC	CACCACGGCA	GCGAGCCGGT	GTCCCGGATC	GCGGACCTGC	52560

CGTACGTGAC	CGTGCCGGAG	CCGCGGAAGA	AGGCGCCGTG	AGGACGACGA	TCCCGGTCCG	52620
CCTGGCGGAA	CGGTCCTACG	ACGTGCTCGT	CGGCCCCGGG	GTGCGGGGG	CGCTGCCCGA	52680
GGTCGTCCGG	CGGCTCGGCG	CGAGACGGGC	CGTGGTCGTG	TCGGCCCGGC	CGGCGGACTG	52740
GGTGCCCGGC	ACCGGCGTCG	AGACCCTGCT	GCTCCAGGCG	CGCGACGGCG	AGCCGACCAA	52800
GCGGCTGTCC	ACAGTGGAGG	AACTGTGCGG	TGAGTTCGCG	CGGTTCGGGC	TCACCCGGTC	52860
CGACGTCGTG	GTCTCCTGCG	GCGGCGGCAC	GACCACGGAC	GTCGTCGGGC	TCGCGGCCGC	52920
GCTGTACCAC	CGGGGGGTCG	CCGTGGTCCA	CCTGCCCACG	TCCCTGCTCG	CCCAGGTCGA	52980
CGCCAGCGTC	GGCGGGAAGA	CCGCGGTGAA	CCTGCCGGCG	GGCAAGAACC	TCGTCGGGGC	53040
GTACTGGCAG	CCCAGCGCGG	TGCTGTGCGA	CACGGACTAC	CTGACGACGC	TGCCGCGGCG	53100
GGAGGTGCTG	AACGGCCTCG	GCGAGATCGC	CCGCTGCCAC	TTCATCGGCG	CGCCGGACCT	53160
eceeecec	TCGCGCCCGG	AGCAGATCGC	CGCCAGCGTC	ACCCTCAAGG	CGGGCATCGT	53220
CGCGCAGGAC	GAGCGGGACA	ccecccece	GCACCTGCTC	AACTACGGCC	ACACGCTGGG	53280
GCACGCGCTG	GAGATCGCGA	CCGGCTTCGC	CCTGCGCCAC	GCCGAGCCGG	TGGCGATCGG	53340
CACGGTCTTC	cccccccc	TGGCCGGCGC	CCTCGCCCGC	CTCGACCAGT	CCGGTGTGGA	53400
CGAACACCTC	GCCGTCGTCC	GCCACTACGG	CCTGCCCGCC	GCGCTGCCCG	CGGACGTCGA	53460
CCCGGCGTG	CTCGTCCGGC	AGATGTACCG	GGACAAGAAG	GCGATCACCG	GGCTCGCCTT	53520
CGTCCTGGCC	GGGCCGCGGG	GCGCGGAGCT	GGTGAGCGAC	CICCCCCCC	CGGTCGTCAC	53580
CGACGTCCTG	GACCGGATGC	CCCGCGACAG	CCTGGAAAAC	CTGGTGGGGA	CGACGGAAGC	53640

- 102 -

GGCGGCGCCG TGAAGCGCA GCCGGACTTC GCGGCCCACG GCCGGGCGGT CGACCGGGTG 53700

CTGGCCGGCC GGCTGAGCGC GGCGCTGGCC CGCCGGCCG CGCAGCAGCC GGCTGGCCG 53760

GACGCCGAGC GGGCGCCGA GGTGAATTC 53789

#### (2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4572 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Phe Tyr Thr Ser Gly Thr Thr Gly Arg Pro Lys Gly Val Val Ser

1 10 15

Thr Gln Arg Asn Cys Leu Trp Ser Val Ala Ser Cys Tyr Val Pro Phe 20 25 30

Pro Gly Leu Ser Asp Gln Asp Arg Val Leu Trp Pro Leu Pro Leu Phe 35 40 45

His Ser Leu Ser His Ile Ala Cys Val Leu Ser Ala Thr Val Val Gly
50 55 60

Ala Ser Val Arg Ile Ala Asp Gly Ser Ser Ala Asp Asp Val Met Arg 65 70 75 80

Leu	Ile	Glu	Ala	Glu 85	Ser	Ser	Thr	Phe	Leu 90	Ala	Gly	Val	Pro	Thr 95	Thr
Tyr	His	His	Leu 100	Val	Arg	Ala	Ala	<b>Ar</b> g 105	Gln	Arg	Gly	Phe	Ser 110	Ala	Pro
Ser	Leu	Arg 115	Ile	Gly	Leu	Ala	Gly 120	Gly	Ala	Val	Leu	Gly 125	Ala	Gly	Leu
Arg	Ser 130	Glu	Phe	Glu	Glu	Thr 135	Phe	Gly	Val	Pro	Leu 140	Ile	Asp	Ala	Tyr
Gly 145	Ser	Thr	Glu	Thr	Cys 150	Gly	Ala	Ile	Thr	Met 155	Asn	Pro	Pro	Asp	Gly 160
Ala	Arg	Val	Glu	Gly 165	Ser	Cys	Gly	Leu	Ala 170	Val	Pro	Gly	Val	<b>As</b> p 175	Val
Arg	Val	Val	Asp 180	Pro	Asp	Thr	Gly	Leu 185	Asp	Val	Pro	Ala	Gly 190	Glu	Glu
Gly	Glu	Val 195	Trp	Val	Ser	Gly	Pro 200	Asn	Val	Met	Leu	Gly 205	Tyr	His	Asn
Ser	Pro 210	Glu	Ala	Thr	Ala	Ala 215	Ala	Met	Arg	Asp	Gly 220	Trp	Phe	Arg	Thr
Gly 225	Asp	Leu	Ala	Arg	Arg 230	Asp	Asp	Ala	Gly	туг 235	Phe	Thr	Ile	Cys	Gly 240
Arg	Ile	Lys	Glu	Leu 245	Ile	Ile	Arg	Gly	Gly 250	Ala	Asn	Ile	His	Pro 255	Gly
Glu	Val	Glu	Ala	Val	Lev	Aro	Thr	Val	Asp	Glv	Val	Ala	Asp	Ala	Ala

265

260

270

Val	Gly	Gly 275	Val	Pro	His	Asp	Thr 280	Leu	Gly	Glu	Val	Pro 285	Val	Ala	Тул
Val	Ile 290	Pro	Gly	Pro	Thr	Gly 295	Phe	Asp	Pro	Ala	Ala 300	Leu	Ile	Glu	Lys
Суз 305	Arg	Glu	Gln	Leu	Ser 310	Ala	Tyr	Lys	Val	Pro 315	Asp	Arg	Ile	Leu	Glu 320
Val	Ala	His	Ile	Pro 325	Arg	Thr	Ala	Ser	Gly 330	Lys	Ile	Arg	Arg	Gly 335	Leu
Leu	Thr	Asp	Glu 340	Pro	Ala	Gln	Leu	Arg 345	Tyr	Ala	Ala	Thr	Glu 350	His	Glu
Glu	Gln	Ser 355	Arg	His	Ala	Asp	Glu 360	Ser	Val	Ala	Ala	Ala 365	Leu	Arg	Ala
Arg	Leu 370	Ser	Gly	Leu	Asp	Glu 375	Arg	Ala	Gln	Cys	Glu 380	Leu	Leu	Glu	Asp
Leu 385	Val	Arg	Thr	Gln	<b>Al</b> a 390	Ala	Ąsp	Val	Leu	Gly 395	Gln	Pro	Val	Pro	Asp 400
Gly	Arg	Ala	Phe	Arg 405	Asp	Leu	Gly	Phe	Thr 410	Ser	Leu	Ala	Ile	<b>Val 415</b>	Glu
Leu	Arg	Asn	Arg 420	Leu	Thr	Glu	His	Thr 425	Gly	Leu	Trp	Leu	Pro 430	Ala	Ser
Ala	Val	Phe 435	Asp	His	Pro	Thr	Pro <b>4</b> 40	Ala	Ala	Leu	Ala	Ala 445	Arg	Val	Arg
Ala	Glu 450	Leu	Leu	Gly	Ile	Thr 455	Gln	Ala	Val	Ala	Glu 460	Pro	Val	Val	Ala

Ala Asp Pro Gly Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg Leu

- 105 -

Pro Gly Gly Val Ala Ser Pro Glu Asp Leu Trp Arg Leu Val Ala Glu Arg Val Asp Ala Val Ser Glu Phe Pro Gly Asp Arg Gly Trp Asp Leu Asp Ser Leu Ile Asp Pro Asp Arg Glu Arg Ala Gly Thr Ser Tyr Val Gly Gln Gly Gly Phe Leu His Asp Ala Gly Glu Phe Asp Ala Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Val Ala Met Asp Pro Gln Gln Arg Leu Leu Glu Thr Ser Trp Glu Ala Leu Glu Asn Ala Gly Val Asp Pro Ile Ala Leu Lys Gly Thr Asp Thr Gly Val Phe Ser Gly Leu Met Gly Gln Gly Tyr Gly Ser Gly Ala Val Ala Pro Glu Leu Glu Gly Phe Val Thr Thr Gly Val Ala Ser Ser Val Ala Ser Gly Arg Val Ser Tyr €20 Val Leu Gly Leu Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Ala Gln Ala Leu Arg Gln Gly €50 Glu Cys Ser Met Ala Leu Ala Gly Gly Val Thr Val Met Ala Thr Pro 

WO 98/07868

- 106 -

Gly	Ser	Phe 675	Val	Glu	Phe	Ser	Arg 680	Gln	Arg	Ala	Leu	Ala 685	Pro	Asp	Gly
Arg	Cys 690	Lys	Ala	Phe	Ala	Ala 695	Ala	Ala	Asp	Gly	Thr 700	Gly	Trp	Ser	Glu
Gly 705	Val	Gly	Val	Val	Val 710	Leu	Glu	Arg	Leu	Ser 715	Val	Ala	Arg	Glu	Arg 720
Gly	His	Arg	Ile	Leu 725	Ala	Val	Leu	Arg	Gly 730	Ser	Ala	Val	Asn	Gln 735	Asp
Gly	Ala	Ser	Asn 740	Gly	Leu	Thr	Ala	Pro 745	Asn	Gly	Leu	Ser	Gln 750	Gln	Arg
Val	Ile	Arg 755	Arg	Ala	Leu	Ala	<b>Al</b> a 760	Ala	Gly	Leu	Ala	Pro 765	Ser	Asp	Val
Asp	Val 770	Val	Glu	Ala	His	Gly 775	Thr	Gly	Thr	Thr	Leu 780	Gly	Asp	Pro	Ile
Glu 785	Ala	Gln	Ala	Leu	Leu 790	Ala	Thr	Tyr	Gly	Gln 795	Glu	Arg	Lys	Gln	Pro 800
Leu	Trp	Leu	Gly	Ser 805	Leu	Lys	Ser	Asn	Ile 810	Gly	His	Ala	Gln	Ala 815	Ala
Ala	Gly	Val	Ala 820	Gly	Val	Ile	Lys	Met 825	Val	Gln	Ala	Leu	Arg 830	His	Glu
Thr	Leu	Pro 835	Pro	Thr	Leu	His	Val 840	Asp	Lys	Pro	Thr	Leu 845	Glu	Val	Asp

Trp Ser Ala Gly Ala Ile Glu Leu Leu Thr Glu Ala Arg Ala Trp Pro

860

855

850

Arg Asn Gly Arg Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Ala His Leu Ile Leu Glu Glu Ala Pro Ala Glu Glu Pro Val Ala Ala Pro Glu Leu Pro Val Val Pro Leu Val Val Ser Ala Arg Ser Thr Glu Ser Leu Ser Gly Gln Ala Glu Arg Leu Ala Ser Leu Leu Glu Gly Asp Val Ser Leu Thr Glu Val Ala Gly Ala Leu Val Ser Arg Arg Ala Val Leu Asp Glu Arg Ala Val Val Ala Gly Ser Arg Glu Glu Ala Val Thr Gly Leu Arg Ala Leu Asn Thr Ala Gly Ser Gly Thr Pro Gly Lys Val Val Trp Val Phe Pro Gly Gln Gly Thr Gln Trp Ala Gly Met Gly Arg Glu Leu Leu Ala Glu Ser Pro Val Phe Ala Glu Arg Ile Ala Glu Cys Ala Ala Ala Leu Ala Pro Trp Ile Asp Trp Ser Leu Val Asp Val Leu Arg Gly Glu Gly Asp Leu Gly Arg Val Asp Val Leu Gln Pro Ala Cys Phe Ala Val Met Val Gly Leu Ala Ala Val Trp Glu Ser Val Gly Val Arg Pro Asp Ala Val Val Gly His Ser Gln Gly Glu

- 108 -

Ile Ala Ala Cys Val Ser Gly Ala Leu Ser Leu Glu Asp Ala Ala Lys Val Val Ala Leu Arg Ser Gln Ala Ile Ala Ala Glu Leu Ser Gly Arg Gly Gly Met Ala Ser Val Ala Leu Gly Glu Asp Asp Val Val Ser Arg Leu Val Asp Gly Val Glu Val Ala Ala Val Asn Gly Pro Ser Ser Val Val Ile Ala Gly Asp Ala His Ala Leu Asp Ala Thr Leu Glu Ile Leu Ser Gly Glu Gly Ile Arg Val Arg Arg Val Ala Val Asp Tyr Ala Ser His Thr Arg His Val Glu Asp Ile Arg Asp Thr Leu Ala Glu Thr Leu Ala Gly Ile Ser Ala Gln Ala Pro Ala Val Pro Phe Tyr Ser Thr Val Thr Ser Glu Trp Val Arg Asp Ala Gly Val Leu Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Asn Gln Val Arg Phe Gly Ala Ala Ala Thr Ala Leu Leu Glu Gln Gly His Thr Val Phe Val Glu Val Ser Ala His Pro Val Thr Val Gln Pro Leu Ser Glu Leu Thr Gly Asp Ala Ile Gly

Thr Leu Arg Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Ala Ser Met Gly Glu Leu Phe Val Arg Gly Ile Asp Val Asp Trp Thr Ala Met Val Pro Ala Ala Gly Trp Val Asp Leu Pro Thr Tyr Ala Phe Glu His Arg His Tyr Trp Leu Glu Pro Ala Glu Pro Ala Ser Ala Gly Asp Pro Leu Leu Gly Thr Val Val Ser Thr Pro Gly Ser Asp Arg Leu Thr Ala Val Ala Gln Trp Ser Arg Arg Ala Gln Pro Trp Ala Val Asp Gly Leu Val Pro Asn Ala Ala Leu Val Glu Ala Ala Ile Arg Leu Gly Asp Leu Ala Gly Thr Pro Val Val Gly Glu Leu Val Val Asp Ala Pro Val Val Leu Pro Arg Arg Gly Ser Arg Glu Val Gln Leu Ile Val Gly Glu Pro Gly Glu Gln Arg Arg Pro Ile Glu Val Phe Ser Arg Glu Ala Asp Glu Pro Trp Thr Arg His Ala His Gly Thr Leu Ala Pro Ala Ala Ala Ala Val Pro Glu Pro Ala Ala Ala Gly Asp Ala Thr Asp Val Thr Val Ala

:

- 110 -

WO 98/07868 PCT/EP97/04495

Gly Leu Arg Asp Ala Asp Arg Tyr Gly Ile His Pro Ala Leu Leu Asp 1460 1465 1470

Ala Ala Val Arg Thr Val Val Gly Asp Asp Leu Leu Pro Ser Val Trp 1475 1480 1485

Thr Gly Val Ser Leu Leu Ala Ser Gly Ala Thr Ala Val Thr 1490 1495 1500

Pro Thr Ala Thr Gly Leu Arg Leu Thr Asp Pro Ala Gly Gln Pro Val 1505 1510 1515 1520

Leu Thr Val Glu Ser Val Arg Gly Thr Pro Phe Val Ala Glu Gln Gly 1525 1530 1535

Thr Thr Asp Ala Leu Phe Arg Val Asp Trp Pro Glu Ile Pro Leu Pro 1540 1545 1550

Thr Ala Glu Thr Ala Asp Phe Leu Pro Tyr Glu Ala Thr Ser Ala Glu 1555 1560 1565

Ala Thr Leu Ser Ala Leu Gln Ala Trp Leu Ala Asp Pro Ala Glu Thr 1570 1575 1580

Arg Leu Ala Val Val Thr Gly Asp Cys Thr Glu Pro Gly Ala Ala Ala 1585 1590 1595 1600

Ile Trp Gly Leu Val Arg Ser Ala Gln Ser Glu His Pro Gly Arg Ile 1605 1610 1615

Val Leu Ala Asp Leu Asp Asp Pro Ala Val Leu Pro Ala Val Val Ala 1620 1625 1630

Ser Gly Glu Pro Gln Val Arg Val Arg Asn Gly Val Ala Ser Val Pro 1635 1640 1645

Arg Leu Thr Arg Val Thr Pro Arg Gln Asp Ala Arg Pro Leu Asp Pro

- 111 -

Glu Gly Thr Val Leu Ile Thr Gly Gly Thr Gly Thr Leu Gly Ala Leu Thr Ala Arg His Leu Val Thr Ala His Gly Val Arg His Leu Val Leu Val Ser Arg Arg Gly Glu Ala Pro Glu Leu Gln Glu Glu Leu Thr Ala Leu Gly Ala Ser Val Ala Ile Ala Ala Cys Asp Val Ala Asp Arg Ala Gln Leu Glu Ala Val Leu Arg Ala Ile Pro Ala Glu His Pro Leu Thr Ala Val Ile His Thr Ala Gly Val Leu Asp Asp Gly Val Val Thr Glu Leu Thr Pro Asp Arg Leu Ala Thr Val Arg Arg Pro Lys Val Asp Ala Ala Arg Leu Leu Asp Glu Leu Thr Arg Glu Ala Asp Leu Ala Ala Phe Val Leu Phe Ser Ser Ala Ala Gly Val Leu Gly Asn Pro Gly Gln Ala Gly Tyr Ala Ala Ala Asn Ala Glu Leu Asp Ala Leu Ala Arg Gln Arg Asn Ser Leu Asp Leu Pro Ala Val Ser Ile Ala Trp Gly Tyr Trp Ala Thr Val Ser Gly Met Thr Glu His Leu Gly Asp Ala Asp Leu Arg Arg

Asn Gln Arg Ile Gly Met Ser Gly Leu Pro Ala Asp Glu Gly Met Ala 1860 1865 1870

Leu Leu Asp Ala Ala Ile Ala Thr Gly Gly Thr Leu Val Ala Ala Lys 1875 1880 1885

Phe Asp Val Ala Ala Leu Arg Ala Thr Ala Lys Ala Gly Gly Pro Val 1890 1895 1900

Pro Pro Leu Leu Arg Gly Leu Ala Pro Leu Pro Arg Arg Ala Ala 1905 1910 1915 1920

Lys Thr Ala Ser Leu Thr Glu Arg Leu Ala Gly Leu Ala Glu Thr Glu
1925 1930 1935

Gln Ala Ala Leu Leu Asp Leu Val Arg Arg His Ala Ala Glu Val 1940 1945 1950

Leu Gly His Ser Gly Ala Glu Ser Val His Ser Gly Arg Thr Phe Lys 1955 1960 1965

Asp Ala Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Arg Leu 1970 1975 1980

Ala Ala Ala Thr Gly Leu Thr Leu Ser Pro Ala Met Ile Phe Asp Tyr 1985 1990 1995 2000

Pro Lys Pro Pro Ala Leu Ala Asp His Leu Arg Ala Lys Leu Phe Gly 2005 2010 2015

Ser Ala Ala Asn Arg Pro Ala Glu Ile Gly Thr Ala Ala Glu Glu 2020 2025 2030

Pro Ile Ala Ile Val Ala Met Ala Cys Arg Phe Pro Gly Gly Val His 2035 2040 2045

Ser Pro Glu Asp Leu Trp Arg Leu Val Ala Asp Gly Ala Asp Ala Val 2050 2055 2060

Thr Glu Phe Pro Ala Asp Arg Gly Trp Asp Thr Asp Arg Leu Tyr His 2065 2070 2075 2080

Glu Asp Pro Asp His Glu Gly Thr Thr Tyr Val Arg His Gly Ala Phe 2085 2090 2095

Leu Asp Asp Ala Ala Gly Phe Asp Ala Ala Phe Phe Gly Ile Ser Pro 2100 2105 2110

Asn Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Glu Thr 2115 2120 2125

Ser Trp Glu Leu Phe Glu Arg Ala Ile Asp Pro Thr Thr Leu Ala 2130 2135 2140

Gly Gln Asp Ile Gly Val Phe Ala Gly Val Asn Ser His Asp Tyr Ser 2145 2150 2155 2160

Met Arg Met His Arg Ala Ala Gly Val Glu Gly Phe Arg Leu Thr Gly
2165 2170 2175

Gly Ser Ala Ser Val Leu Ser Gly Arg Val Ala Tyr His Phe Gly Val 2180 2185 2190

Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val 2195 2200 2205

Ala Leu His Met Ala Val Gln Ala Leu Gln Arg Gly Glu Cys Ser Met 2210 2215 2220

Ala Leu Ala Gly Gly Val Met Val Met Gly Thr Val Glu Thr Phe Val
2225 2230 2235 2240

Glu Phe Ser Arg Gln Arg Gly Leu Ala Pro Asp Gly Arg Cys Lys Ala

- 114 -

Phe Ala Asp Gly Ala Asp Gly Thr Gly Trp Ser Glu Gly Val Gly Leu Leu Leu Val Glu Arg Leu Ser Glu Ala Gln Arg Arg Gly His Gln Val Leu Ala Val Val Arg Gly Ser Ala Val Asn Ser Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Lys Ala Leu Ala Ala Gly Leu Ser Thr Ser Asp Val Asp Ala Val Glu Ala His Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ala Glu Ala Leu Leu Ala Thr Tyr Gly Gln Asn Arg Glu Thr Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Leu Gly His Thr Gln Ala Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Met Ala Met Arg His Gly Val Leu Pro Arg Thr Leu His Val Asp Arg Pro Ser Ser Tyr Val Asp Trp Ser Ala Gly Ala Val Glu Leu Leu Thr Glu Ala Arg Asp Trp Val Ser Asn Gly His Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Ile Gly Gly Thr Asn Ala

- 115 -

His Val Val Leu Glu Glu Val Ala Ala Pro Ile Thr Thr Pro Gln Pro
2450 2455 2460

Glu Pro Ala Glu Phe Leu Val Pro Val Leu Val Ser Ala Arg Thr Ala
2465 2470 2475 2480

Ala Gly Leu Arg Gly Gln Ala Gly Arg Leu Ala Ala Phe Leu Gly Asp 2485 2490 2495

Arg Thr Asp Val Arg Val Pro Asp Ala Ala Tyr Ala Leu Ala Thr Thr 2500 2505 2510

Arg Ala Gln Leu Asp His Arg Ala Val Val Leu Ala Ser Asp Arg Ala 2515 2520 2525

Gln Leu Cys Ala Asp Leu Ala Ala Phe Gly Ser Gly Val Val Thr Gly 2530 2535 2540

Thr Pro Val Asp Gly Lys Leu Ala Val Leu Phe Thr Gly Gln Gly Ser 2545 2550 2555 2560

Gln Trp Ala Gly Met Gly Arg Glu Leu Ala Glu Thr Phe Pro Val Phe 2565 2570 2575

Arg Asp Ala Phe Glu Ala Ala Cys Glu Ala Val Asp Thr His Leu Arg 2580 2585 2590

Glu Arg Pro Leu Arg Glu Val Val Phe Asp Asp Ser Ala Leu Leu Asp 2595 2600 2605

Gln Thr Met Tyr Thr Gln Gly Ala Leu Phe Ala Val Glu Thr Ala Leu 2610 2615 2620

Phe Arg Leu Phe Glu Ser Trp Gly Val Arg Pro Gly Leu Leu Ala Gly 2625 2630 2635 2640

- 116 -

WO 98/07868 PCT/EP97/04495

His Ser Ile Gly Glu Leu Ala Ala Ala His Val Ser Gly Val Leu Asp 2645 2650 2655

Leu Ala Asp Ala Gly Glu Leu Val Ala Ala Arg Gly Arg Leu Met Gln 2660 2665 2670

Ala Leu Pro Ala Gly Gly Ala Met Val Ala Val Gln Ala Thr Glu Asp 2675 2680 2685

Glu Val Ala Pro Leu Leu Asp Gly Thr Val Cys Val Ala Ala Val Asn 2690 2695 2700

Gly Pro Asp Ser Val Val Leu Ser Gly Thr Glu Ala Ala Val Leu Ala 2705 2710 2715 2720

Val Ala Asp Glu Leu Ala Gly Arg Gly Arg Lys Thr Arg Arg Leu Ala 2725 2730 2735

Val Ser His Ala Phe His Ser Pro Leu Met Glu Pro Met Leu Asp Asp 2740 2745 2750

Phe Arg Ala Val Ala Glu Arg Leu Thr Tyr Arg Ala Gly Ser Leu Pro 2755 2760 2765

Val Val Ser Thr Leu Thr Gly Glu Leu Ala Ala Leu Asp Ser Pro Asp 2770 2775 2780

Tyr Trp Val Gly Gln Val Arg Asn Ala Val Arg Phe Ser Asp Ala Val 2785 2790 2795 2800

Thr Ala Leu Gly Ala Gln Gly Ala Ser Thr Phe Leu Glu Leu Gly Pro 2805 2810 2815

Gly Gly Ala Leu Ala Ala Met Ala Leu Gly Thr Leu Gly Gly Pro Glu 2820 2825 2830

Gln Ser Cys Val Ala Thr Leu Arg Lys Asn Gly Ala Glu Val Pro Asp

- 117 -

Val Leu Thr Ala Leu Ala Glu Leu His Val Arg Gly Val Gly Val Asp Trp Thr Thr Val Leu Asp Glu Pro Ala Thr Ala Val Gly Thr Val Leu Pro Thr Tyr Ala Phe Gln His Gln Arg Phe Trp Val Asp Val Asp Glu Thr Ala Ala Val Ser Val Thr Pro Pro Pro Ala Glu Pro Ile Val Asp Arg Pro Val Gln Asp Val Leu Glu Leu Val Arg Glu Ser Ala Ala Val Val Leu Gly His Arg Asp Ala Gly Ser Phe Asp Leu Asp Arg Ser Phe Lys Asp His Gly Phe Asp Ser Leu Ser Ala Val Lys Leu Arg Asn Arg. Leu Arg Asp Phe Thr Gly Val Glu Leu Pro Ser Thr Leu Ile Phe Asp Tyr Pro Asn Pro Ala Val Leu Ala Asp His Leu Arg Ala Glu Leu Leu Gly Glu Arg Pro Ala Ala Pro Ala Pro Val Thr Arg Asp Val Ser Asp Glu Pro Ile Ala Ile Val Gly Met Ser Thr Arg Leu Pro Gly Glv Ala Asp Ser Pro Glu Glu Leu Trp Lys Leu Val Ala Glu Gly Arg Asp Ala

Val Ser Gly Phe Pro Val Asp Arg Gly Trp Asp Leu Asp Gly Leu Tyr 3045 3050 3055

His Pro Asp Pro Ala His Ala Gly Thr Ser Tyr Thr Arg Ser Gly Gly 3060 3065 3070

Phe Leu His Asp Ala Ala Gln Phe Asp Ala Gly Leu Phe Gly Ile Ser 3075 3080 3085

Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Glu 3090 3095 3100

Thr Ser Trp Glu Ala Leu Glu Arg Ala Gly Val Asp Pro Leu Ser Ala 3105 3110 3115 3120

Arg Gly Ser Asp Val Gly Val Phe Thr Gly Ile Val His His Asp Tyr 3125 3130 3135

Val Thr Arg Leu Arg Glu Val Pro Glu Asp Val Gln Gly Tyr Thr Met 3140 3145 3150

Thr Gly Thr Ala Ser Ser Val Ala Ser Gly Arg Val Ala Tyr Val Phe 3155 3160 3165

Gly Phe Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser 3170 3175 3180

Leu Val Ala Met His Leu Ala Ala Gln Ala Leu Arg Gln Gly Glu Cys 3185 3190 3195 3200

Ser Met Ala Leu Ala Gly Gly Ala Thr Val Met Ala Ser Pro Asp Ala 3205 3210 3215

Phe Leu Glu Phe Ser Arg Gln Arg Gly Leu Ser Ala Asp Gly Arg Cys 3220 3225 3230

Lys Ala Tyr Ala Glu Gly Ala Asp Gly Thr Gly Trp Ala Glu Gly Val 3235 3240 3245

Gly Val Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His 3250 3255 3260

Arg Val Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala 3265 3270 3275 3280

Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile 3285 3290 3295

Arg Gly Ala Leu Ala Ser Ala Gly Leu Ala Pro Ser Asp Val Asp Val 3300 3305 3310

Val Glu Gly His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu Val 3315 3320 3325

Gln Ala Leu Leu Ala Thr Tyr Gly Gln Glu Arg Glu Gln Pro Leu Trp 3330 3340

Leu Gly Ser Leu Lys Ser Asn Leu Gly His Thr Gln Ala Ala Ala Gly 3345 3350 3355 3360

Val Val Gly Val Ile Lys Met Ile Met Ala Met Arg His Gly Val Met 3365 3370 3375

Pro Ala Thr Leu His Val Asp Glu Arg Thr Ser Gln Val Asp Trp Ser 3380 3385 3390

Ala Gly Ala Ile Glu Val Leu Thr Glu Ala Arg Glu Trp Pro Arg Thr
3395 3400 3405

Gly Arg Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Ala Ser Gly Thr 3410 3415 3420

Asn Ala His Leu Ile Ile Glu Glu Gly Pro Ala Glu Glu Ala Val Asp

- 120 -

Glu Glu Val Ala Ser Val Val Pro Leu Val Val Ser Ala Arg Ser Ala Gly Ser Leu Ala Gly Gln Ala Gly Arg Leu Ala Ala Val Leu Glu Asn Glu Ser Leu Ala Gly Val Ala Gly Ala Leu Val Ser Gly Arg Ala Thr Leu Asn Glu Arg Ala Val Val Ile Ala Gly Ser Arg Asp Glu Ala Gln Asp Gly Leu Gln Ala Leu Ala Arg Gly Glu Asn Ala Pro Gly Val Val Thr Gly Thr Ala Gly Lys Pro Gly Lys Val Val Trp Val Phe Pro Gly . 3525 Gln Gly Ser Gln Trp Met Gly Met Gly Arg Asp Leu Leu Asp Ser Ser Pro Val Phe Ala Ala Arg Ile Lys Glu Cys Ala Ala Ala Leu Glu Gln Trp Thr Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Asp Ala Asp Leu Leu Asp Arg Val Asp Val Val Gln Pro Ala Ser Phe Ala Met Met Val Gly Leu Ala Ala Val Trp Thr Ser Leu Gly Val Thr Pro Asp Ala Val Leu Gly His Ser Gln Gly Glu Ile Ala Ala Ala Cys Val Ser Gly Ala

- 121 -

Leu Ser Leu Asp Asp Ala Ala Lys Val Val Ala Leu Arg Ser Gln Ala 3625 3640 3645

Ile Ala Gly Glu Leu Ala Gly Arg Gly Gly Met Ala Ser Val Ala Leu 3650 3655 3660

Ser Glu Glu Asp Ala Val Ala Arg Leu Thr Pro Trp Ala Asn Arg Val 3665 3670 3675 3680

Glu Val Ala Ala Val Asn Ser Pro Ser Ser Val Val Ile Ala Gly Asp 3695 3690 3695

Ala Gln Ala Leu Asp Glu Ala Leu Glu Ala Leu Ala Gly Asp Gly Val 3700 3705 3710

Arg Val Arg Arg Val Ala Val Asp Tyr Ala Ser His Thr Arg His Val 3715 3720 3725

Glu Ala Ile Ala Glu Thr Leu Ala Lys Thr Leu Ala Gly Ile Asp Ala 3730 3735 3740

Arg Val Pro Ala Ile Pro Phe Tyr Ser Thr Val Leu Gly Thr Trp Ile 3745 3750 3755 3760

Glu Gln Ala Val Val Asp Ala Gly Tyr Trp Tyr Arg Asn Leu Arg Gln 3765 3770 3775

Gln Val Arg Phe Gly Pro Ser Val Ala Asp Leu Ala Gly Leu Gly His 3780 3785 3790

Thr Val Phe Val Glu Ile Ser Ala His Pro Val Leu Val Gln Pro Leu 3795 3800 3805

Ser Glu Ile Ser Asp Asp Ala Val Val Thr Gly Ser Leu Arg Arg Asp 3810 3815 3820

Asp Gly Gly Leu Arg Arg Leu Leu Ala Ser Ala Ala Glu Leu Tyr Val Arg Gly Val Ala Val Asp Trp Thr Ala Ala Val Pro Ala Ala Gly Trp Val Asp Leu Pro Thr Tyr Ala Phe Asp Arg Arg His Phe Trp Leu His Glu Ala Glu Thr Ala Glu Ala Ala Glu Gly Met Asp Gly Glu Phe Tro Thr Ala Ile Glu Gln Ser Asp Val Asp Ser Leu Ala Glu Leu Leu Glu Leu Val Pro Glu Gln Arg Gly Ala Leu Ser Thr Val Val Pro Val Leu Ala Gln Trp Arg Asp Arg Arg Glu Arg Ser Thr Ala Glu Lys Leu Arg Tyr Gln Val Thr Trp Gln Pro Leu Glu Arg Glu Ala Ala Gly Val Pro Gly Gly Arg Trp Leu Ala Val Val Pro Ala Gly Thr Thr Asp Ala Leu Leu Lys Glu Leu Thr Gly Gln Gly Leu Asp Ile Val Arg Leu Glu Ile Glu Glu Ala Ser Arg Ala Gln Leu Ala Glu Gln Leu Arg Asn Val Leu Ala Glu His Asp Leu Thr Gly Val Leu Ser Leu Leu Ala Leu Asp 

Gly Gly Pro Ala Asp Ala Ala Glu Ile Thr Ala Ser Thr Leu Ala Leu

- 123 -

Val Gln Ala Leu Gly Asp Thr Thr Thr Ser Ala Pro Leu Trp Cys Leu Thr Ser Gly Ala Val Asn Ile Gly Ile Gln Asp Ala Val Thr Ala Pro Ala Gln Ala Ala Val Trp Gly Leu Gly Arg Ala Val Ala Leu Glu Arg Leu Asp Arg Trp Gly Gly Leu Val Asp Leu Pro Ala Ala Ile Asp Ala Arg Thr Ala Gln Ala Leu Leu Gly Val Leu Asn Gly Ala Ala Gly Glu Asp Gln Leu Ala Val Arg Arg Ser Gly Val Tyr Arg Arg Arg Leu Val Arg Lys Pro Val Pro Glu Ser Ala Thr Ser Arg Trp Glu Pro Arg Gly Thr Val Leu Val Thr Gly Gly Ala Glu Gly Leu Gly Arg His Ala Ser 

Val Trp Leu Ala Gln Ser Gly Ala Glu Arg Leu Ile Val Thr Gly Thr
4165 4170 4175

Asp Gly Val Asp Glu Leu Thr Ala Glu Leu Ala Glu Phe Gly Thr Thr 4180 4185 4190

Val Glu Phe Cys Ala Asp Thr Asp Arg Asp Ala Ile Ala Gln Leu Val 4195 4200 4205

Ala Asp Ser Glu Val Thr Ala Val Val His Ala Ala Asp Ile Ala Gln 4210 4215 4220

Thr Ser Ser Val Asp Asp Thr Gly Val Ala Asp Leu Asp Glu Val Phe
4225 4230 4235 4240

Ala Ala Lys Val Thr Thr Ala Val Trp Leu Asp Gln Leu Phe Glu Asp
4245
4250
4255

Thr Pro Leu Asp Ala Phe Val Val Phe Ser Ser Ile Ala Gly Ile Trp
4260 4265 4270

Gly Gly Gly Gln Gly Pro Ala Gly Ala Ala Asn Ala Val Leu Asp 4275 4280 4285

Ala Leu Val Glu Trp Arg Arg Ala Arg Gly Leu Lys Ala Thr Ser Ile 4290 4295 4300

Ala Trp Gly Ala Leu Asp Gln Ile Gly Ile Gly Met Asp Glu Ala Ala 4305 4310 4315 4320

Leu Ala Gln Leu Arg Arg Gly Val Ile Pro Met Ala Pro Pro Leu
4325 4330 4335

Ala Val Thr Ala Met Val Gln Ala Val Ala Gly Asn Glu Lys Ala Val
4340 4345 4350

Ala Val Ala Asp Met Asp Trp Ala Ala Phe Ile Pro Ala Phe Thr Ser 4355 4360 4365

Val Arg Pro Ser Pro Leu Phe Ala Asp Leu Pro Glu Ala Lys Ala Ile 4370 4375 4380

Leu Arg Ala Ala Gln Asp Asp Gly Glu Asp Gly Asp Thr Ala Ser Ser 4385 4390 4395 4400

Leu Ala Asp Ser Leu Arg Ala Val Pro Asp Ala Glu Gln Asn Arg Ile 4405 4410 4415

Leu Leu Lys Leu Val Arg Gly His Ala Ser Thr Val Leu Gly His Ser 4420 4430

Gly Ala Glu Gly Ile Gly Pro Arg Gln Ala Phe Gln Glu Val Gly Phe 4435 4440 4445

Asp Ser Leu Ala Ala Val Asn Leu Arg Asn Ser Leu His Ala Ala Thr 4450 4455 4460

Gly Leu Arg Leu Pro Ala Thr Leu Ile Phe Asp Tyr Pro Thr Pro Glu 4465 4470 4475 4480

Ala Leu Val Gly Tyr Leu Arg Val Glu Leu Leu Arg Glu Ala Asp Asp 4485 4490 4495

Gly Leu Asp Gly Arg Glu Asp Asp Leu Arg Arg Val Leu Ala Ala Val 4500 4505 4510

Pro Phe Ala Arg Phe Lys Glu Ala Gly Val Leu Asp Thr Leu Leu Gly 4515 4520 4525

Leu Ala Asp Thr Gly Thr Glu Pro Gly Thr Asp Ala Glu Thr Thr Glu 4530 4535 4540

Ala Ala Pro Ala Ala Asp Asp Ala Glu Leu Ile Asp Ala Leu Asp Ile 4545 4550 4555 4560

Ser Gly Leu Val Gln Arg Ala Leu Gly Gln Thr Ser 4565 4570

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5069 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(XI) MOINCOIN TIFE, DEDCIO	(ii)	MOLECULE	TYPE:	peptide
----------------------------	------	----------	-------	---------

(Xi)	SEQUENCE	DESCRIPTION:	SEQ	ID	NO:	5:
------	----------	--------------	-----	----	-----	----

Met Ala Asn Gln Ser Trp Arg Lys Asn Met Ser Ala Pro Asn Glu Gln 1 5 10 15

Ile Val Asp Ala Leu Arg Ala Ser Leu Lys Glu Asn Val Arg Leu Gln
20 25 30

Gln Glu Asn Ser Ala Leu Ala Ala Ala Ala Ala Glu Pro Val Ala Ile 35 40 45

Val Ser Met Ala Cys Arg Tyr Ala Gly Gly Ile Arg Gly Pro Glu Asp 50 55 60

Phe Trp Arg Val Val Ser Glu Gly Ala Asp Val Tyr Thr Gly Phe Pro 65 70 75 80

Glu Asp Arg Gly Trp Asp Val Glu Gly Leu Tyr His Pro Asp Pro Asp 85 90 95

Asn Pro Gly Thr Thr Tyr Val Arg Glu Gly Ala Phe Leu Gln Asp Ala 100 105 110

Ala Gln Phe Asp Ala Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu 115 120 125

Ala Met Asp Pro Gln Gln Arg Gln Leu Leu Glu Val Ser Trp Glu Thr 130 135 140

Leu Glu Arg Ala Gly Ile Asp Pro His Ser Val Arg Gly Ser Asp Ile 145 150 155 160

Gly	Val	Tyr	Ala	165	Val	Val	HIS	GIN	170	туг	ATS	PIO	Asp	175	ser
Gly	Phe	Glu	Gly 180	Phe	Met	Ser	Leu	Glu 185	Arg	Ala	Leu	Gly	Thr 190	Ala	Gly
Gly	Val	Ala 195	Ser	Gly	Arg	Val	Ala 200	Tyr	Thr	Leu	Gly	Leu 205	Glu	Gly	Pro
Ala	Val 210	Thr	Val	Ąsp	Thr	Met 215	Cys	Ser	Ser	Ser	Leu 220	Val	Ala	Ile	His
Leu 225	Ala	Ala	Gln	Ala	Leu 230	Arg	Arg	Gly	Glu	Cys 235	Ser	Met	Ala	Leu	Ala 240
Gly	Gly	Ser	Thr	Val 245	Met	Ala	Thr	Pro	Gly 250	Gly	Phe	Val	Gly	Phe 255	Ala
Arg	Gln	Arg	Ala 260	Leu	Ala	Phe	qzA	Gly 265	Arg	Cys	ŗĀs	Ser	Tyr 270	Ala	Ala
		275			Gly		280					285			
	290				Ala	295					300				
11e 305	Arg	Gly	Ser	Ala	Val 310	Asn	Gln	Asp	Gly	Ala 315	Ser	Asn	Gly	Leu	Thr 320
				325	Ala				330					335	
Ser	Ala	Gly	Leu 340	Thr	Pro	Ser	Asp	Val 345	Asp	Thr	Val	Glu	Gly 350	His	Gly

- 128 -

WO 98/07868 PCT/EP97/04495

Thr Gly Thr Val Leu Gly Asp Pro Ile Glu Val Gln Ala Leu Leu Ala 355 360 365

Thr Tyr Gly Gln Gly Arg Asp Pro Gln Gln Pro Leu Trp Leu Gly Ser 370 375 380

Val Lys Ser Val Val Gly His Thr Gln Ala Ala Ser Gly Val Ala Gly 385 390 395 400

Val Ile Lys Met Val Gln Ser Leu Arg His Gly Gln Leu Pro Ala Thr 405 410 415

Gln His Val Asp Ala Pro Thr Pro Gln Val Asp Trp Ser Ala Gly Ala
420 425 430

Ile Glu Leu Leu Ala Glu Gly Arg Glu Trp Pro Arg Asn Gly His Pro
435 440 445

Arg Arg Gly Gly Ile Ser Ser Phe Gly Ala Ser Gly Thr Asn Ala His 450 455 460

Met Ile Leu Glu Glu Ala Pro Glu Asp Glu Pro Val Thr Glu Ala Pro 465 470 475 480

Ala Pro Thr Gly Val Val Pro Leu Val Val Ser Ala Ala Thr Ala Ala
485 490 495

Ser Leu Ala Ala Gln Ala Gly Arg Leu Ala Glu Val Gly Asp Val Ser
500 505 510

Leu Ala Asp Val Ala Gly Thr Leu Val Ser Gly Arg Ala Met Leu Ser 515 520 525

Glu Arg Ala Val Val Val Ala Gly Ser His Glu Glu Ala Val Thr Gly 530 535 540

Leu Arg Ala Leu Ala Arg Gly Glu Ser Ala Pro Gly Leu Leu Ser Gly

- 129 -

545					550					555					560
Arg	Gly	Ser	Gly	Val 565	Pro	Gly	Lys	Val	Val 570	Trp	Val	Phe	Pro	Gly 5 <b>7</b> 5	
Gly	Thr	Gln	Trp 580	Ala	Gly	Met	Gly	Arg 585	Glu	Leu	Leu	Asp	Ser 590	Ser	Glu
Val	Phe	Ala 595	Ala	Arg	Ile	Ala	Glu 600	Cys	Glu	Thr	Ala	Leu 605	Gly	Arg	Trp
Val	Asp 610	Trp	Ser	Leu	Thr	Asp 615	Val	Leu	Arg	Gly	Glu 620	Ala	Asp	Leu	Leu
Asp 625	Arg	Val	Asp	Val	Val 630	Gln	Pro	Ala	Ser	Phe 635	Ala	Val	Met	Val	Gly 640
Leu	Ala	Ala	Val	Trp 645	Ala	Ser	Leu	Gly	Val 650	Glu	Pro	Glu	Ala	Val 655	Val
Gly	<b>His</b>	Ser	Gln 660	Gly	Glu	Ile	Ala	Ala 665	Ala	Cys	Val	Ser	Gly 670	Ala	Leu
Ser	Leu	Glu 675	Asp	Ala	Ala	Ŀys	Val 680	Val	Ala	Leu	Arg	Ser 685	Gln	Ala	Ile
Ala	Ala 690	Ser	Leu	Ala	Gly	Arg 695	Gly	Gly	Met	Ala	Ser 700	Val	Ala	Leu	Ser
Glu 705	Glu	Asp	Ala	Thr	Ala 710	Arg	Leu	Glu	Pro	Trp 715	Ala	Gly	Arg	Val	Glu 720
Val	Ala	Ala	Val	Asn 725	Gly	Pro	Thr	Ser	Val 730	Val	Ile	Ala	Gly	<b>A</b> sp 735	Ala
Glu	Ala	Leu	Asp	Glu	Ala	Leu	qzA	Ala 745	Leu	Asp	Asp	Gln	Gly 750	Val	Arg

WO 98/07868

- 130 -

Ile Arg Arg Val Ala Val Asp Tyr Ala Ser His Thr Arg His Val Glu
755 760 765

Ala Ala Arg Asp Ala Leu Ala Glu Met Leu Gly Gly Ile Arg Ala Gln
770 775 780

Ala Pro Glu Val Pro Phe Tyr Ser Thr Val Thr Gly Gly Trp Val Glu
785 790 795 800

Asp Ala Gly Val Leu Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Arg 805 810 815

Gln Val Arg Pne Gly Pro Ala Val Ala Glu Leu Ile Glu Gln Gly His 820 825 830

Arg Val Phe Val Glu Val Ser Ala His Pro Val Leu Val Gln Pro Ile 835 840 845

Asn Glu Leu Val Asp Asp Thr Glu Ala Val Val Thr Gly Thr Leu Arg 850 855 860

Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Ala Ser Ala Ala Glu Leu 865 870 875 885

Phe Val Arg Gly Val Thr Val Asp Trp Ser Gly Val Leu Pro Pro Ser 885 890 895

Arg Arg Val Glu Leu Pro Thr Tyr Ala Phe Asp His Gln His Tyr Trp
900 905 910

Leu Gln Met Gly Gly Ser Ala Thr Asp Ala Val Ser Leu Gly Leu Ala 915 920 925

Gly Ala Asp His Pro Leu Leu Gly Ala Val Val Pro Leu Pro Gln Ser 930 935 940

:

WO 98/07868 PCT/EP97/04495

- 131 -

Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys Ser His Pro Trp Leu Ala Gly His Ala Ile Gly Gly Val Val Leu Ile Pro Gly Thr Val Tyr Val Asp Leu Ala Leu Arg Ala Gly Asp Glu Leu Gly Phe Gly Val Leu Glu Glu Leu Val Ile Glu Ala Pro Leu Val Leu Gly Glu Arg Gly Gly Val Arg Val Gln Val Ala Val Ser Gly Pro Asn Glu Thr Gly Ser Arg Ala Val Asp Val Phe Ser Met Arg Glu Asp Gly Asp Glu Trp Thr Arg His Ala Thr Gly Leu Leu Gly Ala Ser Thr Ser Arg Glu Pro Ser Arg Phe Asp Phe Ala Ala Trp Pro Pro Ala Gly Ala Glu Pro Ile Asp Val Glu Asn Phe Tyr Thr Asp Leu Thr Glu Arg Gly Tyr Ala Tyr Ser Gly Ala Phe Gln Gly Met Arg Ala Val Trp Arg Arg Gly Asp Glu Val Phe Ala Glu Val Ala Leu Pro Asp Asp His Arg Glu Asp Ala Gly Lys Phe Gly Leu His Pro Ala Leu Leu Asp Ala Ala Leu His Thr Asn Ala

Phe Ala Asn Pro Asp Asp Asp Arg Ser Val Leu Pro Phe Ala Trp Asn

- 132 -

			114	0				114	5				115	0	
Gly	Leu	Val 115		His	Ala	Val	Gly 1160		Ser	Ala	Leu	Arg 116		Arg	Val
Ala	Pro 1170		Gly	Pro	Asp	Ala 117		Thr	Phe	Gln	Ala 1180		qzA	Glu	Thr
Gly 1185		Leu	Val	Val	Thr 1190		Asp	Ser	Leu	Val		Arg	Glu	Val	Ser 1200
Ala	Ala	Gln	Leu	Glu 120		Ala	Ala	Gly	Glu 1210		Arg	Asp	Ser	Leu 1215	Phe
Gln	Val	Asp	Trp 1220		Glu	Val	Pro	Ala 1225		Glu	Thr	Ala	Ala 1230		Glu
His	Ala	Glu 1235		Leu	Glu	Ala	Phe 1240	_	Glu	Ala	Ala	Pro 1245		Glu	Leu
Thr	Ser 1250		Val	Leu	Glu	Ala 1255		Gln	Ser	Trp	Leu 1260		Asp	Ala	Ala
Asp 1265		Ala	Arg	Leu	Val 1270		Val	Thr	Arg	Gly 1275		Val	Arg	Glu	Val 1280
Thr	Asp	Pro	Ala	Gly 1285		Ala	Val	Trp	Gly 1290		Val	Arg	Ala	Ala 1295	Gln
Ala	Glu	Asn	Pro 1300	_	Arg	Ile	Ile	Leu 1305		Asp	Thr	Asp	Gly 1310	Asp )	Val
Pro	Leu	Gly 1315		Val	Leu	Ala	Ser 1320	_	Glu	Pro	Gln	Leu 1325		Val	Arg
Gly	Asn 1330		Phe	Ser	Val	Pro 1335	_	Leu	Ala	Arg	Ala 1340		Gly	Glu	Val

Pro Glu Ala Pro Ala Val Phe Ser Pro Glu Gly Thr Val Leu Leu Thr Gly Gly Thr Gly Ser Leu Gly Gly Leu Val Ala Lys His Leu Val Ala Arg His Gly Val Arg Arg Leu Val Leu Ala Ser Arg Arg Gly Val Ala Ala Glu Asp Leu Val Thr Glu Leu Thr Glu Gln Gly Ala Thr Val Ser Val Val Ala Cys Asp Val Ser Asp Arg Asp Gln Val Ala Ala Leu Leu Ala Glu His Arg Pro Thr Gly Ile Val His Leu Ala Gly Leu Leu Asp Asp Gly Val Ile Gly Ala Leu Asn Arg Glu Arg Leu Ala Gly Val Phe Ala Pro Lys Val Asp Ala Val Gln His Leu Asp Glu Leu Thr Arg Asp Leu Gly Leu Asp Ala Phe Val Val Phe Ser Ser Ala Ala Leu Met Gly Ser Ala Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu Met Ala Gly Arg Arg Ala Ala Gly Leu Pro Gly Val Ser Leu Ala Trp Gly Leu Trp Glu Gln Ala Asp Gly Leu Thr Ala Asn Leu Ser

- 134 -

Ala Thr Asp Gln Ala Arg Met Ser Arg Gly Gly Val Leu Pro Met Thr Pro Ala Glu Ala Leu Asp Ile Phe Asp Ile Gly Leu Ala Ala Glu Gln Ala Leu Leu Val Pro Ile Lys Leu Asp Leu Arg Thr Leu Arg Gly Gln Ala Thr Ala Gly Gly Glu Val Pro His Leu Leu Arg Gly Leu Val Arg Ala Ser Arg Arg Val Thr Arg Thr Ala Ala Ala Ser Gly Gly Gly Gly Leu Val His Lys Leu Ala Gly Arg Pro Ala Glu Glu Glu Glu Ala Val Leu Leu Gly Ile Val Gln Ala Glu Ala Ala Ala Val Leu Gly Phe Asn Ala Pro Glu Leu Ala Gln Gly Thr Arg Gly Phe Ser Asp Leu Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Arg Leu Ser Ala Ala Thr Gly Val Lys Leu Pro Ala Thr Leu Val Phe Asp Tyr Pro Thr Pro Val Ala Leu Ala Arg His Leu Arg Glu Glu Leu Gly Glu Thr Val Ala Gly 

Ala Pro Ala Thr Pro Val Thr Thr Val Ala Asp Ala Gly Glu Pro Ile

Ala Ile Val Gly Met Ala Cys Arg Leu Pro Gly Gly Val Met Ser Pro

- 135 -

PCT/EP97/04495

Asp Asp Leu Trp Arq Met Val Ala Glu Gly Arg Asp Gly Met Ser Pro Phe Pro Gly Asp Arg Gly Trp Asp Leu Asp Gly Leu Phe Asp Ser Asp Pro Glu Arg Pro Gly Thr Ala Tyr Ile Arg Gln Gly Gly Phe Leu His Glu Ala Ala Leu Phe Asp Pro Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Glu Ala Ser Trp Glu Ala Leu Glu Arg Ala Gly Ile Asp Pro Thr Lys Ala Arg Gly Asp Ala Val Gly Val Phe Ser Gly Val Ser Ile His Asp Tyr Leu Glu Ser Leu Ser Asn Met Pro Ala Glu Leu Glu Gly Phe Val Thr Thr Ala Thr Ala Gly Ser Val Ala Ser Gly Arg Val Ser Tyr Thr Phe Gly Phe Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala Ala Gln Ala Leu Arg Gln Gly Glu Cys Thr Met Ala 192C Leu Ala Gly Gly Val Ala Val Met Gly Ser Pro Ile Gly Val Ile Gly

WO 98/07868

- 136 -

- Met Ser Arg Gln Arg Gly Met Ala Glu Asp Gly Arg Val Lys Ala Phe 1940 1945 1950
- Ala Asp Gly Ala Asp Gly Thr Val Leu Ser Glu Gly Val Gly Ile Val
  1955 1960 1965
- Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Arg Val Leu 1970 1975 1980
- Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly
  1985 1990 1995 2000
- Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Ser Ala
  2005 2010 2015
- Leu Ala Gly Ala Gly Leu Gln Pro Ser Glu Val Asp Val Val Glu Ala 2020 2025 2030
- His Gly Thr Gly Thr Ala Leu Gly Glu Pro Ile Glu Ala Gln Ala Leu 2035 2040 2045
- Leu Ala Thr Tyr Gly Lys Ser Arg Glu Thr Pro Leu Trp Leu Gly Ser 2050 2055 2060
- Leu Lys Ser Asn Ile Gly His Thr Gln Ala Ala Gly Val Ala Ala 2065 2070 2075 2080
- Val Ile Lys Met Val Gln Ala Leu Arg Gln Asp Thr Leu Pro Pro Thr
  2085 2090 2095
- Leu His Val Gln Glu Pro Thr Lys Gln Val Asp Trp Ser Ala Gly Ala 2100 2105 2110
- Val Glu Leu Leu Thr Glu Gly Arg Glu Trp Ala Arg Asn Gly His Pro 2115 2120 2125

Arg Arg Ala Gly Val Ser Ser Phe Gly Ile Ser Gly Thr Asn Ala His 2130 2135 2140

Leu Ile Leu Glu Glu Ala Pro Ala Asp Asp Thr Ala Glu Ala Asp Val 2145 2150 2155 2160

Pro Asp Ala Val Val Pro Val Val Ile Ser Ala Arg Ser Thr Gly Ser 2165 2170 2175

Leu Ala Gly Gln Ala Gly Arg Leu Ala Ala Phe Leu Asp Gly Asp Val

Pro Leu Thr Arg Val Ala Gly Ala Leu Leu Ser Thr Arg Ala Thr Leu 2195 2200 2205

2180

2185

2190

Thr Asp Arg Ala Val Val Ala Gly Ser Ala Glu Glu Ala Arg Ala 2210 2215 2220

Gly Leu Thr Ala Leu Ala Arg Gly Glu Ser Ala Ser Gly Leu Val Thr 2225 2230 2235 2240

Gly Thr Ala Gly Met Pro Gly Lys Thr Val Trp Val Phe Pro Gly Gln 2245 2250 2255

Gly Thr Gln Trp Ala Gly Met Gly Arg Glu Leu Leu Glu Ala Ser Pro 2260 2265 2270

Val Phe Ala Glu Arg Ile Glu Glu Cys Ala Ala Ala Leu Gln Pro Trp 2275 2280 2285

Ile Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Glu Gly Glu Leu Asp 2290 2295 2300

Arg Val Asp Val Leu Gln Pro Ala Cys Phe Ala Val Met Val Gly Leu 2305 2310 2315 2320

Ala Ala Val Trp Ala Ser Val Gly Val Val Pro Asp Ala Val Leu Gly

- 138 -

His Ser Gln Glv Glu Ile Ala Ala Cys Val Ser Glv Ala Leu Ser Leu Glu Asp Ala Ala Lys Val Val Ala Leu Arg Ser Gln Ala Ile Ala Ala Glu Leu Ser Gly Arg Gly Gly Met Ala Ser Ile Gln Leu Ser His Asp Glu Val Ala Ala Arg Leu Ala Pro Trp Ala Gly Arg Val Glu Ile Ala Ala Val Asn Gly Pro Ala Ser Val Val Ile Ala Gly Asp Ala Glu Ala Leu Thr Glu Ala Val Glu Val Leu Gly Gly Arg Arg Val Ala Val Asp Tyr Ala Ser His Thr Arg His Val Glu Asp Ile Gln Asp Thr Leu Ala Glu Thr Leu Ala Gly Ile Asp Ala Gln Ala Pro Val Val Pro Phe Tyr Ser Thr Val Ala Gly Glu Trp Ile Thr Asp Ala Gly Val Val Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Asn Gln Val Gly Phe Gly Pro Ala Val Ala Glu Leu Ile Glu Gln Gly His Gly Val Phe Val Glu Val 

Ser Ala His Pro Val Leu Val Gln Pro Ile Ser Glu Leu Thr Asp Ala

- 139 -

Val Val Thr Gly Thr Leu Arg Arg Asp Asp Gly Gly Val Arg Arg Leu 2530 2535 2540

Leu Thr Ser Met Ala Glu Leu Phe Val Arg Gly Val Pro Val Asp Trp 2545 2550 2555 2560

Ala Thr Met Ala Pro Pro Ala Arg Val Glu Leu Pro Thr Tyr Ala Phe 2565 2570 2575

Asp His Gln His Phe Trp Leu Ser Pro Pro Ala Val Ala Asp Ala Pro 2580 2585 2590

Ala Leu Gly Leu Ala Gly Ala Asp His Pro Leu Leu Gly Ala Val Leu 2595 2600 2605

Pro Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Val 2610 2615 2620

Arg Thr His Pro Trp Leu Ala Asp Gly Val Pro Ala Ala Ala Leu Val 2625 2630 2635 2640

Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys Pro Val Leu Ala 2645 2650 2655

Asp Leu Thr Val Glu Lys Leu Leu Val Leu Pro Glu Ser Gly Gly Leu 2660 2665 2670

Arg Val Gln Val Ile Val Ser Gly Glu Arg Thr Val Glu Val Tyr Ser 2675 2680 2685

Gln Leu Glu Gly Ala Glu Asp Trp Ile Arg Asn Ala Thr Gly His Leu 2690 2695 2700

Ser Ala Thr Ala Pro Ala His Glu Ala Phe Asp Phe Thr Ala Trp Pro 2705 2710 2715 2720

Pro Ala Gly Ala Gln Gln Val Asp Gly Leu Trp Arg Arg Gly Asp Glu 2725 2730 2735

Ile Phe Ala Glu Val Ala Leu Pro Glu Glu Leu Asp Ala Gly Ala Phe 2740 2745 2750

Gly Ile His Pro Phe Leu Leu Asp Ala Ala Val Gln Pro Val Leu Ala 2755 2760 2765

Asp Asp Glu Gln Pro Ala Glu Trp Arg Ser Leu Val Leu His Ala Ala 2770 2775 2780

Gly Ala Ser Ala Leu Arg Val Arg Leu Val Pro Gly Gly Ala Leu Gln 2785 2790 2795 2800

Ala Ala Asp Glu Thr Gly Gly Leu Val Leu Thr Ala Asp Ser Val Ala 2805 2810 2815

Gly Arg Glu Leu Ser Ala Gly Lys Thr Arg Ala Gly Ser Leu Tyr Arg 2820 2825 2830

Val Asp Trp Thr Glu Val Ser Ile Ala Asp Ser Ala Val Pro Ala Asn 2835 2840 2845

Ile Glu Val Val Glu Ala Pne Gly Glu Glu Pro Leu Glu Leu Thr Gly 2850 2855 2860

Arg Val Leu Glu Ala Val Gln Thr Trp Leu Val Thr Ala Ala Asp Asp 2865 2870 2875 2880

Ala Arg Leu Val Val Val Thr Arg Gly Ala Val Arg Glu Val Thr Asp 2885 2890 2895

Pro Ala Gly Ala Ala Val Trp Gly Leu Val Arg Ala Ala Gln Ala Glu 2900 2905 2910

Asn Pro Gly Arg Ile Phe Leu Ile Asp Thr Asp Gly Glu Ile Pro Ala

Leu Thr Gly Asp Glu Pro Glu Ile Ala Val Arg Gly Gly Lys Phe Phe Val Pro Arg Ile Thr Arg Ala Glu Pro Ser Gly Ala Ala Val Phe Arg Pro Asp Gly Thr Val Leu Ile Ser Gly Ala Gly Ala Leu Gly Gly Leu Val Ala Arg Arg Leu Val Glu Arg His Gly Val Arg Lys Leu Val Leu Ala Ser Arg Arg Gly Arg Asp Ala Asp Gly Val Ala Asp Leu Val Ala Asp Leu Ala Ala Asp Val Ser Val Val Ala Cys Asp Val Ser Asp Arg Ala Gln Val Ala Ala Leu Leu Asp Glu His Arg Pro Thr Ala Val Val His Thr Ala Glv Val Ile Asp Ala Gly Val Ile Glu Thr Leu Asp Arg Asp Arg Leu Ala Thr Val Phe Ala Pro Lys Val Asp Ala Val Arg His Leu Asp Glu Leu Thr Arg Asp Arg Asp Leu Asp Ala Phe Val Val Tyr Ser Ser Val Ser Ala Val Phe Met Gly Ala Gly Ser Gly Ser Tyr Ala

Ala Ala Asn Ala Phe Leu Asp Gly Leu Met Ala Asn Arg Arg Ala Ala

- 142 -

Gly Leu Pro Gly Leu Ser Leu Ala Trp Gly Leu Trp Asp Gln Ser Thr Gly Met Ala Ala Gly Thr Asp Glu Ala Thr Arg Ala Arg Met Ser Arg Arg Gly Gly Leu Gln Ile Met Thr Gln Ala Glu Gly Met Asp Leu Phe Asp Ala Ala Leu Ser Ser Ala Glu Ser Leu Leu Val Pro Ala Lys Leu Asp Leu Arg Gly Val Arg Ala Asp Ala Ala Ala Gly Gly Val Val Pro His Met Leu Arg Gly Leu Val Arg Ala Gly Arg Ala Gln Ala Arg Ala Ala Ser Thr Val Asp Asn Gly Leu Ala Gly Arg Leu Ala Gly Leu Ala Pro Ala Asp Gln Leu Thr Leu Leu Leu Asp Leu Val Arq Ala Gln Val Ala Ala Val Leu Gly His Ala Asp Ala Ser Ala Val Arg Val Asp Thr Ala Phe Lys Asp Ala Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Arg Met Arg Thr Ala Thr Gly Leu Lys Leu Pro Ala Thr Leu Val 

Phe Asp Tyr Pro Asn Pro Gln Ala Leu Ala Arg His Leu Arg Asp Glu

Leu Gly Gly Ala Ala Gln Thr Pro Val Thr Thr Ala Ala Ala Lys Ala 3315 3320 3325

Asp Leu Asp Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg Leu Pro 3330 3335 3340

Gly Gly Val Ala Gly Pro Glu Asp Leu Trp Arg Leu Val Ala Glu Gly 3345 3350 3355 3360

Arg Asp Ala Val Ser Ser Phe Pro Thr Asp Arg Gly Trp Asp Thr Asp 3365 3370 3375

Ser Leu Tyr Asp Pro Asp Pro Ala Arg Pro Gly Lys Thr Tyr Thr Arg 3380 3385 3390

His Gly Gly Phe Leu His Glu Ala Gly Leu Phe Asp Ala Gly Phe Phe 3395 3400 3405

Gly Ile Ser Pro Arg Glu Ala Val Ala Met Asp Pro Gln Gln Arg Leu 3410 3415 3420

Leu Leu Glu Ala Ser Trp Glu Ala Met Glu Asp Ala Gly Val Asp Pro 3425 3430 3435 3440

Leu Ser Leu Lys Gly Asn Asp Val Gly Val Phe Thr Gly Met Phe Gly 3445 3450 3455

Gln Gly Tyr Val Ala Pro Gly Asp Ser Val Val Thr Pro Glu Leu Glu 3460 3465 3470

Gly Phe Ala Gly Thr Gly Gly Ser Ser Ser Val Ala Ser Gly Arg Val 3475 3480 3485

Ser Tyr Val Phe Gly Phe Glu Gly Pro Ala Val Thr Ile Asp Ser Ala 3490 3495 3500

Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Ala Gln Ser Leu Arg

WO 98/07868

PCT/EP97/04495

Gln Gly Glu Cys Ser Met Ala Leu Ala Gly Gly Ala Thr Val Met Ala Asn Prc Gly Ala Phe Val Glu Phe Ser Arg Gln Arg Gly Leu Ala Val Asp Gly Arg Cys Lys Ala Phe Ala Ala Ala Ala Asp Gly Thr Gly Trp Ala Glu Gly Val Gly Val Ile Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Arg Ile Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Arg Ala Leu Val Ser Ala Gly Leu Ala Pro Ser Asp Val Asp Val Val Glu Ala His Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Lys Asp Arg Glu Ser Pro Leu Trp Leu Gly Ser Leu Lys Ser Asn Ile Gly His Ala Gln Ala Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Gln Ala Leu Arg 

His Glu Val Leu Pro Pro Thr Leu His Val Asp Arg Pro Thr Pro Glu

Val Asp Trp Ser Ala Gly Ala Val Glu Leu Leu Thr Glu Ala Arg Glu 3715 3720 3725

Trp Pro Arg Asn Gly Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly 3730 3735 3740

Val Ser Gly Thr Asn Ala His Leu Ile Leu Glu Glu Ala Pro Ala Glu 3745 3750 3755 3760

Glu Pro Val Pro Thr Pro Glu Val Pro Leu Val Pro Val Val Ser 3765 3770 3775

Ala Arg Ser Arg Ala Ser Leu Ala Gly Gln Ala Gly Arg Leu Ala Gly 3780 3785 3790

Phe Val Ala Gly Asp Ala Ser Leu Ala Gly Val Ala Arg Ala Leu Val 3795 3800 3805

Thr Asn Arg Ala Ala Leu Thr Glu Arg Ala Val Met Val Val Gly Ser 3810 3815 3820

Arg Glu Glu Ala Val Thr Asn Leu Glu Ala Leu Ala Arg Gly Glu Asp 3825 3830 3835 3840

Pro Ala Ala Val Val Thr Gly Arg Ala Gly Ser Pro Gly Lys Leu Val 3845 3850 3855

Trp Val Phe Pro Gly Gln Gly Ser Gln Trp Ile Gly Met Gly Arg Glu 3860 3865 3870

Leu Leu Asp Ser Ser Pro Val Phe Ala Glu Arg Val Ala Glu Cys Ala 3875 3890 3885

Ala Ala Leu Glu Pro Trp Ile Asp Trp Ser Leu Leu Asp Val Leu Arg 3890 3895 3900

Gly Glu Ser Asp Leu Leu Asp Arg Val Asp Val Val Gln Pro Ala Ser 3905 3910 3915 3920

Phe Ala Met Met Val Gly Leu Ala Ala Val Trp Gln Ser Val Gly Val
3925 3930 3935

Arg Pro Asp Ala Val Val Gly His Ser Gln Gly Glu Ile Ala Ala Ala 3940 3950

Cys Val Ser Gly Ala Leu Ser Leu Gln Asp Ala Ala Lys Val Val Ala 3955 3960 3965

Leu Arg Ser Gln Ala Ile Ala Thr Arg Leu Ala Gly Arg Gly Met 3970 3975 3980

Ala Ser Val Ala Leu Ser Glu Glu Asp Ala Thr Ala Trp Leu Ala Pro 3985 3990 3995 4000

Trp Ala Asp Arg Val Gln Val Ala Ala Val Asn Ser Pro Ala Ser Val
4005 4010 4015

Val Ile Ala Gly Glu Ala Gln Ala Leu Asp Glu Val Val Asp Ala Leu 4020 4025 4030

Ser Gly Gln Glu Val Arg Val Arg Val Ala Val Asp Tyr Gly Ser 4035 4040 4045

His Thr Asn Gln Val Glu Ala Ile Glu Asp Leu Leu Ala Glu Thr Leu 4050 4055 4060

Ala Gly Ile Glu Ala Gln Ala Pro Lys Val Pro Phe Tyr Ser Thr Leu 4065 4070 4075 4080

Ile Gly Asp Trp Ile Arg Asp Ala Gly Ile Val Asp Gly Gly Tyr Trp
4085 4090 4095

Tyr Arg Asn Leu Arg Asn Gln Val Gly Phe Gly Pro Ala Val Ala Glu

WO 98/07868

- 147 -

Leu Val Arg Gln Gly His Gly Val Phe Val Glu Val Ser Ala His Pro Val Leu Val Gln Pro Leu Ser Glu Leu Ser Asp Asp Ala Val Val Thr Gly Ser Leu Arg Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Thr Ser Met Ala Glu Leu Tyr Val Gln Gly Val Pro Leu Asp Trp Thr Ala Val Leu Pro Arg Thr Gly Arg Val Asp Leu Pro Lys Tyr Ala Phe Asp His Arg His Tyr Trp Leu Arg Pro Ala Glu Ser Ala Thr Asp Ala Ala Ser Leu Gly Gln Ala Ala Ala Asp His Pro Leu Leu Gly Ala Val Val Glu Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Val Arg Thr His Pro Trp Leu Ala Asp His Ala Val Gly Gly Val Val Ile Leu Pro Gly Ser Gly Leu Ala Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys Thr Ala Leu Asp Glu Leu Ile Ile Glu Ala Pro Leu Val Val Pro Ala Gln Gly Ala Val Arg Val Gln Val Ala Leu Ser Gly Pro Asp

Glu Thr Gly Ser Arg Thr Val Asp Leu Tyr Ser Gln Arg Asp Gly Gly Ala Gly Thr Trp Thr Arg His Ala Thr Gly Val Leu Ser Thr Ala Pro Ala Gln Glu Pro Glu Phe Asp Phe His Ala Trp Pro Pro Ala Asp Ala Glu Arg Ile Asp Val Glu Thr Phe Tyr Thr Asp Leu Ala Glu Arg Gly Tyr Gly Tyr Gly Pro Ala Phe Gln Gly Leu Gln Ala Val Trp Arg Arg Asp Gly Asp Val Phe Ala Glu Val Ala Leu Pro Glu Asp Leu Arg Lys Asp Ala Gly Arg Phe Gly Val His Pro Ala Leu Leu Asp Ala Ala Leu Gln Ala Ala Thr Ala Val Gly Gly Asp Glu Pro Gly Gln Pro Val Leu Ala Phe Ala Trp Asn Gly Leu Val Leu His Ala Ala Gly Ala Ser Ala Leu Arg Val Arg Leu Ala Pro Ser Gly Pro Asp Thr Leu Ser Val Ala Ala Ala Asp Glu Thr Gly Gly Leu Val Leu Thr Met Glu Ser Leu Val Ser Arg Pro Val Ser Ala Glu Gln Leu Gly Ala Ala Ala Asp Ala Gly

His Asp Ala Met Phe Arg Val Asp Trp Thr Glu Leu Pro Ala Val Pro 4500 4510

Arg Ala Glu Leu Pro Pro Trp Val Arg Ile Asp Thr Ala Asp Asp Val 4515  $\rangle$  4520 4525

Ala Ala Leu Ala Glu Lys Ala Asp Ala Pro Pro Val Val Val Trp Glu 4530 4535 4540

Ala Ala Gly Gly Asp Pro Ala Leu Ala Val Ser Ser Arg Val Leu Glu 4545 4550 4555 4560

Ile Met Gln Ala Trp Leu Ala Ala Pro Ala Phe Glu Glu Ala Arg Leu
4565 4570 4575

Val Val Thr Thr Arg Gly Ala Val Pro Ala Gly Gly Asp His Thr Leu 4580 4585 4590

Thr Asp Pro Ala Ala Ala Ala Val Trp Gly Leu Val Arg Ser Ala Gln 4595 4600 4605

Ala Glu His Pro Asp Arg Val Val Leu Leu Asp Thr Asp Gly Glu Val
4610 4615 4620

Pro Leu Gly Ala Val Leu Ala Ser Gly Glu Pro Gln Leu Ala Val Arg 4625 4630 4635 4640

Gly Thr Thr Phe Phe Val Pro Arg Leu Ala Arg Ala Thr Arg Leu Ser 4645 4650 4655

Asp Ala Pro Pro Ala Phe Asp Pro Asp Gly Thr Val Leu Val Ser Gly 4660 4665 4670

Ala Gly Ser Leu Gly Thr Leu Val Ala Arg His Leu Val Thr Arg His 4675 4680 4685

Gly Val Arg Arg Val Val Leu Ala Ser Arg Gln Gly Arg Asp Ala Glu

- 150 -

4690 4695 4700

Gly Ala Gln Asp Leu Ile Thr Glu Leu Thr Gly Glu Gly Ala Asp Val 4705 4710 4715 4720

Ser Phe Val Ala Cys Asp Val Ser Asp Arg Asp Gln Val Ala Ala Leu 4725 4730 4735

Leu Ala Gly Leu Pro Asp Leu Thr Gly Val Val His Thr Ala Gly Val
4740 4745 4750

Phe Glu Asp Gly Val Ile Glu Ala Leu Thr Pro Asp Gln Leu Ala Asn 4755 4760 4765

Val Tyr Ala Ala Lys Val Thr Ala Ala Met His Leu Asp Glu Leu Thr 4770 4775 4780

Arg Asp Arg Asp Leu Gly Ala Phe Val Val Phe Ser Ser Val Ala Gly 4785 4790 4795 4800

Val Met Gly Gly Gly Gln Gly Pro Tyr Ala Ala Ala Asn Ala Phe
4805 4810 4815

Leu Asp Ala Ala Met Ala Ser Arg Gln Ala Ala Gly Leu Pro Gly Leu 4820 4825 4830

Ser Leu Ala Trp Gly Leu Trp Glu Arg Ser Ser Gly Met Ala Ala His 4835 4840 4845

Leu Ser Glu Val Asp His Ala Arg Ala Ser Arg Asn Gly Val Leu Glu 4850 4855 4860

Leu Thr Arg Ala Glu Gly Leu Ala Leu Phe Asp Leu Gly Leu Arg Met 4865 4870 4875 4880

Ala Glu Ser Leu Leu Val Pro Ile Lys Leu Asp Leu Ala Ala Met Arg 4885 4890 4895

Ala Ser Thr Val Pro Val Leu Phe Arg Gly Leu Val Arg Pro Ser Arg 4900 4905 4910

Thr Gln Ala Arg Thr Ala Ser Thr Val Asp Arg Gly Leu Ala Gly Arg 4915 4920 4925

Leu Ala Gly Leu Pro Val Ala Glu Arg Ala Ala Val Leu Val Asp Leu 4930 4935 4940

Val Arg Gly Gln Val Ala Val Val Leu Gly Tyr Asp Gly Pro Glu Ala 4945 4950 4955 4960

Val Arg Pro Asp Thr Ala Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr
4965 4970 4975

Ser Val Glu Leu Arg Asn Arg Leu Arg Glu Ala Thr Gly Leu Lys Leu 4980 4985 4990

Pro Ala Thr Leu Val Phe Asp Tyr Pro Asn Pro Leu Ala Val Ala Arg 4995 5000 5005

Tyr Leu Gly Ala Arg Leu Val Pro Asp Gly Thr Ala Asn Gly Asn Gly 5010 5015 5020

Asn Gly Asn Gly His Ser Glu Asp Asp Arg Leu Arg His Ala Leu Ala 5025 5030 5035 5040

Ala Ile Ala Ala Glu Asp Ala Gly Glu Glu Arg Ser Ile Ala Asp Leu 5045 5050 5055

Gly Val Asp Asp Leu Val Gln Leu Ala Phe Gly Asp Glu 5060 5065

- (2) INFORMATION FOR SEQ ID NO: 6:
  - (i) SEQUENCE CHARACTERISTICS:

<sub>-</sub> 15

WO 98/07868

- 152 -

PCT/EP97/04495

(A) LENGTH: 1721 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Ala Cys Arg Leu Pro Gly Gly Val Thr Gly Pro Gly Asp Leu Trp

1 5 10 15

Arg Leu Val Ala Glu Gly Gly Asp Ala Val Ser Gly Phe Pro Thr Asp
20 25 30

Arg Cys Trp Asp Leu Asp Thr Leu Phe Asp Pro Asp Pro Asp His Ala 35 40 45

Gly Thr Ser Tyr Thr Asp Gln Gly Gly Phe Leu His Asp Ala Ala Leu
50 55 60

Phe Asp Pro Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met 65 70 75 80

Asp Pro Gln Gln Arg Leu Leu Glu Ala Ser Trp Glu Ala Leu Glu
85 90 95

Gly Val Gly Leu Asp Pro Ala Ser Leu Gln Gly Thr Asp Val Gly Val
100 105 110

Phe Thr Gly Ala Gly Gly Ser Gly Tyr Gly Gly Gly Leu Thr Gly Pro 115 120 125

Glu Met Gln Ser Phe Ala Gly Thr Gly Leu Ala Ser Ser Val Ala Ser

- 153 -

Gly Arg Val Ser Tyr Val Phe Gly Phe Glu Gly Pro Ala Val Thr Ile Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Ala Gln Ala Leu Arg Gln Gly Asp Cys Ser Met Ala Leu Ala Gly Gly Ala Met Val Met Ser Gly Pro Asp Ser Phe Val Val Phe Ser Arg Gln Arg Gly Leu Ala Thr Asp Gly Arg Cys Lys Ala Phe Ala Ser Gly Ala Asp Gly Met Val Leu Ala Glu Gly Ile Ser Val Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Arg Val Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Ala Ala Leu Ala Asn Ala Gly Ile Gly Pro Ser Asp Val Asp Leu Val Glu Ala His Gly Thr Gly Thr Ser Leu Gly Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Gln Asp Arg Glu Thr Pro Leu Trp Leu Gly Ser Leu Lys Ser Asn Ile Gly 

His Thr Gln Ala Ala Ala Gly Val Ala Ser Val Ile Lys Val Val Gln Ala Leu Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Glu Pro Ser Ser Gln Val Asp Trp Ser Glu Gly Ala Val Glu Leu Leu Thr Gly Ser Arg Asp Tro Pro Arg Gly Asp Arg Pro Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Val His Leu Ile Ile Glu Glu Ala Pro Glu Glu Pro Ala Ala Ala Val Pro Thr Ser Ala Asp Val Val Pro Leu Val Val Ser Ala Arg Ser Thr Gly Ser Leu Ala Gly Gln Ala Asp Arg Leu Thr Glu Val Asp Val Pro Leu Gly His Leu Ala Gly Ala Leu Val Ala Gly Arg Ala Val Leu Glu Glu Arg Ala Val Val Ala Gly Ser Ala Glu Glu Ala Arg Ala Gly Leu Gly Ala Leu Ala Arg Gly Glu Ala Ala Pro Gly Val Val Thr Gly Thr Ala Gly Lys Pro Gly Lys Val Val Trp Val Phe Pro Gly Gln Gly Thr Gln Trp Val Gly Met Gly Arg

Glu	Leu 530	Leu	Asp	Ala	Ser	Pro 535	Val	Phe	Ala	Glu	Arg 540	Ile	Lys	Glu	Cys
Ala 545	Ala	Ala	Leu	Asp	Gln 550	Trp	Thr	Asp	Trp	Ser 555	Leu	Leu	Asp	Val	<b>Leu</b> 560
Arg	Gly	qzA	Gly	<b>Asp</b> 565	Leu	Asp	Ser	Val	Glu 570	Val	Leu	Gln	Pro	Ala 575	Cys
Phe	Ala	Val	Met 580	Val	Gly	Leu	Ala	Ala 585	Val	Trp	Glu	Ser	Ala 590	Gly	Val
Arg	Pro	Asp 595	Ala	Val	Val	Gly	His 600	Ser	Gln	Gly	Glu	Ile 605	Ala	Ala	Ala
Cys	Val 610	Ser	Gly	Ala	Leu	Thr 615	Leu	Asp	Asp	Ala	Ala 620	Lys	Val	Val	Ala
Leu 625	Arg	Ser	Gln	Ala	Ile 630	Ala	Ala	Arg	Leu	Ser 635	Gly	Arg	Gly	Gly	<b>Met</b> 640
Ala	Ser	Val	Ala	Leu 645	Ser	Glu	Ąsp	Glu	Ala 650	Asn	Ala	Arg	Leu	Gly 655	Leu
Trp	qzA	Gly	Arg 660	Ile	Glu	Val	Ala	Ala 665	Val	Asn	Gly	Pro	Ala 670	Ser	Val
Val	Ile	Ala 675	Gly	Asp	Ala	Gln	Ala 680	Leu	Asp	Glu	Ala	Leu 685	Glu	Val	Leu
Ala	Gly 690	qaA	Gly	Val	Arg	Val 695	Arg	Gln	Val	Ala	Val 700	Asp	Tyr	Ala	Ser
His 705	Thr	Arg	His	Val	Glu 710	ązA	Ile	Arg	Asp	Thr 715	Leu	Ala	Glu	Thr	Leu 720

Ala Gly Ile Thr Ala Gln Ala Pro Asp Val Pro Phe Arg Ser Thr Val

- 156 -

				725					730					735	
Thr	Gly	Gly	Trp 740	Val	Arg	Asp	Ala	Asp 745	Val	Leu	Asp	Gly	Gly 750	Tyr	Trp
Tyr	Arg	Asn 755	Leu	Arg	Asn	Gln	Val 760	Arg	Phe	Gly	Pro	Ala 765	Val	Ala	Glu
Leu	Leu 770	Glu	Gln	Gly	His	Gly 775	Val	Phe	Val	Glu	Val 780	Ser	Ala	His	Pro
Val 785	Leu	Val	Gln	Pro	Ile 790	Ser	Glu	Leu	Thr	Asp 795	Ala	Val	Val	Thr	Gly Gly
Thr	Leu	Arg	Arg	Asp 805	Ąsp	Gly	Gly	Leu	Arg 810	Arg	Leu	Leu	Thr	Ser 815	Met
Ala	Glu	Leu	Phe 820	Val	Arg	Gly	Val	Arg 825	Val	qaA	Trp	Ala	Thr 830	Leu	Val
Pro	Prc	Ala 835	Arg	Val	Asp	Leu	Pro 840	Thr	Tyr	Ala	Phe	Asp 845	His	Gln	His
Phe	Trp 850	Leu	Arg	Pro	Ala	Ala 855	Gln	Ala	Asp	Ala	Val 860	Ser	Leu	Gly	Gln
Ala 865		Ala	Glu	His	Pro 870	Leu	Leu	Gly	Ala	Val 875	Val	Arg	Leu	Pro	Gln 880
Ser	Asp	Gly	Leu	Val 885	Phe	Thr	Ser	Arg	Leu 890	Ser	Leu	Arg	Thr	His 895	Pro
Trp	Leu	Ala	Asp 900	His	Thr	Ile	Gly	Gly 905	Val	Val	Leu	Phe	Pro 910	Gly	Thr
Gly	Leu	Val	Glu	Leu	Ala	Val	Arg	Ala	Gly	Asp	Glu	Ala	Gly	Cys	Pro

1105

Val	Leu 930	<b>A</b> sp	Glu	Leu	Val	Thr 935	Glu	Ala	Pro	Leu	Val	Val	Pro	Gly	Gln
								**- 7	0	01		<b>3</b>	<b>63</b>	7	C]
G1y 945	Gly	Val	Asn	Val	950	Vai	Thr	vaı	ser	955	PIO	Asp	GIN	Asn	960
Leu	Arg	Thr	Val	Asp 965	Ile	His	Ser	Gln	Arg 970	Asp	Asp	Val	Trp	Thr 975	Arg
His	Ala	Thr	Gly 980	Thr	Val	Ser	Ala	Thr 985	Pro	Ala	Ser	Ser	Pro 990	Gly	Phe
Asp	Phe	Thr 995	Ala	Trp	Pro	Pro	Pro 1000		Gly	Gln	Arg	Val 1005		Ile	Gly
qaA	Phe 1010	_	Ala	ąsĄ	Leu	Ala 1015		Arg	Gly	Tyr	Ala 1020		Gly	Pro	Leu
Phe		Gly	Val	Arg	Ala 1030		Trp	Gln	Arg	Gly 1035		Asp	Val	Phe	Ala 1040
102.	,				1050	,				100-					10.10
Glu	Val	Ala	Leu	Pro 1045		Asp	Arg	Ärg	Glu 1050		Ala	Ala	Arg	Phe 1055	
Leu	His	Pro	Ala 1060		Leu	Asp	Ala	Ala 1065		Gln	Thr	Gly	Thr 1070	Ile	Ala
Ala	Ala	Ala 1075		Gly	Gln	Pro	Gly 1080		Ser	Val	Met	Pro 1085		Ser	Trp
Asn	Arg 1090		Ala	Leu	His	Ala 1095		Gly	Ala	Ala	Gly 1100		Arg	Val	Arg

1110

1115

Thr Gly Ala Pro Val Leu Thr Met Asp Ser Leu Ile Leu Arg Glu Val 1125 1130 1135

Ala Leu Asp Gln Leu Asp Thr Ala Arg Ala Gly Ser Leu Tyr Arg Val 1140 1150

Asp Trp Thr Pro Leu Pro Thr Val Asp Ser Ala Val Pro Ala Gly Arg 1155 1160 1165

Ala Glu Val Leu Glu Ala Phe Gly Glu Glu Pro Leu Asp Leu Thr Gly 1170 1175 1180

Ala Arg Leu Val Val Val Thr Arg Gly Ala Val Pro Ala Gly Asp Gly
1205 1210 1215

Val Val Ser Asp Pro Ala Gly Ala Ala Val Trp Gly Leu Val Arg Ala 1220 1225 1230

Ala Glu Asn Pro Asp Arg Phe Val Leu Leu Asp Thr Asp Gly
1235 1240 1245

Glu Val Pro Leu Glu Ala Val Leu Ala Thr Gly Glu Pro Gln Leu Ala 1250 1255 1260

Leu Arg Gly Thr Thr Phe Ser Val Pro Arg Leu Ala Arg Val Thr Glu 1265 1270 1275 1280

Pro Ala Glu Ala Pro Leu Thr Phe Arg Pro Asp Gly Thr Val Leu Val 1285 1290 1295

Ser Gly Ala Gly Thr Leu Gly Ala Leu Ala Ala Arg Asp Leu Val Thr 1300 1305 1310

Arg His Gly Val Arg Arg Leu Val Leu Ala Ser Arg Arg Gly Arg Ala

- 159 -

	1315			1320	)				1325	5		
Ala Glu 1330	Gly Ile	Asp Asp	Leu 1335		Ala	Glu	Leu	Thr 1340		His	Gly	Ala
Glu Val	Thr Val	Ala Ala 135		Asp	Val	Ser	Asp 1355		Ąsp	Gln	Val	Ala 1360
Ala Leu	Leu Lys	Glu His	Ala	Leu	Thr	Ala 1370		Val	His	Thr	Ala 1375	
Val Phe	Asp Ala	_	Thr	Gly	Ala 1385		Thr	Arg	Glu	Arg 1390		Ala
Lys Val	Phe Ala 1395	Pro Lys		Asp 1400		Ala	Asn	His	Leu 1405		Glu	Leu
Thr Arg	Asp Leu )	Asp Leu	Asp 1415		Phe	Ile	Val	Tyr 1420		Ser	Ala	Ser
Ser Ile 1425	Phe Met	Gly Ala		Ser	Gly	Gly	Tyr 1435		Ala	Ala	Asn	Ala 1440
Tyr Leu	Asp Gly	_	Ala	Ala	Arg	Arg 1450		Ala	Gly	Leu	Pro 1455	Gly
	Asp Gly Leu Ala 1460	Leu Met 1445 Trp Gly				1450 Gln	)				1455 Ala	Gly
Leu Ser	Leu Ala	Leu Met 1445 Trp Gly	Pro	Trp	Glu 1465 Arg	1450 Gln	Leu	Thr	Gly	Met 1470 Glu	1455 Ala	Gly
Leu Ser	Leu Ala 1460 Asp Asp 1475 Val Arg	Leu Met 1445 Trp Gly	Pro Leu	Trp Ala 1480 Ser	Glu 1465 Arg	Gln Met	Leu Ser	Thr Arg	Gly Arg 1485 Glu	Met 1470 Glu	Ala O	Gly Asp Arg

1510

1505

1515

Leu Arg Glu Val Arg Ala Asp Ala Ala Gly Gly Gly Thr Val Pro His 1525 1530 1535

Leu Leu Arg Gly Leu Val Arg Ala Gly Arg Gln Ala Ala Arg Thr Ala 1540 1550

Ala Thr Glu Asp Gly Gly Leu Glu Arg Arg Leu Ala Gly Leu Thr Val 1555 1560 1565

Ala Glu Gln Glu Ala Leu Leu Leu Asp Leu Val Arg Gly Gln Val Ala 1570 1575 1580

Val Val Leu Gly His Ala Asp Ser Ser Gly Val Arg Ala Asp Ala Ala 1585 1590 1595 1600

Phe Lys Asp Ala Gly Phe Asp Ser Leu Thr Ser Val Glu Leu Arg Asn 1605 1610 1615

Arg Leu Arg Glu Thr Thr Gly Leu Lys Leu Pro Ala Thr Leu Val Phe 1620 1625 1630

Asp His Pro Asn Pro Leu Ala Leu Ala Arg His Leu Arg Ala Glu Leu 1635 1640 1645

Ala Val Asp Glu Ala Ser Pro Ala Asp Ala Val Leu Ala Gly Leu Ala 1650 1655 1660

Gly Leu Glu Ala Ala Ile Ala Ala Ala Gly Ala Pro Asp Gly Asp Arg 1665 1670 1675 1680

Ile Thr Ala Arg Leu Arg Glu Leu Leu Lys Ala Ala Glu Ala Ala Glu 1685 1690 1695

Ala Arg Pro Gly Thr Ser Gly Asp Leu Asp Thr Ala Ser Asp Glu Glu 1700 1705 1710 WO 98/07868

- 161 -

PCT/EP97/04495

Leu Phe Ala Leu Val Asp Gly Leu Asp 1715 1720

- (2) INFORMATION FOR SEQ ID NO: 7:
  - (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1688 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Met Ala Cys Arg Tyr Pro Gly Gly Val Ser Ser Pro Glu Asp Leu Trp

1 5 10 15

Arg Leu Val Ala Glu Gly Thr Asp Ala Val Ser Ala Phe Pro Gly Asp 20 25 30

Arg Gly Trp Asp Val Asp Gly Leu Val Asp Pro Asp Pro Asp Arg Pro 35 40 45

Gly Thr Thr Tyr Thr Asp Gln Gly Gly Phe Leu His Glu Ala Gly Leu 50 55 60

Phe Asp Ala Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Val Ala Met 55 70 75 80

Asp Pro Gln Gln Arg Leu Leu Glu Thr Ser Trp Glu Ala Ile Glu 85 90 95

Arg Thr Gly Thr Asp Pro Leu Ser Leu Lys Gly Ser Asp Ile Gly Val

			100					105					110		
Phe	Thr	Gly 115	Val	Ala	Ser	Met	Gly 120	Tyr	Gly	Ala	Gly	Gly 125	Gly	Val	Val
Ala	Pro 130	Glu	Leu	Glu	Gly	Phe 135	Val	Gly	Thr	Gly	Ala 140	Ala	Pro	Cys	Ile
Ala 145	Ser	Gly	Arg	Val	Ser 150	Tyr	Val	Leu	Gly	Phe 155	Glu	Gly	Pro	Ala	Val
Thr	Val	Asp	Thr	Gly 165	Cys	Ser	Ser	Ser	Leu 170	Val	Ala	Met	His	Leu 175	Ala
Ala	Gln	Ala	Leu 180	Arg	Arg	Gly	Glu	Cys 185	Ser	Met	Ala	Leu	Ala 190	Gly	Gly
Ala	Met	Val 195	Met	Ala	Gln	Pro	Gly 200	Ser	Phe	Val	Ser	Phe 205	Ser	Arg	Gln
Arg	Gly 210	Leu	Ala	Leu	Asp	Gly 215	Arg	Cys	Lys	Ala	Phe 220	Ser	Asp	Ser	Ala
Asp 225	Gly	Met	Gly	Leu	Ala 230	Glu	Gly	Val	Gly	Val 235	Ile	Ala	Leu	Glu	Arg 240
Leu	Ser	Val	Ala	Arg 245	Glu	Arg	Gly	His	Arg 250	Val	Leu	Ala	Val	Leu 255	Arg
Gly	Ile	Ala	Val 260	Asn	Gln	qaA	Gly	Ala 265	Ser	Asn	Gly	Leu	Thr 270	Ala	Pro
Asn	Gly	Pro 275	Ser	Gln	Gln	Arg	Val 280	Ile	Arg	Ala	Ala	Leu 285	Ala	Glu	Ala
Gly	Leu 290	Ser	Pro	Ser	Asp	Val 295	qaA	Ala	Val	Glu	Gly 300	His	Gly	Thr	Gly

305					310					315					320
Gly	Lys	Gly	Arg	<b>Asp</b> <b>32</b> 5	Pro	Glu	Lys	Pro	Leu 330	Trp	Leu	Gly	Ser	Val 335	Lys
Ser	Asn	Leu	Gly 340	His	Thr	Gln	Ala	Ala 345	Ala	Gly	Val	Ala	Ser 350	Val	Ile
Lys	Met	<b>Val</b> 355	Gln	Ala	Leu	Arg	His 360	Gly	Val	Leu	Pro	Pro 365	Thr	Leu	His
Val	<b>As</b> p 370	Arg	Pro	Ser	Thr	Glu 375	Val	Asp	Trp	Ser	Ala 380	Gly	Ala	Val	Ser
Leu 385	Leu	Thr	Glu	Ala	Arg 390	Glu	Trp	Pro	Arg	Glu 395	Gly	Arg	Pro	Arg	<b>Arg</b> 400
Ala	Gly	Val	Ser	Ser 405	Phe	Gly	Ile	Ser	Gly 410	Thr	Asn	Ala	His	Leu 415	Ile
Leu	Glu	Glu	Ala 420	Pro	Glu	Glu	Glu	Pro 425	Pro	Val	Ala	Glu	Ala 430	Pro	Ser
Ala	Gly	Val 435	Val	Pro	Val	Val	Val 440	Ser	Ala	Arg	Gly	Ala 445	Leu	Ala	Gly
Gln	Ala 450	Gly	Arg	Leu	Ala	Ala 455	Phe	Leu	Glu	Ala	Ser 460	Asp	Glu	Pro	Leu
Val 465	Thr	Val	Ala	Gly	Ala 470	Leu	Ile	Cys	Gly	Arg 475	Ser	Arg	Phe	Gly	Asp 480
Arg	Ala	Val	Val	Val	Ala	Gly	Thr	Arg	Ala 490	Glu	Ala	Thr	Ala	Gly 495	Leu

Ala Ala Leu Ala Arg Gly Glu Ser Ala Ala Asp Val Val Thr Gly Thr Val Ala Ala Ser Gly Val Pro Gly Lys Leu Val Trp Val Phe Pro Gly Gln Gly Ser Gln Trp Val Gly Met Gly Arg Glu Leu Leu Glu Ala Ser Pro Val Phe Ala Ala Arg Ile Ala Glu Cys Ala Ala Ala Leu Glu Pro Trp Ile Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Glu Gly Asp Leu Asp Arg Val Asp Val Val Gln Pro Ala Ser Phe Ala Val Met Val Gly Leu Ala Ala Val Trp Ser Ser Val Gly Val Val Pro Asp Ala Val Leu Gly His Ser Gln Gly Glu Ile Ala Ala Ala Cys Val Ser Gly Ala Leu Ser Leu Gln Asp Ala Ala Lys Val Val Ala Leu Arg Ser Gln Ala Ile Ala Ala Lys Leu Ala Gly Arg Gly Gly Met Ala Ser Val Ala Leu Ser Glu Glu Asp Ala Val Ala Arg Leu Arg His Trp Ala Asp Arg Val Glu

Val Ala Ala Val Asn Ser Pro Ser Ser Val Val Ile Ala Gly Asp Ala 675 680 685

Glu Ala Leu Asp Gln Ala Leu Glu Ala Leu Thr Gly Gln Asp Ile Arg

- 165 -

Val Arg Arg Val Ala Val Asp Tyr Ala Ser His Thr Arg His Val Glu Asp Ile Gln Glu Pro Leu Ala Glu Ala Leu Ala Gly Ile Glu Ala His Ala Pro Thr Leu Pro Phe Phe Ser Thr Leu Thr Gly Asp Trp Ile Arg Glu Ala Gly Val Val Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Asn Gln Val Gly Phe Gly Pro Ala Val Ala Glu Leu Leu Gly Leu Gly His Arg Val Phe Val Glu Val Ser Ala His Pro Val Leu Val Gln Ala Ile Ser Ala Ile Ala Asp Asp Thr Asp Ala Val Val Thr Gly Ser Leu Arg Arg Glu Glu Gly Leu Arg Arg Leu Leu Thr Ser Met Ala Glu Leu Phe Val Arg Gly Val Asp Val Asp Trp Ala Thr Met Val Pro Pro Ala Arg Val Asp Leu Pro Thr Tyr Ala Phe Asp His Gln His Tyr Trp Leu Arg Tyr Val Glu Thr Ala Thr Asp Ala Ala Gly Pro Val Val Arg Leu Pro Gln Thr Gly Gly Leu Val Phe Thr Thr Glu Trp Ser Leu Lys Ser 

Gln Pro Trp Leu Ala Glu His Thr Leu Glu Asp Leu Val Val Pro 900 905 910

- Gly Ala Ala Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly
  915 920 925
- Thr Pro Val Leu Asp Glu Leu Val Ile Glu Thr Pro Leu Val Val Pro 930 935 940
- Glu Arg Gly Ala Ile Arg Val Gln Val Thr Val Ser Gly Pro Asp Asp 945 950 955 960
- Gly Thr Arg Thr Leu Glu Val His Ser Gln Pro Glu Asp Ala Thr Asp 965 970 975
- Glu Trp Thr Arg His Ala Thr Gly Thr Leu Ser Ala Thr Pro Asp Glu 980 985 990
- Ser Ser Gly Phe Asp Phe Thr Ala Trp Pro Pro Pro Gly Ala Arg Gln 995 1000 1005
- Leu Asp Gly Val Pro Ala Ile Trp Arg Ala Gly Asp Glu Ile Phe Ala 1010 1015 1020
- Glu Val Ser Leu Pro Asp Asp Ala Asp Ala Glu Ala Phe Gly Ile His 1025 . 1030 1035 1040
- Pro Ala Leu Leu Asp Ala Ala Leu His Pro Ala Leu Pro Gly Asp Asp 1045 1050 1055
- Gly Leu Thr Gln Pro Met Glu Trp Arg Gly Leu Thr Leu His Ala Ala 1060 1065 1070
- Gly Ala Ser Thr Leu Arg Val Arg Leu Val Pro Gly Gly Phe Leu Glu 1075 1080 1085

Ala Ala Asp Gly Ala Gly Ser Leu Val Val Thr Ala Lys Glu Val Ala 1090 1095 1100

Leu Arg Pro Val Thr Ile Ala Arg Ser Arg Thr Thr Thr Arg Asp Ser 1105 1110 1115 1120

Leu Phe Gln Leu Asn Trp Ile Glu Leu Pro Glu Ser Gly Val Val Ala 1125 1130 1135

Ala Ala Asp Asp Thr Glu Val Leu Glu Val Pro Ala Gly Asp Ser Pro 1140 1145 1150

Leu Ala Ala Thr Ser Arg Val Leu Glu Arg Leu Gln Thr Trp Leu Thr 1155 1160 1165

Glu Pro Glu Ala Glu Gln Leu Val Val Val Thr Arg Gly Ala Val Pro 1170 1175 1180

Ala Gly Asp Thr Pro Val Thr Asp Pro Ala Ala Ala Ala Val Trp Gly
1185 1190 1195 1200

Leu Val Arg Ser Ala Gln Ala Glu Asn Pro Asp Arg Ile Val Leu Leu 1205 1210 1215

Asp Thr Asp Gly Glu Val Pro Leu Gly Ala Val Leu Ala Gly Glu 1220 1225 1230

Pro Gln Val Ala Val Arg Gly Thr Ala Leu Tyr Val Pro Arg Leu Ala 1235 1240 1245

Arg Ala Asp Ala Ala Pro Val Ser Gly Leu His Gly Thr Val Leu Val 1250 1255 1260

Ser Gly Ala Gly Val Leu Gly Glu Ile Val Ala Arg His Leu Val Thr 1265 1270 1275 1280

Arg His Gly Val Arg Lys Leu Val Leu Ala Ser Arg Arg Gly Leu Asp

- 168 **-**

				1285	5				1290	)				1295	
Ala	Asp	Gly	Ala 1300	_	Asp	Leu	Val	Thr 1305		Leu	Thr	Gly	Glu 1310		Ala
Asp	Val	Ser 1315		Val	Ala	Cys	Asp 1320		Ala	Ąsp	Arg	Asn 1325		Val	Ala
Ala	Leu 1330		Ala	Asp	His	Arg 1335		Ala	Ser	Val	Ile 1340		Thr	Ala	Gly
Val 1345		Asp	Asp	Gly	Val 1350		Gly	Thr	Leu	Thr 1355		Glu	Arg	Leu	Ala 1360
Lys	Val	Phe	Aļla	Pro 1365	_	Val	Asp	Ala	Val 1370		His	Leu	Asp	Glu 1375	Leu
Thr	Arg	Asp	Leu 1380		Leu	Asp	Ala	Phe 1385		Val	Phe	Ser	Ser 1390	Gly )	Ser
Gly	Val	Phe 1395	_	Ser	Pro	Gly	Gln 1400		Asn	Tyr	Ala	Ala 1405		Asn	Ala
Phe	Leu 1410	_	Ala	Ala	Met	Ala 141		Arg	Arg	Ala	Ala 1420		Leu	Pro	Gly
Leu 142		Leu	Ala	Trp	Gly 1430	_	Trp	Glu	Gln	Ala 1435	_	Gly	Met	Thr	Ala 1440
His	Leu	Gly	Gly	Thr 144	_	Gln	Ala	Arg	Met 1450		Arg	Gly	Gly	Val	_
Pro	Ile	Thr	Ala 1460		Glu	Gly	Met	Ala 1465		Phe	Asp	Thr	Ala 1470	Leu )	Gly
Ala	Gln	Pro	Ala	Leu	Leu	Val	Pro	Val	Lys	Leu	Asp	Leu	Arg	Glu	Val

1480

1485

Arg Ala Gly Gly Ala Val Pro His Leu Leu Arg Gly Leu Val Arg Ala 1490 1495 1500

Gly Arg Arg Gln Ala Gln Ala Ala Ser Thr Val Asp Asn Gln Leu Leu 1505 1510 1515 1520

Gly Arg Leu Ala Gly Leu Gly Ala Pro Glu Gln Glu Ala Leu Leu Val 1525 1530 1535

Asp Leu Val Arg Gly Gln Val Ala Ala Val Leu Gly His Ala Gly Pro 1540 1545 1550

Asp Ala Val Arg Ala Asp Thr Ala Phe Lys Asp Ala Gly Phe Asp Ser 1555 1560 1565

Leu Thr Ser Val Asp Leu Arg Asn Arg Leu Arg Glu Ser Thr Gly Leu 1570 1575 1580

Ala Arg His Leu Arg Asp Glu Leu Gly Ala Gly Asp Asp Ala Leu Ser 1605 1610 1615

Val Val His Ala Arg Leu Glu Asp Val Glu Ala Leu Leu Gly Gly Leu 1620 1630

Arg Leu Asp Glu Ser Thr Lys Thr Gly Leu Thr Leu Arg Leu Gln Gly 1635 1640 1645

Leu Val Ala Arg Cys Asn Gly Val Asn Asp Gln Thr Gly Glu Thr 1650 1655 1660

Leu Ala Asp Arg Leu Glu Ala Ala Ser Ala Asp Glu Val Leu Asp Phe 1665 1670 1675 1680

- 170 -

Ile Asp Glu Glu Leu Gly Leu Thr 1685

- (2) INFORMATION FOR SEQ ID NO: 8:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 3413 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Ala Thr Asp Glu Lys Leu Leu Lys Tyr Leu Lys Arg Val Thr Ala 1 5 10 15

Glu Leu His Ser Leu Arg Lys Gln Gly Ala Arg His Ala Asp Glu Pro 20 25 30

Leu Ala Val Val Gly Met Ala Cys Arg Phe Pro Gly Gly Val Ser Ser
35 40 45

Pro Glu Asp Leu Trp Gln Leu Val Ala Gly Gly Val Asp Ala Leu Ser 50 55 60

Asp Phe Pro Asp Asp Arg Gly Trp Glu Leu Asp Gly Leu Phe Asp Pro 65 70 75 80

Asp Pro Asp His Pro Gly Thr Ser Tyr Thr Ser Gln Gly Gly Phe Leu 85 90 95

Arg Gly Ala Gly Leu Phe Asp Ala Gly Leu Phe Gly Ile Ser Pro Arg

- 171 -

			100					105					110		
Glu	Ala	Leu 115	Val	Met	Asp	Pro	Gln 120	Gln	Arg	Val	Leu	Leu 125	Glu	Thr	Ser
Trp	Glu 130	Ala	Leu	Glu	qzA	Ala 135	Gly	Val	Asp	Pro	Leu 140	Ser	Leu	Lys	Gly
Ser 145	Asp	Val	Gly	Val	Phe 150	Ser	Gly	Val	Phe	Thr 155	,Gln	Gly	Tyr	Gly	Ala
Gly	Ala	Ile	Thr	Pro 165	Asp	Leu	Glu	Ala	Phe 170	Ala	Gly	Ile	Gly	Ala 175	Ala
Ser	Ser	Val	Ala 180	Ser	Gly	Arg	Val	Ser 185	Tyr	Val	Phe	Gly	Leu 190	Glu	Gly
Pro	Ala	Val 195	Thr	Ile	Asp	Thr	Ala 200	Cys	Ser	Ser	Ser	Leu 205	Val	Ala	Ile
His	Leu 210	Ala	Ala	Gln	Ala	Leu 215	Arg	Ala	Gly	Glu	Cys 220	Ser	Met	Ala	Leu
Ala 225	Gly	Gly	Ala	Thr	Val 230	Met	Pro	Thr	Pro	Gly 235	Thr	Phe	Val	Ala	Phe 240
Ser	Arg	Gln	Arg	Val 245	Leu	Ala	Ala	Asp	Gly 2 <b>5</b> 0		Ser	Lys	Ala	Phe 255	Ser
Ser	The	<u>Al</u> a	Asp 260	Gly	Thr	Gly	Trp	Ala 265	Glu	Gly	Ala	Gly	Val 270	Leu	Val
Leu	Glu	Arg 275	Leu	Ser	Val	Ala	Gln 280	Glu	Arg	Gly	His	Arg 285	Ile	Leu	Ala
Val	Leu 290	Arg	Gly	Ser	Ala	Val 295	Asn	Gln	Asp	Gly	Ala 300	Ser	Asn	Gly	Leu

WO 98/07868

Thr	Ala	Pro	Asn	GLY	Pro	Ser	GIn	GIn	Arg	Val	Ile	Arg	Lys	Ala	Leu
305					310					315					320
Ala	Gly	Ala	Gly	Leu 325	Val	Ala	Ser	Asp	Val 330	Asp	Val	Val	Glu	Ala 335	His
Gly	Thr	Gly	Thr 340	Ala	Leu	Gly	qzA	Pro 345	Ile	Glu	Ala	Gln	Ala 350	Leu	Leu
Ala	Thr	Туг 355	Gly	Gln	Gly	Arg	Glu 360	Arg	Pro	Leu	Trp	Leu 365	Gly	Ser	Val
Lys	Ser 370	Asn	Phe	Gly	His	Thr 375	Gln	Ala	Ala	Ala	380 GJA	Val	Ala	Gly	Val
Ile 385	Lys	Met	Val	Gln	Ala 390	Leu	Arg	His	Gly	Ala 395	Met	Pro	Pro	Thr	Leu 400
His	Val	Ala	Glu	Pro 405	Thr	Pro	Glu	Val	Asp 410	Trp	Ser	Ala	Gly	Ala 415	Val
Glu	Leu	Leu	Thr 420	Glu	Pro	Arg	Glu	Trp 425	Pro	Ala	Gly	Asp	Arg 430	Pro	Arg
Arg	Ala	Gly 435	Val	Ser	Ala	Phe	Gly 440	Ile	Ser	Gly	Thr	Asn 445	Ala	His	Leu
Ile	Leu 450	Glu	Glu	Ala	Pro	Pro 455	Ala	Asp	Ala	Val	Ala 460	Glu	Glu	Pro	Glu
Phe 465	Lys	Gly	Pro	Val	Pro 470	Leu	Val	Val	Ser	Ala 475	Gly	Ser	Pro	Thr	Ser 480
Leu	Ala	Ala	Gln	Ala 485	Gly	Arg	Leu	Ala	Glu 490	Val	Leu	Ala	Ser	Gly 495	Gly

Val Ser Arg Ala Arg Leu Ala Ser Gly Leu Leu Ser Gly Arg Ala Leu Leu Gly Asp Arg Ala Val Val Val Ala Gly Thr Asp Glu Asp Ala Val Ala Gly Leu Arg Ala Leu Ala Arg Gly Asp Arg Ala Pro Gly Val Leu Thr Gly Ser Ala Lys His Gly Lys Val Val Tyr Val Phe Pro Gly Gln Gly Ser Gln Arg Leu Gly Met Gly Arg Glu Leu Tyr Asp Arg Tyr Pro Val Phe Ala Thr Ala Phe Asp Glu Ala Cys Glu Gln Leu Asp Val Cys Leu Ala Gly Arg Ala Gly His Arg Val Arg Asp Val Val Leu Gly Glu Val Pro Ala Glu Thr Gly Leu Leu Asn Gln Thr Val Phe Thr Gln Ala Glv Leu Phe Ala Val Glu Ser Ala Leu Phe Arg Leu Ala Glu Ser Trp Gly Val Arg Pro Asp Val Val Leu Gly His Ser Ile Gly Glu Ile Thr Ala Ala Tyr Ala Ala Gly Val Phe Ser Leu Pro Asp Ala Ala Arg Ile Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu Ala Pro Gly Gly Ala Met Val Ala Val Ala Ala Ser Glu Ala Glu Val Ala Glu Leu Leu Gly

	690					695					700				
Asp 705	Gly	Val	Glu	Leu	Ala 710	Ala	Val	Asn	Gly	Pro 715	Ser	Ala	Val	Val	Leu 720
Ser	Gly	Asp	Ala	Asp 725	Ala	Val	Val	Ala	Ala 730	Ala	Ala	Arg	Met	Arg 735	Glu
Arg	Gly	His	Lys 740	Thr	Lys	Gln	Leu	Lys 745	Val	Ser	His	Ala	Phe 750	His	Ser
Ala	Arg	Met 755	Ala	Pro	Met	Leu	Ala 760	Glu	Phe	Ala	Ala	Glu 765	Leu	Ala	Gly
Val	Thr 770	Trp	Arg	Glu	Pro	Glu 775	Ile	Pro	Val	Val	Ser 780	Asn	Val	Thr	Gly
Arg 785	Phe	Ala	Glu	Pro	Gly <b>79</b> 0	Glu	Leu	Thr	Glu	Pro 795	Gly	Tyr	Trp	Ala	<b>Gl</b> u 800
His	Val	Arg	Arg	Pro 805	Val	Arg	Phe	Ala	Glu 810	Gly	Val	Ala	Ala	Ala 815	Thr
Glu	Ser	Gly	Gly 820	Ser	Leu	Phe	Val	Glu 825	Leu	Gly	Pro	Gly	Ala 830	Ala	Leu
Thr	Ala	Leu 835	Val	Glu	Glu	Thr			Val		Cys	Val 845	Ala	Ala	Leu
Arg	<b>Asp</b> 850	Asp	Arg	Pro	Glu	Val 855	Thr	Ala	Leu	Ile	Thr 860	Ala	Val	Ala	Glu
Leu 865	Phe	Val	Arg	Gly	<b>Val</b> 870	Ala	Val	Asp	Trp	Pro 875	Ala	Leu	Leu	Pro	Pro 880
Val	Thr	Gly	Phe	Val 885	Asp	Leu	Pro	Lys	Tyr 890	Ala	Phe	Asp	Gln	Gln 895	His

WO 98/07868

- 175 -

Tyr Trp Leu Gln Pro Ala Ala Gln Ala Thr Asp Ala Ala Ser Leu Gly 900 905 910

Gln Val Ala Ala Asp His Pro Leu Leu Gly Ala Val Val Arg Leu Pro 915 920 925

Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys Ser His 930 935 940

Pro Trp Leu Ala Asp His Val Ile Gly Gly Val Val Leu Val Ala Gly 945 950 955 960

Thr Gly Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys 965 970 975

Pro Val Leu Glu Glu Leu Val Ile Glu Ala Pro Leu Val Val Pro Asp 980 985 990

His Gly Gly Val Arg Ile Gln Val Val Gly Ala Pro Gly Glu Thr 995 1000 1005

Gly Ser Arg Ala Val Glu Val Tyr Ser Leu Arg Glu Asp Ala Gly Ala 1010 1015 1020

Glu Val Trp Ala Arg His Ala Thr Gly Phe Leu Ala Ala Thr Pro Ser 1025 1030 1035 1040

Gln His Lys Pro Phe Asp Phe Thr Ala Trp Pro Pro Pro Gly Val Glu 1045 1050 1055

Arg Val Asp Val Glu Asp Phe Tyr Asp Gly Leu Val Asp Arg Gly Tyr
1060 1065 1070

Ala Tyr Gly Pro Ser Phe Arg Gly Leu Arg Ala Val Trp Arg Arg Gly 1075 1080 1085

Asp Glu Val Phe Ala Glu Val Ala Leu Ala Glu Asp Asp Arg Ala Asp 1090 1095 1100

Ala Ala Arg Phe Gly Ile His Pro Gly Leu Leu Asp Ala Ala Leu His 1105 1110 1115 1120

Ala Gly Met Ala Gly Ala Thr Thr Glu Glu Pro Gly Arg Pro Val 1125 1130 1135

Leu Pro Phe Ala Trp Asn Gly Leu Val Leu His Ala Ala Gly Ala Ser 1140 1145 1150

Ala Leu Arg Val Arg Leu Ala Pro Ser Gly Pro Asp Ala Leu Ser Val 1155 1160 1165

Glu Ala Ala Asp Glu Ala Gly Gly Leu Val Val Thr Ala Asp Ser Leu 1170 1175 1180

Val Ser Arg Pro Val Ser Ala Glu Gln Leu Gly Ala Ala Ala Asn His 1185 1190 1195 1200

Asp Ala Leu Phe Arg Val Glu Trp Thr Glu Ile Ser Ser Ala Gly Asp 1205 1210 1215

Val Pro Ala Asp His Val Glu Val Leu Glu Ala Val Gly Glu Asp Pro 1220 1225 1230

Leu Glu Leu Thr Gly Arg Val Leu Glu Ala Val Gln Thr Trp Leu Ala 1235 1240 1245

Asp Ala Ala Asp Asp Ala Arg Leu Val Val Val Thr Arg Gly Ala Val 1250 1255 1260

His Glu Val Thr Asp Pro Ala Gly Ala Ala Val Trp Gly Leu Ile Arg 1265 1270 1275 1280

Ala Ala Gln Ala Glu Asn Pro Asp Arg Ile Val Leu Leu Asp Thr Asp

1475 "

- 177 -

Gly Glu Val Pro Leu Gly Arg Val Leu Ala Thr Gly Glu Pro Gln Thr Ala Val Arg Gly Ala Thr Leu Phe Ala Pro Arg Leu Ala Arg Ala Glu Ala Ala Glu Ala Pro Ala Val Thr Gly Gly Thr Val Leu Ile Ser Gly Ala Gly Ser Leu Gly Ala Leu Thr Ala Arg His Leu Val Ala Arg His Gly Val Arg Arg Leu Val Leu Val Ser Arg Arg Gly Pro Asp Ala Asp Gly Met Ala Glu Leu Thr Ala Glu Leu Ile Ala Gln Gly Ala Glu Val Ala Val Val Ala Cys Asp Leu Ala Asp Arg Asp Gln Val Arg Val Leu Leu Ala Glu His Arg Pro Asn Ala Val Val His Thr Ala Gly Val Leu Asp Asp Gly Val Phe Glu Ser Leu Thr Arg Glu Arg Leu Ala Lys Val Phe Ala Pro Lys Val Thr Ala Ala Asn His Leu Asp Glu Leu Thr Arg Glu Leu Asp Leu Arg Ala Phe Val Val Phe Ser Ser Ala Ser Gly Val Phe Gly Ser Ala Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Tyr Leu

- 178 -

Asp Ala Val Val Ala Asn Arg Arg Ala Ala Gly Leu Pro Gly Thr Ser 1490 1495 1500

Leu Ala Trp Gly Leu Trp Glu Gln Thr Asp Gly Met Thr Ala His Leu 1505 1510 1515 1520

Gly Asp Ala Asp Gln Ala Arg Ala Ser Arg Gly Gly Val Leu Ala Ile 1525 1530 1535

Ser Pro Ala Glu Gly Met Glu Leu Phe Asp Ala Ala Pro Asp Gly Leu 1540 1545 1550

Val Val Pro Val Lys Leu Asp Leu Arg Lys Thr Arg Ala Gly Gly Thr 1555 1560 1565

Val Pro His Leu Leu Arg Gly Leu Val Arg Pro Gly Arg Gln Gln Ala 1570 1575 1580

Arg Pro Ala Ser Thr Val Asp Asn Gly Leu Ala Gly Arg Leu Ala Gly
1585 1590 1595 1600

Leu Ala Pro Ala Glu Glu Glu Ala Leu Leu Leu Asp Val Val Arg Thr
1605 1610 1615

Gln Val Ala Leu Val Leu Gly His Ala Gly Pro Glu Ala Val Arg Ala 1620 1625 1630

Asp Thr Ala Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr Ser Val Glu 1635 1640 1645

Leu Arg Asn Arg Leu Arg Glu Ala Ser Gly Leu Lys Leu Pro Ala Thr 1650 1660

Leu Val Phe Asp Tyr Pro Thr Pro Val Ala Leu Ala Arg Tyr Leu Arg 1665 1670 1675 1680

- 179 -

Asp Glu Leu Gly Asp Thr Val Ala Thr Thr Pro Val Ala Thr Ala Ala 

Ala Ala Asp Ala Gly Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg 

Leu Pro Gly Gly Val Thr Asp Pro Glu Gly Leu Trp Arg Leu Val Arg 

Asp Gly Leu Glu Gly Leu Ser Pro Phe Pro Glu Asp Arg Gly Trp Asp 

Leu Glu Asn Leu Phe Asp Asp Asp Pro Asp Arg Ser Gly Thr Thr Tyr 

Thr Ser Arg Gly Gly Phe Leu Asp Gly Ala Gly Leu Phe Asp Ala Gly 

Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln 

Arg Leu Leu Glu Ala Ala Trp Glu Ala Leu Glu Gly Thr Gly Val 

Asp Pro Gly Ser Leu Lys Gly Ala Asp Val Gly Val Phe Ala Gly Val 

Ser Asn Gln Gly Tyr Gly Met Gly Ala Asp Pro Ala Glu Leu Ala Gly 

Tyr Ala Ser Thr Ala Gly Ala Ser Ser Val Val Ser Gly Arg Val Ser 

Tyr Val Phe Gly Phe Glu Gly Pro Ala Val Thr Ile Asp Thr Ala Cys 

Ser Ser Ser Leu Val Ala Met His Leu Ala Gly Gln Ala Leu Arg Gln

- 180 **-**

1875	5	1880	1885	
Gly Glu Cys 1890	Ser Met Ala Le	ս Ala Gly Gly Va 95	l Thr Val Met Gl 1900	y Thr
Pro Gly Thr 1905	Phe Val Glu Phe	e Ala Lys Gln Ar 19		y <b>As</b> p 1920
Gly Arg Cys	Lys Ala Tyr Ala 1925	a Glu Gly Ala As 1930	p Gly Thr Gly Tr	
Glu Gly Val	Gly Val Val Val	l Leu Glu Arg Le 1945	u Ser Val Ala Ar 1950	g Glu
Arg Gly His	_	a Val Leu Arg Gl	y Ser Ala Val Ası 1965	n Ser
Asp Gly Ala 1970	Ser Asn Gly Let	u Thr Ala Pro Ass	n Gly Pro Ser Gl	n Gln
Arg Val Ile 1985	Arg Arg Ala Let	u Ala Gly Ala Gly	_	2000
Val Asp Ile	Val Glu Gly His	s Gly Thr Gly Th 2010	r Ala Leu Gly Asp 201	
Ile Glu Ala	Gln Ala Leu Leu 2020	u Ala Thr Tyr Gly 2025	y Lys Asp Arg Asp 2030	Pro
Glu Thr Pro 2035		y Ser Val Lys Ser 2040	r Asn Phe Gly His	s Thr
Gln Ser Ala 2050	Ala Gly Val Ala	a Gly Val Ile Ly: 55	s Met Val Gln Ala 2060	e Leu
Arg His Gly 2065	Val Met Pro Pro 2070	o Thr Leu His Val		2080

٠,

WO 98/07868 PCT/EP97/04495

Gln Val Asp Trp Ser Ala Gly Ala Val Glu Val Leu Thr Glu Ala Arg 2085 2090 2095

Glu Trp Pro Arg Asn Gly Arg Pro Arg Arg Ala Gly Val Ser Ser Phe 2100 2105 2110

Gly Ile Ser Gly Thr Asn Ala His Leu Ile Ile Glu Glu Ala Pro Ala 2115 2120 2125

Glu Pro Gln Leu Ala Gly Pro Pro Pro Asp Gly Gly Val Val Pro Leu 2130 2135 2140

Val Val Ser Ala Arg Ser Pro Gly Ala Leu Ala Gly Gln Ala Arg Arg 2145 2150 2155 2160

Leu Ala Thr Phe Leu Gly Asp Gly Pro Leu Ser Asp Val Ala Gly Ala 2165 2170 2175

Leu Thr Ser Arg Ala Leu Phe Gly Glu Arg Ala Val Val Ala Asp 2180 2185 2190

Ser Ala Glu Glu Ala Arg Ala Gly Leu Gly Ala Leu Ala Arg Gly Glu 2195 2200 2205

Asp Ala Pro Gly Leu Val Arg Gly Arg Val Pro Ala Ser Gly Leu Pro 2210 2215 2220

Gly Lys Leu Val Trp Val Phe Pro Gly Gln Gly Thr Gln Trp Val Gly
2225 2230 2235 2240

Met Gly Arg Glu Leu Leu Glu Glu Ser Pro Val Phe Ala Glu Arg Ile
2245 2250 2255

Ala Glu Cys Ala Ala Ala Leu Glu Pro Trp Ile Gly Trp Ser Leu Phe 2260 2265 2270 WO 98/07868

- Asp Val Leu Arg Gly Asp Gly Asp Leu Asp Arg Val Asp Val Leu Gln 2275 2280 2285
- Pro Ala Cys Phe Ala Val Met Val Gly Leu Ala Ala Val Trp Ser Ser 2290 2295 2300
- Ala Gly Val Val Pro Asp Ala Val Leu Gly His Ser Gln Gly Glu Ile 2305 2310 2315 2320
- Ala Ala Cys Val Ser Gly Ala Leu Ser Leu Glu Asp Ala Ala Lys 2325 2330 2335
- Val Val Ala Leu Arg Ser Gln Ala Ile Ala Ala Lys Leu Ser Gly Arg 2340 2345 2350
- Gly Gly Met Ala Ser Val Ala Leu Gly Glu Ala Asp Val Val Ser Arg 2355 2360 2365
- Leu Ala Asp Gly Val Glu Val Ala Ala Val Asn Gly Pro Ala Ser Val 2370 2375 2380
- Val Ile Ala Gly Asp Ala Gln Ala Leu Asp Glu Thr Leu Glu Ala Leu 2385 2390 2395 2400
- Ser Gly Ala Gly Ile Arg Ala Arg Arg Val Ala Val Asp Tyr Ala Ser 2405 2410 2415
- His Thr Arg His Val Glu Asp Ile Glu Asp Thr Leu Ala Glu Ala Leu 2420 2425 2430
- Ala Gly Ile Asp Ala Arg Ala Pro Leu Val Pro Phe Leu Ser Thr Leu 2435 2440 2445
- Thr Gly Glu Trp Ile Arg Asp Glu Gly Val Val Asp Gly Gly Tyr Trp 2450 2455 2460
- Tyr Arg Asn Leu Arg Gly Arg Val Arg Phe Gly Pro Ala Val Glu Ala

- 183 -

Leu Leu Ala Gln Gly His Gly Val Phe Val Glu Leu Ser Ala His Pro Val Leu Val Gln Pro Ile Thr Glu Leu Thr Asp Glu Thr Ala Ala Val Val Thr Gly Ser Leu Arg Arg Asp Asp Gly Gly Leu Arg Arg Leu Leu Thr Ser Met Ala Glu Leu Phe Val Arg Gly Val Glu Val Asp Trp Thr Ser Leu Val Pro Pro Ala Arg Ala Asp Leu Pro Thr Tyr Ala Phe Asp His Glu His Tyr Trp Leu Arg Ala Ala Asp Thr Ala Ser Asp Ala Val Ser Leu Gly Leu Ala Gly Ala Asp His Pro Leu Leu Gly Ala Val Val Gin Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Arg Ser His Pro Trp Leu Ala Asp His Ala Val Arg Asp Val Val Ile Val Pro Gly Thr Gly Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys Pro Val Leu Asp Glu Leu Val Ile Glu Ala Pro Leu Val Val Pro Arg Arg Gly Gly Val Arg Val Gln Val Ala Leu Gly Gly Pro

WO 98/07868 PCT/EP97/04495

Ala Asp Asp Gly Ser Arg Thr Val Asp Val Phe Ser Leu Arg Glu Asp 2675 2680 2685

Ala Asp Ser Trp Leu Arg His Ala Thr Gly Val Leu Val Pro Glu Asn 2690 2695 2700

Arg Pro Arg Gly Thr Ala Ala Phe Asp Phe Ala Ala Trp Pro Pro Pro 2705 2710 2715 2720

Glu Ala Lys Pro Val Asp Leu Thr Gly Ala Tyr Asp Val Leu Ala Asp 2725 2730 2735

Val Gly Tyr Gly Pro Thr Phe Arg Ala Val Arg Ala Val Trp · 2740 2745 2750

Arg Arg Gly Ser Gly Asn Thr Thr Glu Thr Phe Ala Glu Ile Ala Leu 2755 2760 2765

Pro Glu Asp Ala Arg Ala Glu Ala Gly Arg Phe Gly Ile His Pro Ala 2770 2775 2780

Leu Leu Asp Ala Ala Leu His Ser Thr Met Val Ser Ala Ala Ala Asp 2785 2790 2795 2800

Thr Glu Ser Tyr Gly Asp Glu Val Arg Leu Pro Phe Ala Trp Asn Gly
2805 2810 2815

Leu Arg Leu His Ala Ala Gly Ala Ser Val Leu Arg Val Arg Val Ala 2820 2825 2830

Lys Pro Glu Arg Asp Ser Leu Ser Leu Glu Ala Val Asp Glu Ser Gly 2835 2840 2845

Gly Leu Val Val Thr Leu Asp Ser Leu Val Gly Arg Pro Val Ser Asn 2850 2855 2860 WO 98/07868 PCT/EP97/04495

Asp Gln Leu Thr Thr Ala Ala Gly Pro Ala Gly Ala Gly Ser Leu Tyr 2865 2870 2875 2880

Arg Val Asp Trp Thr Pro Leu Ser Ser Val Asp Thr Ser Gly Arg Val 2885 2890 2895

Pro Ser Trp Leu Pro Val Ala Thr Ala Glu Glu Val Ala Thr Leu Ala 2900 2905 2910

Asp Asp Val Leu Thr Gly Ala Thr Glu Ala Pro Ala Val Ala Val Met 2915 2920 2925

Glu Ala Val Ala Asp Glu Gly Ser Val Leu Ala Leu Thr Val Arg Val 2930 2935 2940

Leu Asp Val Val Gln Cys Trp Leu Ala Gly Gly Gly Leu Glu Gly Thr
2945 2950 2955 2960

Lys Leu Ala Ile Val Thr Arg Gly Ala Val Pro Ala Gly Asp Gly Val 2965 2970 2975

Val His Asp Pro Ala Ala Ala Ala Val Trp Gly Leu Val Arg Ala Ala 2980 2985 2990

Gln Ala Glu Asn Pro Asp Arg Ile Val Leu Leu Asp Val Glu Pro Glu 2995 3000 3005

Ala Asp Val Pro Pro Leu Leu Gly Ser Val Leu Ala Asp Gly Glu Pro 3010 3015 3020

Gln Val Ala Val Arg Gly Thr Thr Leu Ser Ile Pro Arg Leu Ala Arg 3025 3030 3035 3040

Ala Ala Arg Pro Asp Pro Ala Ala Gly Phe Lys Thr Arg Gly Pro Val 3045 3050 3055

Leu Val Thr Gly Gly Thr Gly Ser Leu Gly Gly Leu Val Ala Arg His

- 186 -

Leu Val Glu Arg His Gly Val Arg Gln Leu Val Leu Ala Ser Arg Arg Gly Leu Asp Ala Glu Gly Ala Lys Asp Leu Val Thr Asp Leu Thr Ala . 3090 Leu Gly Ala Asp Val Ala Val Ala Ala Cys Asp Val Ala Asp Arg Asp Gln Val Ala Ala Leu Leu Thr Glu His Arg Pro Ser Ala Val Val His Thr Ala Gly Val Pro Asp Ala Gly Val Ile Gly Thr Val Thr Pro Asp Arg Leu Ala Glu Val Phe Ala Pro Lys Val Thr Ala Ala Arg His Leu Asp Glu Leu Thr Arg Asp Leu Asp Leu Asp Ser Phe Val Val Tyr Ser Ser Val Ser Ala Val Phe Met Gly Ala Gly Ser Gly Ser Tyr Ala Ala Ala Asn Ala Tyr Leu Asp Gly Leu Met Ala His Arg Arg Ala Ala Gly Leu Pro Gly Gln Ser Leu Ala Trp Gly Leu Trp Asp Gln Thr Thr Gly 

Arg Gly Gly Leu Val Ala Met Lys Pro Ala Ala Gly Leu Asp Leu Phe 3250 3255 3260

Gly Met Ala Ala Gly Thr Asp Glu Ala Gly Arg Ala Arg Met Thr Arg

WO 98/07868 PCT/EP97/04495

- 187 -

Asp Ala Ala Ile Gly Ser Gly Glu Pro Leu Leu Val Pro Ala Gln Leu 

Asp Leu Arg Gly Leu Arg Ala Glu Ala Ala Gly Gly Thr Glu Val Pro 

His Leu Leu Arg Gly Leu Val Arg Ala Gly Arg Gln Gln Ala Arg Ala 

Ala Ser Thr Val Glu Glu Asn Trp Ala Gly Arg Leu Ala Gly Leu Glu 

Pro Ala Glu Arg Gly Gln Val Leu Leu Glu Leu Val Arg Ala Gln Val 

Ala Gly Val Leu Gly Tyr Arg Ala Ala His Gln Val Asp Pro Asp Gln 

Gly Leu Phe Glu Ile Gly Phe Asp Ser Leu Thr Ala Ile Glu Leu Arg 

Asn Arg Leu Arg Ala Arg Thr Glu Arg Lys Ile Ser Pro Gly Val Val 

Phe Asp His Pro Thr Pro Ala Leu Leu Ala Ala His Leu Asn Glu Leu 

Leu Arg Lys Lys Val 

### (2) INFORMATION FOR SEQ ID NO: 9:

### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 226 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

WO 98/07868 PCT/EP97/04495

- 188 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Met Ala Ile Pro Tyr Ser Ser Leu Ala Tyr Glu Leu Arg Asp Ala Val 1 5 10 15

Asn Val Val Asp Leu Asp Glu Asp Asp Val Phe Val Thr Ser Ile Ala
20 25 30

Glu Gly Gln Gly Ala Cys Tyr His Leu Asn Arg Leu Phe His Arg 35 40 45

Leu Leu Thr Glu Leu Gly Tyr Asp Val Thr Pro Leu Ala Gly Ser Thr 50 55 60

Ala Glu Gly Arg Glu Thr Phe Gly Thr Asp Val Glu His Met Phe Asn 65 70 75 80

Leu Val Thr Leu Asp Gly Ala Asp Trp Leu Val Asp Val Gly Tyr Pro 85 90 95

Gly Pro Thr Tyr Val Glu Pro Leu Ala Val Ser Pro Ala Val Gln Thr 100 105 110

Gln Tyr Gly Ser Gln Phe Arg Leu Val Glu Gln Glu Thr Gly Tyr Ala 115 120 125

Leu Gln Arg Arg Gly Ala Val Thr Arg Trp Ser Val Val Tyr Thr Phe 130 135 140

Thr Thr Gln Pro Arg Gln Trp Ser Asp Trp Lys Glu Leu Glu Asp Asn

WO 98/07868 PCT/EP97/04495

- 189 -

145 150 155 160

Phe Arg Ala Leu Val Gly Asp Thr Thr Arg Thr Asp Thr Gln Glu Thr
165 170 175

Leu Cys Gly Arg Ala Phe Ala Asn Gly Gln Val Phe Leu Arg Gln Arg 180 185 190

Arg Tyr Leu Thr Val Glu Asn Gly Arg Glu Gln Val Arg Thr Ile Thr 195 200 205

Asp Asp Glu Phe Arg Ala Leu Val Ser Arg Val Leu Ser Gly Asp 210 215 220

His Gly 225 Ciba-Geigy AG

CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

1. IDENTIFICATION OF THE MICROORGANISM Identification reference given by the DEPOSITOR: Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: pRi7-3 DSM 11114 11. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under I, above was accompanied by: (X) a scientific description (X) a proposed taxonomic designation (Mark with a cross where applicable). III. RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under 1. above, which was received by it on 1996-08-10 (Date of the original deposit)1. IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion). V. INTERNATIONAL DEPOSITARY AUTHORITY DSMZ-DEUTSCHE SAMMLUNG VON Name: Signature(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized official(s): Address: Mascheroder Weg 1b U. Weiles D-38124 Braunschweig Date: 1996-08-14

Form DSMZ-BP/4 (sole page) 0196

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

Ciba-Geigy AG

CH-4002 Basel

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
	Ciba-Geigy AG CH-4002 Basel	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11114  Date of the deposit or the transfer 1996-08-10	
III. VIABII	ITY STATEMENT		
On that dat	y of the microorganism identified under II above was tested on I  the said microorganism was  viable  or no longer viable	996-08-12 '.	
IV. CONDI	TIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PR	ERFORMED'	
V. INTERN	ATIONAL DEPOSITARY AUTHORITY		
Name: Address:	DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 1996-08-14	

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

Mark with a cross the applicable box.

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Fill in if the information has been requested and if the results of the test were negative.

CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM				
Identification reference given by the DEPOSITOR:  pRi44-2	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11655			
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DE	SIGNATION			
The microorganism identified under 1. above was accompanied by:  (X) a scientific description (X) a proposed taxonomic designation  (Mark with a cross where applicable).				
III. RECEIPT AND ACCEPTANCE	·			
This International Depositary Authority accepts the microorganism identified (Date of the original deposit)!	under 1. above, which was received by it on 1997-07-14			
IV. RECEIPT OF REQUEST FOR CONVERSION				
The microorganism identified under I above was received by this Internation and a request to convert the original deposit to a deposit under the Budapest for conversion).	al Depositary Authority on (date of original deposit)  Treaty was received by it on (date of receipt of request			
V. INTERNATIONAL DEPOSITARY AUTHORITY				
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s)  Date: 1997-07-15			

Form DSMZ-BP/4 (sole page) 0196

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

CH-4002 Basel

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM
Address: CH-4002 Basel		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11655  Date of the deposit or the transfer!:  1997-07-14
III. VIABILITY STATEM	ENT	
On that date, the said micro (X) <sup>3</sup> viable ( ) <sup>3</sup> no longer v		
V. INTERNATIONAL DE	POSITARY AUTHORITY	<del></del>
		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 1997-07-15

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

Mark with a cross the applicable box.

Form DSMZ-BP/9 (sole page) 0196

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Fill in if the information has been requested and if the results of the test were negative.

CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM					
Identification	n reference given by the DEPOSITOR:	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11656			
II. SCIENT	IFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESI	GNATION			
The microon	The microorganism identified under I. above was accompanied by:  (X ) a scientific description				
(Décado sode)	(X) a proposed taxonomic designation				
(Mark With	a cross where applicable).				
III. RECEIP	T AND ACCEPTANCE				
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1997-07-14 (Date of the original deposit).					
IV. RECEIF	IV. RECEIPT OF REQUEST FOR CONVERSION				
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).					
V. INTERNATIONAL DEPOSITARY AUTHORITY					
Name:	DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):			
Address:	Mascheroder Weg 1b D-38124 Braunschweig	U, Werles  Date: 1997-07-15			
1					

Form DSMZ-BP/4 (sole page) 0196

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

CH-4002 Basel

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. DEPOSITO	DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM	
Name: Novartis AG  Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11656  Date of the deposit or the transfer!:  1997-07-14		INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11656  Date of the deposit or the transfer!:
III. VIABILI	ITY STATEMENT	
On that date	of the microorganism identified under II above was tested on the said microorganism was  viable  no longer viable	1997-07- <b>14</b> '
IV. CONDI	TIONS UNDER WHICH THE VIABILITY TEST HAS BEEN	PERFORMED*
V. INTERN	ATIONAL DEPOSITARY AUTHORITY	
Name: Address:	DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the international Depositary Authority or of authorized official(s):  Date: 1997-07-15,

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Mark with a cross the applicable box.

Fill in if the information has been requested and if the results of the test were negative.

Form DSMZ-BP/9 (sole page) 0196

CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM				
Identification reference given by the DEPOSITOR:  pNE112	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11657			
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAX	XONOMIC DESIGNATION			
The microorganism identified under I. above was accompanied by:  (X ) a scientific description (X ) a proposed taxonomic designation  (Mark with a cross where applicable).				
III. RECEIPT AND ACCEPTANCE				
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1997-07-14 (Date of the original deposit)!				
IV. RECEIPT OF REQUEST FOR CONVERSION				
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).				
V. INTERNATIONAL DEPOSITARY AUTHORITY				
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTURE Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  One was a second of the power to represent the International Depositary Authority or of authorized official(s):  Date: 1997-07-15			

Form DSMZ-BP/4 (sole page) 0196

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

CH-4002 Basel

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

1. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
Name: Address:	Novartis AG CH-4002 Basel	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11657  Date of the deposit or the transfer!:  1997-07-14	
II. VIABI	ILITY STATEMENT		
(X	ity of the microorganism identified under II above was tested on the the said microorganism was  (C) viable  (THONS UNDER WHICH THE VIABILITY TEST HAS BEEN F		
	NATIONAL DEPOSITARY AUTHORITY		
Name:	DSMZ-DEUTSCHE SAMMLUNG VON	Signature(s) of person(s) having the power to represent the	
	MIKROORGANISMEN UND ZELLKULTUREN GmbH  Mascheroder Weg 1b D-38124 Braunschweig	International Depositary Authority or of authorized official(s):	

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

Mark with a cross the applicable box.

Form DSMZ-BP/9 (sole page) 0196

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Fill in if the information has been requested and if the results of the test were negative.

### What is claimed is:

- 1. A DNA fragment from the genome of Amycolatopsis mediterranei which comprises a DNA region which is involved directly or indirectly in the gene cluster responsible for rifamycin synthesis, including the adjacent DNA regions to the right and left which, by reason of their function in connection with rifamycin biosynthesis, qualify as constituent of this rifamycin gene cluster; and functional fragments, derivatives or constituents thereof.
- 2. A DNA fragment according to claim 1, which is directly or indirectly involved in the gene cluster responsible for rifamycin synthesis.
- 3. A DNA fragment according to claim 1, which comprises sequence portions which code for a polyketide synthase or an enzymatically active domain thereof.
- A DNA fragment according to claim 1, which comprises SEQ ID NO 1 or SEQ ID NO
   3 or at least 15 consecutive nucleotides therefrom.
- 5. A DNA fragment according to claim 1, wherein said fragment comprises one or more of the partial nucleotide sequences depicted in SEQ ID NOS 1 and/or 3, or functional fragments thereof, and all other DNA sequences in the vicinity of this sequence which can, by reason of homologies which are present, be regarded as structural or functional equivalents and are therefore able to hybridize with this sequence.
- 6. A DNA fragment according to claim 1, wherein said fragment comprises a nucleotide sequence selected from the group consisting of ORF A, B, C, D, E and F or functional fragments thereof, or encodes one or more of the proteins or polypeptides, or functional derivatives thereof, depicted in SEQ ID NOS 4 to 9.
- 7. A method for identifying, isolating and cloning a DNA fragment according to claim 1.

- 8. A method according to claim 7, which comprises the following steps:
  - · setting up of a genomic gene bank,
  - screening of this gene bank with the assistance of the DNA sequences according to the invention, and
  - isolation of the clones identified as positive.
- 9. The use of a DNA fragment according to claim 1 in the production of ansamycins or precursors thereof; including those in which the aliphatic bridge is connected only at one end to the aromatic nucleus.
- The use of a DNA fragment according to claim 1 in the production of rifamycin, rifamycin analogues or precursors thereof.
- 11. The use of a DNA fragment according to claim 1 for inactivating or modifying genes of ansamycin biosynthesis.
- 12. The use of a DNA fragment according to claim 1 for inactivating or modifying genes of rifamycin biosynthesis, or the biosynthesis of rifamycin analogues.
- 13. The use of a DNA fragment according to claim 1 for constructing mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted.
- 14. The use of DNA fragments according to claim 1 for assembling a library of polyketide synthases.
- 15. The use of the polyketide synthases according to claim 14 for assembling a library of polyketides.
- 16. A polyketide synthase from *Amycolatopsis mediterranei* which is directly or indirectly involved in rifamycin synthesis; and functional constituents or domains thereof.

# WO 98/07868 PCT/EP97/04495 - 200 -

- 17. The use of the polyketide synthase according to claim 16 for synthesizing ansamycins.
- 18. The use of polyketide synthases according to claim 14 for synthesizing a library of ansamycins.
- 19. A hybrid vector comprising a DNA fragment according to claim 1.
- 20. A hybrid vector comprising an expression vector comprising a DNA fragment according to claim 1.
- 21. A host organism comprising a hybrid vector according to claim 19.
- 22. A hybridization probe comprising a DNA fragment according to claim 1.
- 23. The use of the hybridization probe according to claim 22 for identifying DNA fragments involved in the biosynthesis of ansamycins.

## INTERNATIONAL SEARCH REPORT

In ational Application No PCT/EP 97/04495

A. CLASS IPC 6	SIFICATION OF SUBJECT MATTER C12N15/52 C12P17/18 C12P17 C12N15/70 C1201/68	7/10 C12N9/00	C12N1/21
According	to International Patent Classification (IPC) or to both national classification	ification and IPC	
8. FIELDS	S SEARCHED		
Minimum d IPC 6	documentation searched (classification system followed by classific C12N C12P	ation symbols)	
	ation searched other than minimum documentation to the extent tha		
Electronic o	data base consulted during the international search (name of data)	base and, where practical, search tei	rms used)
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the r	elevant passages	Relevant to claim No.
Y	LAL, R. ET AL: "Rifamycins: strimprovement program" CRIT. REV. MICROBIOL. (1995), 20 CODEN: CRVMAC; ISSN: 1040-841X, 30 see the whole document	1(1), 19-30	1
Y	MADON J ET AL: "TRANSFORMATION AMYCOLATOPSIS -MEDITERRANEI DIRE TRANSFORMATION OF MYCELIUM WITH DNA." J BACTERIOL 173 (20). 1991. 6325 CODEN: JOBAAY ISSN: 0021-9193, ) see the whole document	ECT PLASMID 5-6331.	1
A	WO 87 03907 A (LUBRIZOL GENETICS July 1987 see claims	-/	1
X Furth	her documents are listed in the continuation of box C.	X Patent family members ar	re listed in annex.
<u> </u>	legories of cited documents :	"T" later document published after	the international filing date
conside	int defining the general state of the art which is not ered to be of particular relevance locument but published on or after the international ate	or priority date and not in con cited to understand the princip invention  X" document of particular relevant	ple or theory underlying the ice: the claimed invention
"L" documer which is citation	nt which may throw doubts on priority claim(s) or is cited to establish the publication date of another is or other special reason (as specified)	"Y" document of particular relevant cannot be considered to invol	in the document is taken alone ice; the claimed invention the an inventive step when the
other m	int referring to an oral disclosure, use, exhibition or neans nt published prior to the international filing date but an the priority date claimed	document is combined with or ments, such combination bein in the art.  "&" document member of the same	ng obvious to a person skilled
	actual completion of theinternational search	Date of mailing of the internation	
	January 1998	13/01/1998	Side Section (Sport
Name and m	nailing address of the ISA European Patent Office P B. 5818 Patentieen 2	Authorized officer	
	NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040. Tx. 31 651 epo nl. Fax: (+31–70) 340–3016	Delanghe, L	

1

### INTERNATIONAL SEARCH REPORT

In: ational Application No
PCT/EP 97/04495

C.(Continu	Ontinuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
A	WO 95 08548 A (UNIV LELAND STANFORD JUNIOR; JOHN INNES CENTRE (GB)) 30 March 1995 see claims	1	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int ational Application No PCT/EP 97/04495

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8703907 A	02-07-87	AU 598516 B AU 6835487 A EP 0262154 A EP 0463707 A	28-06-90 15-07-87 06-04-88 02-01-92
WO 9508548 A	30-03-95	US 5672491 A AU 678058 B AU 7731794 A CA 2171629 A EP 0725778 A JP 9505983 T	30-09-97 15-05-97 10-04-95 30-03-95 14-08-96 17-06-97